Erlotinib

Name: Erlotinib
Brand: Selleck Chemicals
SKU: S7786
Rating: 5 (421 reviews)

For research use only.

Catalog No.S7786 Synonyms: CP358774, NSC 718781

421 publications

CAS No. 183321-74-6

Erlotinib (CP358774, NSC 718781) is an EGFR inhibitor with IC50 of 2 nM, >1000-fold more sensitive for EGFR than human c-Src or v-Abl. Erlotinib induces autophagy.

Selleck's Erlotinib has been cited by 421 publications

Nat Med, 2019, 25(1):111-118

PubMed: 30478424 ( click the link to review the publication )

Cell, 2019, 178(4):807-819

PubMed: 31398338 ( click the link to review the publication )

Cancer Cell, 2019, 35(3):504-518

PubMed: 30827889 ( click the link to review the publication )

Cancer Cell, 2019, 10.1016/j.ccell.2019.09.001

PubMed: 31588020 ( click the link to review the publication )

Nat Immunol, 2019, 20(7):835-851

PubMed: 31160797 ( click the link to review the publication )

Nat Med, 2018, 24(11):1752-1761

PubMed: 30349086 ( click the link to review the publication )

Nat Med, 2018, 24(7):968-977

PubMed: 29808010 ( click the link to review the publication )

Nat Med, 2018, 24(4):512-517

PubMed: 29505033 ( click the link to review the publication )

Nat Methods, 2018, 15(8):631-639

PubMed: 30038414 ( click the link to review the publication )

Nat Med, 2017, 23(10):1167-1175

PubMed: 28920960 ( click the link to review the publication )

Nat Genet, 2017, 49(12):1693-1704

PubMed: 29106415 ( click the link to review the publication )

Gastroenterology, 2017, 153(4):1082-1095

PubMed: 28625833 ( click the link to review the publication )

Cancer Cell, 2016, 29(4):563-573

PubMed: 27070703 ( click the link to review the publication )

Cancer Discov, 2015, 5(11):1155-63

PubMed: 26286086 ( click the link to review the publication )

Cancer Cell, 2015, 27(3):397-408

PubMed: 25759024 ( click the link to review the publication )

Cancer Cell, 2015, 27(4):533-46

PubMed: 25873175 ( click the link to review the publication )

Cancer Discov, 2013, 3(12):1404-15

PubMed: 24065731 ( click the link to review the publication )

Cell Metab, 2013, 17(6):1000-8

PubMed: 23707073 ( click the link to review the publication )

Cell, 2012, 151(5):937-50

PubMed: 23178117 ( click the link to review the publication )

Nat Genet, 2012, 44(8):852-60

PubMed: 22751098 ( click the link to review the publication )

J Cell Biol, 2021, 220(2)e202004229

PubMed: 33443570 ( click the link to review the publication )

Theranostics, 2021, 11(2):824-840

PubMed: 33391507 ( click the link to review the publication )

PLoS Pathog, 2021, 17(1):e1009216

PubMed: 33481911 ( click the link to review the publication )

Drug Metab Dispos, 2021, 49(1):53-61

PubMed: 33148688 ( click the link to review the publication )
Exp Ther Med, 2021, 21(1):9

PubMed: 33235618 ( click the link to review the publication )

Oncol Rep, 2021, 45(1):217-229

PubMed: 33200228 ( click the link to review the publication )

Oncol Lett, 2021, 21(1):44

PubMed: 33262836 ( click the link to review the publication )

Acta Neuropathol, 2020, 10.1007/s00401-020-02226-7

PubMed: 33009951 ( click the link to review the publication )

Nat Commun, 2020, 10;11(1):2935

PubMed: 32523045 ( click the link to review the publication )

Nat Commun, 2020, 11(1):3157

PubMed: 32572029 ( click the link to review the publication )

EMBO J, 2020, 2;39(5):e101679

PubMed: 32009252 ( click the link to review the publication )

EMBO Mol Med, 2020, e11099

PubMed: 32558295 ( click the link to review the publication )

EMBO Mol Med, 2020, 12(8):e11987

PubMed: 32672423 ( click the link to review the publication )

Cancer Res, 2020, 80(22):4998-5010

PubMed: 33023947 ( click the link to review the publication )

Cell Rep, 2020, 31(11):107764

PubMed: 32553168 ( click the link to review the publication )

Elife, 2020, 2;9:e54954

PubMed: 32484436 ( click the link to review the publication )

Mucosal Immunol, 2020, 4

PubMed: 32132671 ( click the link to review the publication )

Oncogene, 2020, 39(20):3997-4013

PubMed: 32242147 ( click the link to review the publication )

Oncogene, 2020, 10.1038/s41388-020-01497-4

PubMed: 33037411 ( click the link to review the publication )

Cancer Lett, 2020, 476:23-33

PubMed: 31958486 ( click the link to review the publication )

Sci Signal, 2020, 28;13(629)

PubMed: 32345725 ( click the link to review the publication )

Cancers (Basel), 2020, 12(11)E3172

PubMed: 33126775 ( click the link to review the publication )

Cancers (Basel), 2020, 10;12(1) pii: E173

PubMed: 31936715 ( click the link to review the publication )

Cancers (Basel), 2020, 27;12(5)pii: E1087

PubMed: 32349331 ( click the link to review the publication )

Cancers (Basel), 2020, 13;12(2) pii: E436

PubMed: 32069833 ( click the link to review the publication )

Cancers (Basel), 2020, 12(2)

PubMed: 32045997 ( click the link to review the publication )

Cancers (Basel), 2020, 12(1)

PubMed: 31968611 ( click the link to review the publication )

Cells, 2020, 17;9(4) pii: E1003

PubMed: 32316635 ( click the link to review the publication )
Cancer Discov, 2020, CD-19-1262

PubMed: 32513774 ( click the link to review the publication )

Mol Cancer Ther, 2020, 5;molcanther.510.2019

PubMed: 32371581 ( click the link to review the publication )

Mol Cancer Ther, 2020, 19;molcanther10362019

PubMed: 32430488 ( click the link to review the publication )

Mol Cancer Ther, 2020, 5 pii: molcanther

PubMed: 32371586 ( click the link to review the publication )

Mol Cancer Ther, 2020, molcanther.1160.2019

PubMed: 33323457 ( click the link to review the publication )

Neurobiol Dis, 2020, 9;104961

PubMed: 32531343 ( click the link to review the publication )

Front Cell Dev Biol, 2020,

PubMed: 32850868 ( click the link to review the publication )

J Cancer, 2020, 11(19):5746-5757

PubMed: 32913468 ( click the link to review the publication )

Transl Res, 2020, S1931-5244(20)30257-7

PubMed: 33197651 ( click the link to review the publication )

Transl Lung Cancer Res, 2020, 9(5):1904-1914

PubMed: 33209611 ( click the link to review the publication )

Cancer Sci, 2020, 111(10):3793-3801

PubMed: 32687646 ( click the link to review the publication )

J Cell Physiol, 2020, 10.1002/jcp.29463

PubMed: 31960422 ( click the link to review the publication )

Eur J Pharm Biopharm, 2020, S0939-6411(20)30305-2

PubMed: 33068736 ( click the link to review the publication )

Mol Cancer Res, 2020, 10.1158/1541-7786.MCR-20-0420

PubMed: 33028660 ( click the link to review the publication )

Front Oncol, 2020, 12;10:696

PubMed: 32528877 ( click the link to review the publication )

Front Oncol, 2020, 10:585292

PubMed: 33194732 ( click the link to review the publication )

Front Oncol, 2020, 10:1593

PubMed: 33014812 ( click the link to review the publication )

Biochem Pharmacol, 2020, 10.1016/j.bcp.2020.113914

PubMed: 32173363 ( click the link to review the publication )

Int J Mol Sci, 2020,

PubMed: 32823915 ( click the link to review the publication )

Int J Mol Sci, 2020, 21(23)E9307

PubMed: 33291316 ( click the link to review the publication )

Sci Rep, 2020, 10(1):17768

PubMed: 33082482 ( click the link to review the publication )

Sci Rep, 2020, 17;10(1):2735

PubMed: 32066763 ( click the link to review the publication )

Sci Rep, 2020, 10(1):3842

PubMed: 32123209 ( click the link to review the publication )

Sci Rep, 2020, 10(1):4748

PubMed: 32179851 ( click the link to review the publication )
J Biol Chem, 2020, jbc.RA120.014960

PubMed: 33273014 ( click the link to review the publication )

Cancer Manag Res, 2020, 12:4453-4460

PubMed: 32606939 ( click the link to review the publication )

Cancer Res Treat, 2020, 10.4143/crt.2020.585

PubMed: 33070556 ( click the link to review the publication )

Oncol Rep, 2020, 44(6):2581-2594

PubMed: 33125153 ( click the link to review the publication )

Oncol Rep, 2020, 45(1):217-229

PubMed: 33200228 ( click the link to review the publication )

J Pharm Biomed Anal, 2020, 195:113864

PubMed: 33387839 ( click the link to review the publication )

Environ Toxicol, 2020, 10.1002/tox.22942

PubMed: 32485087 ( click the link to review the publication )

Onco Targets Ther, 2020, 13:10983-10994

PubMed: 33149613 ( click the link to review the publication )

Thorac Cancer, 2020, 11

PubMed: 32525282 ( click the link to review the publication )

Chin Med, 2020, 15:66

PubMed: 32612672 ( click the link to review the publication )

Hum Cell, 2020, 10.1007/s13577-020-00420-z

PubMed: 32870449 ( click the link to review the publication )

J Cell Commun Signal, 2020, 10.1007

PubMed: 32157550 ( click the link to review the publication )

Cancer Lett, 2020, 477:19-30

PubMed: 32120023 ( click the link to review the publication )

J Am Soc Nephrol, 2020, ASN.2019111215

PubMed: 32616537 ( click the link to review the publication )

Neurooncol Adv, 2020, 2(1):vdaa067

PubMed: 32642717 ( click the link to review the publication )

Radiat Oncol, 2020, 15(1):58

PubMed: 32143669 ( click the link to review the publication )

Redox Biol, 2020, 36:101652

PubMed: 32750669 ( click the link to review the publication )

Nat Commun, 2020, 11(1):3521

PubMed: 32665556 ( click the link to review the publication )

J Pharmacol Toxicol Methods, 2020, 106895

PubMed: 32629158 ( click the link to review the publication )

Cancer Manag Res, 2020, 12:4283-4297

PubMed: 32606925 ( click the link to review the publication )

Cancer Cell, 2020, 38(6):872-890.e6

PubMed: 33217342 ( click the link to review the publication )

Chin Med J (Engl), 2020, 5;133(11):1304-1311

PubMed: 32452893 ( click the link to review the publication )

J Thorac Oncol, 2020, 15(5):752-765

PubMed: 31972351 ( click the link to review the publication )

Biochem Pharmacol, 2020, 114154

PubMed: 32681833 ( click the link to review the publication )
Nat Commun, 2019, 10(1):2532

PubMed: 31182717 ( click the link to review the publication )

Nano Lett, 2019, 19(10):7526-7533

PubMed: 31487192 ( click the link to review the publication )

Autophagy, 2019, 10.1080/15548627.2019.1659654

PubMed: 31448672 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432

PubMed: 31776128 ( click the link to review the publication )

Small, 2019, 15(33):e1900309

PubMed: 31245925 ( click the link to review the publication )

Cancer Res, 2019, 79(11):2947-2961

PubMed: 30987999 ( click the link to review the publication )

Cell Syst, 2019, 10.1016/j.cels.2019.10.002

PubMed: 31668800 ( click the link to review the publication )

Clin Cancer Res, 2019, 25(11):3341-3351

PubMed: 30796031 ( click the link to review the publication )

Mol Syst Biol, 2019, 15(3):e8323

PubMed: 30858180 ( click the link to review the publication )

Cancer Res, 2019, 79(19):5048-5059

PubMed: 31416839 ( click the link to review the publication )

Cell Rep, 2019, 28(8):2012-2022

PubMed: 31433979 ( click the link to review the publication )

Cell Rep, 2019, 28(2):512-525.e6

PubMed: 31291585 ( click the link to review the publication )

Int J Cancer, 2019, 10.1002/ijc.32487

PubMed: 31162839 ( click the link to review the publication )

Oncogene, 2019, 38(5):656-670

PubMed: 30171258 ( click the link to review the publication )

Cancer Lett, 2019, 466:23-34

PubMed: 31521695 ( click the link to review the publication )

Cancer Lett, 2019, 454:78-89

PubMed: 30980868 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):84

PubMed: 30777099 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):154

PubMed: 30971297 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):83

PubMed: 30770740 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):211

PubMed: 31118055 ( click the link to review the publication )

Cancers (Basel), 2019, 11(1)

PubMed: 30609749 ( click the link to review the publication )

Cancers (Basel), 2019, 11(6)

PubMed: 31181806 ( click the link to review the publication )

Breast Cancer Res, 2019, 21(1):77

PubMed: 31262335 ( click the link to review the publication )

Anal Chem, 2019, 91(15):10026-10032

PubMed: 31282657 ( click the link to review the publication )
Cell Death Dis, 2019, 10(4):282

PubMed: 30910997 ( click the link to review the publication )

Cell Chem Biol, 2019, 26(3):400-410

PubMed: 30595532 ( click the link to review the publication )

Cancer Discov, 2019, 9(6):756-777

PubMed: 30862724 ( click the link to review the publication )

J Cancer, 2019, 10(9):2063-2073

PubMed: 31205567 ( click the link to review the publication )

Am J Cancer Res, 2019, 9(8):1708-1721

PubMed: 31497352 ( click the link to review the publication )

Oncogenesis, 2019, 8(12-:70

PubMed: 31772161 ( click the link to review the publication )

Artif Cells Nanomed Biotechnol, 2019, 47(1):3231-3238

PubMed: 31373232 ( click the link to review the publication )

Front Oncol, 2019, 9:586

PubMed: 31428570 ( click the link to review the publication )

Front Oncol, 2019, 9:461

PubMed: 31214503 ( click the link to review the publication )

Front Oncol, 2019, 9:1070

PubMed: 31681603 ( click the link to review the publication )

Biochem Pharmacol, 2019, 169:113640

PubMed: 31536726 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(19)

PubMed: 31546690 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(18)

PubMed: 31514305 ( click the link to review the publication )

Sci Rep, 2019,

PubMed: 31882684 ( click the link to review the publication )

Sci Rep, 2019, 9(1):845

PubMed: 30696915 ( click the link to review the publication )

Sci Rep, 2019, 9(1):5309

PubMed: 30926929 ( click the link to review the publication )

J Biol Chem, 2019, 294(27):10530-10543

PubMed: 31126985 ( click the link to review the publication )

Cytotherapy, 2019, 21(6):603-611

PubMed: 31010733 ( click the link to review the publication )

Mol Pharmacol, 2019, 95(5):528-536

PubMed: 30858165 ( click the link to review the publication )

Cancer Cell Int, 2019, 19:10

PubMed: 30636931 ( click the link to review the publication )

Gene, 2019, 687:143-150

PubMed: 30359740 ( click the link to review the publication )

Respir Res, 2019, 20(1-:270

PubMed: 31791326 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(10)

PubMed: 31121829 ( click the link to review the publication )

Int J Oncol, 2019, 54(2):527-536

PubMed: 30535494 ( click the link to review the publication )
J Ethnopharmacol, 2019, 239:111928

PubMed: 31077779 ( click the link to review the publication )

Cancer Biol Ther, 2019, 10.1080/15384047.2019.1665952

PubMed: 31559898 ( click the link to review the publication )

Transl Oncol, 2019, 12(3):432-440

PubMed: 30562682 ( click the link to review the publication )

Oncol Rep, 2019, 41(1):447-454

PubMed: 30365151 ( click the link to review the publication )

Eur J Pharmacol, 2019, 850:97-108

PubMed: 30753867 ( click the link to review the publication )

Biosci Rep, 2019, 39(8)

PubMed: 31316001 ( click the link to review the publication )

PLoS One, 2019, 14(9):e0214901

PubMed: 31539380 ( click the link to review the publication )

Biochem Biophys Res Commun, 2019, 513(3):546-552

PubMed: 30981504 ( click the link to review the publication )

Oncol Lett, 2019, 17(3):2729-2736

PubMed: 30854046 ( click the link to review the publication )

Anticancer Res, 2019, 39(7):3785-3793

PubMed: 31262905 ( click the link to review the publication )

FEBS Open Bio, 2019, 9(10):1689-1704

PubMed: 31314158 ( click the link to review the publication )

Clin Respir J, 2019, 13(1):23-33

PubMed: 30480362 ( click the link to review the publication )

J Thorac Oncol, 2019, 14(9):1556-1566

PubMed: 31108249 ( click the link to review the publication )

JCI Insight, 2019, 4(4)

PubMed: 30830869 ( click the link to review the publication )

Am J Cancer Res, 2019, 9(12):2719-2729

PubMed: 31911857 ( click the link to review the publication )

Endocr Connect, 2019, 8(6):680-690

PubMed: 31035254 ( click the link to review the publication )

JCI Insight, 2019, 4(21)

PubMed: 31600169 ( click the link to review the publication )

Sci Rep, 2019, 9(1):5692

PubMed: 30952931 ( click the link to review the publication )

J Clin Invest, 2018, 128(6):2500-2518

PubMed: 29613856 ( click the link to review the publication )

Nat Commun, 2018, 9(1):4655

PubMed: 30405134 ( click the link to review the publication )

Nat Commun, 2018, 13;9(1):2720

PubMed: 30006524 ( click the link to review the publication )

J Exp Med, 2018, 215(1):115-140

PubMed: 29191914 ( click the link to review the publication )

J Thorac Oncol, 2018, 13(7):926-937

PubMed: 29596910 ( click the link to review the publication )

EMBO Mol Med, 2018, 10(9)

PubMed: 30108112 ( click the link to review the publication )
Clin Cancer Res, 2018, 24(11):2594-2604

PubMed: 29298799 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(13):3126-3136

PubMed: 29618618 ( click the link to review the publication )

Clin Cancer Res, 2018, 10.1158/1078-0432.CCR-18-0792

PubMed: 29967251 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2018, 115(26):E6030-E6038

PubMed: 29875142 ( click the link to review the publication )

Cancer Immunol Res, 2018, 10.1158/2326-6066

PubMed: 29382670 ( click the link to review the publication )

PLoS Biol, 2018, 16(12):e2006660

PubMed: 30543635 ( click the link to review the publication )

PLoS Biol, 2018,

PubMed: 30261040 ( click the link to review the publication )

Cancer Res, 2018, 78(16):4642-4657

PubMed: 29760048 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(23):6066-6077

PubMed: 30061362 ( click the link to review the publication )

Cancer Res, 2018, 78(24):6866-6880

PubMed: 30322862 ( click the link to review the publication )

Int J Cancer, 2018, 143(8):1994-2007

PubMed: 29756386 ( click the link to review the publication )

Sci Signal, 2018, 11(549)

PubMed: 30254057 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2018, 31(2):253-266

PubMed: 28972303 ( click the link to review the publication )

Cell Death Dis, 2018, 9(3):262

PubMed: 29449529 ( click the link to review the publication )

Cell Death Dis, 2018,

PubMed: 29880898 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(10):2217-2225

PubMed: 30045926 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(4):806-813

PubMed: 29167314 ( click the link to review the publication )

Endocr Relat Cancer, 2018, 25(4):471-480

PubMed: 29440231 ( click the link to review the publication )

Mol Cancer Res, 2018, 16(11):1773-1784

PubMed: 29967110 ( click the link to review the publication )

Mol Cancer Res, 2018, 16(7):1185-1195

PubMed: 29724813 ( click the link to review the publication )

Lung Cancer, 2018, 126:72-79

PubMed: 30527195 ( click the link to review the publication )

Mol Pharm, 2018, 15(5):1892-1900

PubMed: 29595984 ( click the link to review the publication )

J Immunol, 2018, 200(8):2809-2818

PubMed: 29531172 ( click the link to review the publication )

J Cell Physiol, 2018, 233(9):6975-6983

PubMed: 29336487 ( click the link to review the publication )
Mol Cancer Res, 2018, 16(5):777-790

PubMed: 29431617 ( click the link to review the publication )

J Virol, 2018,

PubMed: 29386292 ( click the link to review the publication )

J Cell Mol Med, 2018, 22(6):3073-3085

PubMed: 29575527 ( click the link to review the publication )

Toxicol Sci, 2018, 166(2):394-408

PubMed: 30496568 ( click the link to review the publication )

Sci Rep, 2018, 8(1):18043

PubMed: 30575780 ( click the link to review the publication )

J Biol Chem, 2018, 293(35):13401-13414

PubMed: 29997256 ( click the link to review the publication )

J Proteome Res, 2018, 17(1):63-75

PubMed: 29164889 ( click the link to review the publication )

Cancer Manag Res, 2018, 10:565-581

PubMed: 29606890 ( click the link to review the publication )

Cancer Commun (Lond), 2018, 38(1):19

PubMed: 29764505 ( click the link to review the publication )

Int J Oncol, 2018,

PubMed: 30226590 ( click the link to review the publication )

BMC Cancer, 2018,

PubMed: 29506489 ( click the link to review the publication )

Cancer Med, 2018, 7(4):1394-1403

PubMed: 29493886 ( click the link to review the publication )

Cancer Med, 2018,

PubMed: 29239135 ( click the link to review the publication )

Molecules, 2018, 23(7)

PubMed: 30037018 ( click the link to review the publication )

Oncol Rep, 2018, 40(1):29-38

PubMed: 29749533 ( click the link to review the publication )

J Pharm Biomed Anal, 2018, 150:112-120

PubMed: 29220734 ( click the link to review the publication )

Biochem Biophys Res Commun, 2018, 495(1):733-739

PubMed: 29137977 ( click the link to review the publication )

Anticancer Res, 2018, 38(11):6195-6200

PubMed: 30396937 ( click the link to review the publication )

Urology, 2018, 112:225.e1-225.e7

PubMed: 29154981 ( click the link to review the publication )

Acta Haematol, 2018, 140(1):30-39

PubMed: 30071517 ( click the link to review the publication )

J Craniomaxillofac Surg, 2018, 46(3):492-497

PubMed: 29311018 ( click the link to review the publication )

Oncotarget, 2018, 9(100):37352-37366

PubMed: 30647837 ( click the link to review the publication )

Oncotarget, 2018, 9(60):31572-31589

PubMed: 30167080 ( click the link to review the publication )

Oncotarget, 2018, 9(51):29680-29697

PubMed: 30038713 ( click the link to review the publication )
JCI Insight, 2018, 3(24)

PubMed: 30568033 ( click the link to review the publication )

Oncotarget, 2018, 9(101):37520-37533

PubMed: 30680067 ( click the link to review the publication )

F1000Res, 2018, 7:1906

PubMed: 30881689 ( click the link to review the publication )

Mol Ther Nucleic Acids, 2018, 11:455-467

PubMed: 29858080 ( click the link to review the publication )

Oncol Lett, 2018, 15(5):6107-6114

PubMed: 29731842 ( click the link to review the publication )

Oncoscience, 2018, 5(1-2):21-38

PubMed: 29556515 ( click the link to review the publication )

Gut, 2017, 66(1):124-136

PubMed: 27402485 ( click the link to review the publication )

Sci Transl Med, 2017, 14;9(394):eaah6144

PubMed: 28615362 ( click the link to review the publication )

Nat Commun, 2017, 8(1):410

PubMed: 28871105 ( click the link to review the publication )

Nat Commun, 2017, 8(1):823

PubMed: 29018192 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(19):5923-5935

PubMed: 28679766 ( click the link to review the publication )

Genes Dev, 2017, 31(2):184-196

PubMed: 28167502 ( click the link to review the publication )

Cancer Res, 2017, 77(8):2018-2028

PubMed: 28202526 ( click the link to review the publication )

Genome Med, 2017, 9(1):40

PubMed: 28446242 ( click the link to review the publication )

Biomaterials, 2017, 148:69-80

PubMed: 28968536 ( click the link to review the publication )

Oncogene, 2017, 36(48):6691-6700

PubMed: 28745317 ( click the link to review the publication )

Cell Death Dis, 2017, 8(8):e2980

PubMed: 28796259 ( click the link to review the publication )

Cell Death Dis, 2017, 8(5):e2773

PubMed: 28492539 ( click the link to review the publication )

Arch Toxicol, 2017, 91(8):2921-2938

PubMed: 28032146 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(10):2234-2245

PubMed: 28729401 ( click the link to review the publication )

Mol Cancer Ther, 2017,

PubMed: 27913578 ( click the link to review the publication )

Mol Oncol, 2017, 11(6):628-639

PubMed: 28306189 ( click the link to review the publication )

Mol Oncol, 2017, 11(8):1065-1077

PubMed: 28486761 ( click the link to review the publication )

J Biomed Nanotechnol, 2017, 13(4):458-68

PubMed: 29388752 ( click the link to review the publication )
Cancer Sci, 2017,

PubMed: 27783866 ( click the link to review the publication )

Lung Cancer, 2017, 106:115-124

PubMed: 28285685 ( click the link to review the publication )

Lung Cancer, 2017, 113:72-78

PubMed: 29110853 ( click the link to review the publication )

J Am Heart Assoc, 2017, 6(10)

PubMed: 29051215 ( click the link to review the publication )

Sci Rep, 2017,

PubMed: 28572590 ( click the link to review the publication )

Sci Rep, 2017, 7(1):781

PubMed: 28396596 ( click the link to review the publication )

Sci Rep, 2017, 7(1):1669

PubMed: 28490807 ( click the link to review the publication )

Sci Rep, 2017, 7:44206

PubMed: 28287179 ( click the link to review the publication )

Clin Lung Cancer, 2017,

PubMed: 28038979 ( click the link to review the publication )

J Proteome Res, 2017, 16(2):1077-1086

PubMed: 28152594 ( click the link to review the publication )

Biomed Pharmacother, 2017, 96:619-625

PubMed: 29035827 ( click the link to review the publication )

Phytomedicine, 2017,

PubMed: 29157829 ( click the link to review the publication )

Int J Oncol, 2017, 50(6):2049-2058

PubMed: 28440469 ( click the link to review the publication )

BMC Cancer, 2017,

PubMed: 28806950 ( click the link to review the publication )

Cancer Res Treat, 2017, 49(4):915-926

PubMed: 28052650 ( click the link to review the publication )

Oncol Rep, 2017, 38(4):2205-2210

PubMed: 28791365 ( click the link to review the publication )

Pancreas, 2017, 46(4):575-581

PubMed: 28196025 ( click the link to review the publication )

J Appl Toxicol, 2017, 37(3):382-390

PubMed: 27480533 ( click the link to review the publication )

Biosci Rep, 2017, 37(3)

PubMed: 28507201 ( click the link to review the publication )

PLoS One, 2017, 12(9):e0184155

PubMed: 28898253 ( click the link to review the publication )

PLoS ONE, 2017,

PubMed: 29253018 ( click the link to review the publication )

Biochem Biophys Res Commun, 2017, 486(4):1027-1033

PubMed: 28366635 ( click the link to review the publication )

SLAS Discov, 2017, 22(7):915-922

PubMed: 28346107 ( click the link to review the publication )

Biol Pharm Bull, 2017, 40(8):1306-1313

PubMed: 28515374 ( click the link to review the publication )
Oncotarget, 2017, 8(35):58417-58429

PubMed: 28938567 ( click the link to review the publication )

Gels, 2017, 3(3)

PubMed: 30920523 ( click the link to review the publication )

Oncotarget, 2017, 8(58):98771-98781

PubMed: 29228726 ( click the link to review the publication )

Tumour Biol, 2017, 39(7):1010428317709639

PubMed: 28714370 ( click the link to review the publication )

Oncotarget, 2017, 8(14):22414-22432

PubMed: 26461472 ( click the link to review the publication )

Oncotarget, 2017, 8(40):68221-68229

PubMed: 28978110 ( click the link to review the publication )

JCO Precis Oncol, 2017, 1:PO.16.00019

PubMed: 32913967 ( click the link to review the publication )

Elife, 2017, 6

PubMed: 28145866 ( click the link to review the publication )

Oncotarget, 2017, 9(9):8206-8222

PubMed: 29492189 ( click the link to review the publication )

Oncotarget, 2017, 8(29):47305-47316

PubMed: 28521301 ( click the link to review the publication )

Oncotarget, 2017,

PubMed: 28978083 ( click the link to review the publication )

Oncotarget, 2017,

PubMed: 28423495 ( click the link to review the publication )

Oncotarget, 2017, 9(2):1641-1655

PubMed: 29416720 ( click the link to review the publication )

Genome Biol, 2016, 17:80

PubMed: 27139883 ( click the link to review the publication )

Nat Commun, 2016, 7:11815

PubMed: 27283993 ( click the link to review the publication )

Nat Commun, 2016, 7:11551

PubMed: 27187615 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2016, 113(21):E2935-44

PubMed: 27162365 ( click the link to review the publication )

Cancer Lett, 2016, 376(1):188-96

PubMed: 26996299 ( click the link to review the publication )

J Pathol, 2016, 239(3):320-34

PubMed: 27102572 ( click the link to review the publication )

PLoS Pathog, 2016,

PubMed: 27711202 ( click the link to review the publication )

PLoS Pathog, 2016, 12(5):e1005622

PubMed: 27152417 ( click the link to review the publication )

Cell Death Dis, 2016,

PubMed: 27685624 ( click the link to review the publication )

Mol Cancer Ther, 2016,

PubMed: 27207775 ( click the link to review the publication )

Neoplasia, 2016, 18(7):425-35

PubMed: 27435925 ( click the link to review the publication )
Neoplasia, 2016, 18(2):111-20

PubMed: 26936397 ( click the link to review the publication )

Cancer Sci, 2016, 107(8):1134-40

PubMed: 27240419 ( click the link to review the publication )

Biochim Biophys Acta, 2016, 1859(11):1449-1458

PubMed: 27412911 ( click the link to review the publication )

Stem Cells Int, 2016, 2016:9601493

PubMed: 26788073 ( click the link to review the publication )

BMC Genomics, 2016, 17(1):723

PubMed: 27613601 ( click the link to review the publication )

Int J Oncol, 2016, 48(6):2558-66

PubMed: 27035631 ( click the link to review the publication )

Int J Oncol, 2016, 49(1):243-52

PubMed: 27177201 ( click the link to review the publication )

Exp Cell Res, 2016, 344(2):194-200

PubMed: 27180268 ( click the link to review the publication )

Eur J Pharmacol, 2016, 789:458-467

PubMed: 27514773 ( click the link to review the publication )

PLoS ONE, 2016,

PubMed: 26962861 ( click the link to review the publication )

PLoS One, 2016, 11(5):e0155230

PubMed: 27153109 ( click the link to review the publication )

BMC Vet Res, 2016, 12:82

PubMed: 27245053 ( click the link to review the publication )

Oncotarget, 2016, 7(30):47998-48010

PubMed: 27384992 ( click the link to review the publication )

Oncotarget, 2016, 7(13):15492-506

PubMed: 26909860 ( click the link to review the publication )

Oncotarget, 2016, 7(32):51922-51933

PubMed: 27409162 ( click the link to review the publication )

Oncotarget, 2016, 7(37):59809-59819

PubMed: 27494858 ( click the link to review the publication )

Cancer Immunol Res, 2016,

PubMed: 27680026 ( click the link to review the publication )

Oncotarget, 2016, 7(4):3847-56

PubMed: 26716903 ( click the link to review the publication )

Oncotarget, 2016,

PubMed: 27590506 ( click the link to review the publication )

Oncotarget, 2016, 7(18-:25983-6002

PubMed: 27036020 ( click the link to review the publication )

Mol Cell, 2015, 57(3):521-36

PubMed: 25658204 ( click the link to review the publication )

Clin Cancer Res, 2015, 21(20):4686-97

PubMed: 26124204 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2015, 112(6):1839-44

PubMed: 25605917 ( click the link to review the publication )

Cancer Res, 2015, 10.1158/0008-5472.CAN-14-2005

PubMed: 25744720 ( click the link to review the publication )
Elife, 2015,

PubMed: 25686219 ( click the link to review the publication )

Int J Cancer, 2015, 10.1002/ijc.29483

PubMed: 25688715 ( click the link to review the publication )

Oncogene, 2015,

PubMed: 25659577 ( click the link to review the publication )

FASEB J, 2015, 29(9):3702-12

PubMed: 25985800 ( click the link to review the publication )

Mol Cancer Ther, 2015, 10.1158/1535-7163.MCT-13-0951

PubMed: 25589492 ( click the link to review the publication )

Cell Commun Signal, 2015, 13:26

PubMed: 25975820 ( click the link to review the publication )

Radiother Oncol, 2015, 116(3):431-7

PubMed: 26320552 ( click the link to review the publication )

Biochem Pharmacol, 2015, 98(4):639-48

PubMed: 26484875 ( click the link to review the publication )

Sci Rep, 2015,

PubMed: 26538233 ( click the link to review the publication )

Sci Rep, 2015,

PubMed: 25705018 ( click the link to review the publication )

J Biol Chem, 2015,

PubMed: 26152725 ( click the link to review the publication )

J Biol Chem, 2015, 290(28):17495-504

PubMed: 26023239 ( click the link to review the publication )

Ann Thorac Surg, 2015, 100(2):414-21

PubMed: 26141774 ( click the link to review the publication )

Biochem J, 2015, 465(2):271-9

PubMed: 25351958 ( click the link to review the publication )

J Chromatogr A, 2015, 1400:117-23

PubMed: 25981288 ( click the link to review the publication )

J Chromatogr A, 2015, 10.1016/j.chroma.2015.04.055

PubMed: ( click the link to review the publication )

Toxicol Appl Pharmacol, 2015, 10.1016/j.taap.2015.05.001

PubMed: 25981168 ( click the link to review the publication )

Am J Physiol Heart Circ Physiol, 2015, 309(9):H1516-27

PubMed: 26371162 ( click the link to review the publication )

Acta Pharmacol Sin, 2015, 10.1038/aps.2015.4

PubMed: 25864651 ( click the link to review the publication )

Prostate, 2015, 10.1002/pros.22945

PubMed: 25560638 ( click the link to review the publication )

Drug Des Devel Ther, 2015, 9:3183-90

PubMed: 26124641 ( click the link to review the publication )

Cancer Chemoth Pharm, 2015, 10.1007/s00280-015-2751-6

PubMed: 25907508 ( click the link to review the publication )

PLoS One, 2015, 10(5):e0127348

PubMed: 25973895 ( click the link to review the publication )

PLoS One, 2015, 10(10):e0140782

PubMed: 26474061 ( click the link to review the publication )
PLoS One, 2015, 10(4):e0123901

PubMed: 25875914 ( click the link to review the publication )

Biochem Biophys Res Commun, 2015, 463(4):612-7

PubMed: 26043686 ( click the link to review the publication )

J Biotechnol, 2015, 10.1016/j.jbiotec.2015.01.012

PubMed: 25615947 ( click the link to review the publication )

Anal Biochem, 2015, 10.1016/j.ab.2015.01.016

PubMed: 25659657 ( click the link to review the publication )

Biomarkers, 2015,

PubMed: 26329528 ( click the link to review the publication )

Pathol Oncol Res, 2015, 10.1007/s12253-015-9916-9

PubMed: 25749811 ( click the link to review the publication )

Oncol Lett, 2015,

PubMed: 26622654 ( click the link to review the publication )

Biochem J, 2015, 471(2):267-79

PubMed: 26285655 ( click the link to review the publication )

Oncotarget, 2015,

PubMed: 26036637 ( click the link to review the publication )

Oncotarget, 2015,

PubMed: 25686822 ( click the link to review the publication )

Oncotarget, 2015,

PubMed: 26325669 ( click the link to review the publication )

BMC Res Notes, 2015, 8:203

PubMed: 26032726 ( click the link to review the publication )

Oncotarget, 2015,

PubMed: 25909220 ( click the link to review the publication )

PLoS One, 2015, 10(2):e0118210

PubMed: 25706985 ( click the link to review the publication )

Oncotarget, 2015, 6(7):5118-33

PubMed: 25742786 ( click the link to review the publication )

Oncotarget, 2015,

PubMed: 25576915 ( click the link to review the publication )

Tumour Biol, 2015, 36(7):5485-95

PubMed: 26036758 ( click the link to review the publication )

J Virol, 2015, 90(4):1918-30

PubMed: 26656684 ( click the link to review the publication )

Cancer Prev Res (Phila), 2015, 8(9):765-76

PubMed: 26100522 ( click the link to review the publication )

Oncotarget, 2015,

PubMed: 26378037 ( click the link to review the publication )

Oncotarget, 2015,

PubMed: 25965827 ( click the link to review the publication )

Oncotarget, 2015,

PubMed: 26486084 ( click the link to review the publication )

Nat Commun, 2014, 3.84166666666667

PubMed: 25366117 ( click the link to review the publication )

J Natl Cancer Inst, 2014, 106(9)

PubMed: 25214559 ( click the link to review the publication )
J Thorac Oncol, 2014, 9(6):775-83

PubMed: 24828661 ( click the link to review the publication )

Clin Cancer Res, 2014, 20(13):3613-22

PubMed: 24803578 ( click the link to review the publication )

Clin Cancer Res, 2014, 20(15):4047-58

PubMed: 24895459 ( click the link to review the publication )

Clin Cancer Res, 2014, 20(18):4806-15

PubMed: 25052479 ( click the link to review the publication )

Cancer Res, 2014, 74(1):253-62

PubMed: 24165158 ( click the link to review the publication )

Elife, 2014, 3:e02523

PubMed: 24844246 ( click the link to review the publication )

Oncogene, 2014, 33(35):4418-23

PubMed: 24469055 ( click the link to review the publication )

Br J Pharmacol, 2014, 171(24):5757-73

PubMed: 25117211 ( click the link to review the publication )

Antioxid Redox Sign, 2014, 10.1089/ars.2013.5304

PubMed: 24684506 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1445

PubMed: 25299770 ( click the link to review the publication )

Mol Oncol, 2014, 10.1016/j.molonc.2014.05.005

PubMed: 24908424 ( click the link to review the publication )

Lung Cancer, 2014, 85(2):152-60

PubMed: 24954871 ( click the link to review the publication )

Antimicrob Agents Chemother, 2014, 10.1128/AAC.02393-14

PubMed: 24663025 ( click the link to review the publication )

J Transl Med, 2014, 12(1):265

PubMed: 25240937 ( click the link to review the publication )

Am J Cancer Res, 2014, 6(6):649-663

PubMed: ( click the link to review the publication )

J Pharmacol Exp Ther, 2014, 351(2):352-8

PubMed: 25187431 ( click the link to review the publication )

Drug Metab Dispos, 2014, 42(11):1851-7

PubMed: 25165131 ( click the link to review the publication )

J Mol Endocrinol, 2014, 52(2):223-34

PubMed: 24463098 ( click the link to review the publication )

Am J Transl Res, 2014, 6(6):649-63

PubMed: 25628777 ( click the link to review the publication )

Oncol Res, 2014, 21(3):137-44

PubMed: 24512728 ( click the link to review the publication )

BMC Microbiol, 2014,

PubMed: 25471819 ( click the link to review the publication )

PLoS One, 2014, 9(12):e114000

PubMed: 25486409 ( click the link to review the publication )

Biomed Res Int, 2014,

PubMed: 24895573 ( click the link to review the publication )

Histochem Cell Biol, 2014, 10.1007/s00418-014-1223-0

PubMed: 24824474 ( click the link to review the publication )
Guangxi Medical University, 2014, Suning Huang

PubMed: ( click the link to review the publication )

Biores Open Access, 2014, 3(4):176-82

PubMed: 25126481 ( click the link to review the publication )

Nat Chem Biol, 2013, 9(5):307-12

PubMed: 23502424 ( click the link to review the publication )

Cell Rep, 2013, 4(4):764-75

PubMed: 23972990 ( click the link to review the publication )

Int J Cancer, 2013, 133(2):505-13

PubMed: 23319394 ( click the link to review the publication )

Sci Signal, 2013,

PubMed: 23532334 ( click the link to review the publication )

BRIT J CANCER, 2013, 109(8):2155-66

PubMed: 24045666 ( click the link to review the publication )

Mol Cancer Ther, 2013, 12(10):2213-25

PubMed: 23918833 ( click the link to review the publication )

Lung Cancer, 2013, 81(3):354-61

PubMed: 23769318 ( click the link to review the publication )

Invest Ophthalmol Vis Sci, 2013, 54(1):864-70

PubMed: 23299479 ( click the link to review the publication )

Prostate, 2013, 73(13):1453-61

PubMed: 23765757 ( click the link to review the publication )

PLoS One, 2013, 8(1):e54509

PubMed: 23349913 ( click the link to review the publication )

PLoS One, 2013, 8(12):e81393

PubMed: 24339922 ( click the link to review the publication )

PLoS One, 2013, 8(12):e82236

PubMed: 24349229 ( click the link to review the publication )

PLoS One, 2013, 8(5):e62104

PubMed: 23690929 ( click the link to review the publication )

Laser in Surg Med, 2013, 45(7):460-8

PubMed: 24037824 ( click the link to review the publication )

Oncotarget, 2013,

PubMed: 23896512 ( click the link to review the publication )

Head Neck, 2013, 35(1):86-93

PubMed: 22495823 ( click the link to review the publication )

Tuberc Respir Dis, 2013, 75(1):9-17

PubMed: 23946753 ( click the link to review the publication )

Tuberc Respir Dis, 2013, 75(3):95-103

PubMed: 24101933 ( click the link to review the publication )

J Clin Invest, 2012, 122(9):3197-210

PubMed: 22886302 ( click the link to review the publication )

Int J Cancer, 2012, 131(12):2961-9

PubMed: 22514082 ( click the link to review the publication )

Int J Cancer, 2012, 131(2):334-43

PubMed: 21858806 ( click the link to review the publication )

Cancer, 2012, 118(21):5198-209

PubMed: 22510844 ( click the link to review the publication )
Cancer Sci, 2012, 103(1):7-16

PubMed: 21951556 ( click the link to review the publication )

Int J Mol Sci, 2012, 13(9):12000-16

PubMed: 23109896 ( click the link to review the publication )

PLoS One, 2012, 7(9):e42441

PubMed: 22957020 ( click the link to review the publication )

PLoS One, 2012, 7(10):e48532

PubMed: 23119048 ( click the link to review the publication )

Oncogene, 2011, 30(22):2547-57

PubMed: 21278786 ( click the link to review the publication )

Mol Cancer Ther, 2011, 10(10):1846-56

PubMed: 21768330 ( click the link to review the publication )

J Immunother, 2011, 34(4):372-81

PubMed: 21499124 ( click the link to review the publication )

Transl Oncol, 2011, 4(2):92-100

PubMed: 21461172 ( click the link to review the publication )

Int J Proteomics, 2011, 2011:215496

PubMed: 22091388 ( click the link to review the publication )

Carcinogenesis, 2010, 31(4):577-86

PubMed: 20097731 ( click the link to review the publication )

Carcinogenesis, 2010, 31(11):1948-55

PubMed: 20837598 ( click the link to review the publication )

Case Western Reserve University, 2010, Zhang Z

PubMed: ( click the link to review the publication )

Eur J Pharm Sci, , 10.1016/j.ejps.2016.04.025

PubMed: 27112992 ( click the link to review the publication )

Purity & Quality Control

Choose Selective EGFR Inhibitors

Biological Activity

Description

Erlotinib (CP358774, NSC 718781) is an EGFR inhibitor with IC50 of 2 nM, >1000-fold more sensitive for EGFR than human c-Src or v-Abl. Erlotinib induces autophagy.

Targets

EGFR ^[1]
(Cell-free assay)

2 nM

In vitro

Erlotinib HCl potently inhibits EGFR activation in intact cells including HNS human head and neck tumor cells (IC50 20nM), DiFi human colon cancer cells and MDA MB-468 human breast cancer cells. Erlotinib HCl (1 μM) induces apoptosis in DiFi human colon cancer cells. ^[1] Erlotinib inhibits growth of a panel of NSCLC cell lines including A549, H322, H3255, H358 H661, H1650, H1975, H1299, H596 with IC50 ranging from 29 nM to >20 μM. ^[2] Erlotinib HCl(2 μM) significantly inhibits growth of AsPC-1 and BxPC-3 pancreatic cells. ^[3] The effects of Erlotinib HCl in combination with gemcitabine are considered additive in KRAS-mutated pancreatic cancer cells. Ten micromolar of Erlotinib HCl inhibits EGFR phospho-rylation at the Y845 (Src-dependent phosphorylation) and Y1068 (auto-phosphorylation) sites. ^[4] Combination with Erlotinib HCl could down-modulate rapamycin-stimulated Akt activity and produces a synergistic effect on cell growth inhibition. ^[5]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Activity Description	PMID
human SKBR3 cells	M3zZd2Z2dmO2aX;uJIF{e2G7			NWC4boMzUW6qaXLpeIlwdiCxZjDISXIzKGmwIHj1cYFvKFONQmKzJINmdGy\|IHL5JGhVWkZiYYPzZZktKEmFNUC9NU45QSEQvF2u	MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQThzNUSxNkc,OTl6MUW0NVI9N2F-
human A431 cells	M{HKTWZ2dmO2aX;uJIF{e2G7			MYjJcohq[mm2aX;uJI9nKEWJRmKgbY4hcHWvYX6gRVQ{OSClZXzsd{BjgSCKVGLGJIF{e2G7LDDJR\|UxRTBwNEKg{txONg>?	NGXIZ5A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUixOVQyOid-MUm4NVU1OTJ:L3G+
Huh7.5	MWLBcpRqfmm{YXygZZN{[Xl?		M3XvRlMxKG2rboO=	NXToRo9lSW62aY\pdoFtKGGldHn2bZR6KGGpYXnud5QhUGWyYYTpeIl{KENidnnyeZMhUjZxSl\IJIlv\mWldHXkJIlvKGi3bXHuJGh2cDdwNTDj[YxteyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKEiFVjDy[ZBtcWOjdHnvckBxemW2cnXheIVlKG[xcjCzNEBucW6\|IH\vcIxwf2WmIHL5JIlv\mWldHnvckBu\WG\|dYLl[EBi\nSncjC3NkBpenNiYomgZYxidWG{IHLseYUh\HmnIHLhd4VlKG[udX;y[ZNk\W6lZTDhd5NigQ>?	MoPVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ7MkWyNFgoRjJ4OUK1NlA5RC:jPh?=
Huh7.5	M17oUGFvfGm4aYLhcEBie3OjeR?=		NYi2e\|FwPzJiaILz	MUDBcpRqfmm{YXygZYN1cX[rdImgZYdicW6\|dDDI[ZBifGm2aYOgR{B3cXK3czDKOk9LTkhiaX7m[YN1\WRiaX6gbJVu[W5iSIXoO{42KGOnbHzzJIF{e2W\|c3XkJIF{KGmwaHnibZRqd25ib3[geolz[WxicnXwcIlk[XSrb36gcYVie3W{ZXSgZYZ1\XJiN{KgbJJ{KGK7IHz1Z4ln\XKjc3WgdoVxd3K2ZYKg[4Vv\SCjc4PhfUwhTUN3MDC9JFAvPSEQvF2u	NUDuWoVzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW4NlI4OzlpPkK1PFIzPzN7PD;hQi=>
Huh7.5	NInPWlJCdnSrdnnyZYwh[XO\|YYm=		NXjoeVJtPzJiaILz	NWHR[VlkSW62aY\pdoFtKGGldHn2bZR6KGGpYXnud5QhUGWyYYTpeIl{KENidnnyeZMhUjZxSl\IJIVt\WO2cn;wc5JifGWmIHnuJIh2dWGwIFj1bFcvPSClZXzsd{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJIlvfHKjY3XscJVt[XJiaX7m[YN1cX[rdImg[JJ2\yC2cnXheIVlKGW4ZYL5JFI1KGi{czDmc5IhPzJiaILzJI1m[XO3cnXkJFczKGi{czDwc5N1KGWuZXP0do9xd3KjdHnvckBjgSCudXPp[oVz[XOnIILldI9zfGW{IHflcoUh[XO\|YYmsJGVEPTBiPTCwMlUh\|ryPLh?=	NH3wWFI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUiyNlc{QSd-MkW4NlI4Ozl:L3G+
Huh7.5	MljxRY51cX[rcnHsJIF{e2G7		MYW3NkBpenN?	NUG1T5FYSW62aY\pdoFtKGGldHn2bZR6KGGpYXnud5QhUGWyYYTpeIl{KENidnnyeZMhUjZxSl\IJIlv\mWldHXkJIlvKGi3bXHuJGh2cDdwNTDj[YxteyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKGW6dILhZ4VtdHWuYYKgbY5n\WO2aY\peJkh\HK3ZzD0doVifGWmIHX2[ZJ6KDJ2IHjyd{Bnd3JiN{KgbJJ{KG2nYYP1doVlKGGodHXyJFczKGi{czDifUBtfWOrZnXyZZNmKHKncH;yeIVzKGenbnWgZZN{[XluIFXDOVAhRSByLkWg{txONg>?	MmfpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV6MkK3N\|koRjJ3OEKyO\|M6RC:jPh?=
NCI-H292	MnznRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		NYPJToU5PzJiaILz	NXXtZZFlSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDOR2kuUDJ7MjDj[YxteyCneIDy[ZN{cW6pIIfpcIQhfHmyZTDFS2ZTKGGodHXyJFczKGi{czDifUBtfW2rbnXzZ4Vv[2ViYYPzZZktKEWFNUCgQUAxNjB\|MTFOwG0v	NV7jNYNWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[0OVU6OTlpPkK2OFU2QTF7PD;hQi=>
A431	NGO4UJdIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		M2LWOFczKGi{cx?=	MmXLS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gRVQ{OSClZXzsd{BwfmW{ZYjwdoV{e2mwZzDFS2ZTKGGodHXyJFczKGi{czDifUBOXFRiYYPzZZktKEeLNUCgQUAxNjR5IN88UU4>	NFnCR\|U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{m4N\|c1PSd-MUe5PFM4PDV:L3G+
A431	NXq5[lNXT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MYC3NkBpenN?	NE\mbpNIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBCPDNzIHPlcIx{KGGodHXyJFczKGi{czDifUBOXFRiYYPzZZktKEeLNUCgQUAxNjlzNTFOwG0v	NWjXTGdSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm5Olk1PjVpPkG5PVY6PDZ3PD;hQi=>
BA/F3	MniwS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MVK5OkBpenN?	M3fISmdzd3e2aDDpcohq[mm2aX;uJI9nKG2xdYPlJGJCN0Z\|IHPlcIx{KGW6cILld5NqdmdiRVfGVkBF\WxzIH31eIFvfCCjZoTldkA6PiCqcoOgZpkh[2WubDD0bZRmei2pbH:gZZN{[XluIFfJOVAhRSByLkWg{txONg>?	MofFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB{MkK3N\|MoRjJyMkKyO\|M{RC:jPh?=
BA/F3	MXfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		M3rH[Vk3KGi{cx?=	NVPrb3ZGT3Kxd4ToJIlvcGmkaYTpc44hd2ZibX;1d4UhSkFxRkOgZ4VtdHNiZYjwdoV{e2mwZzDFS2ZTKESnbEOgcZV1[W62IHHmeIVzKDl4IHjyd{BjgSClZXzsJJRqfGW{LXfsc{Bie3OjeTygS2k2OCB;IECuOUDPxE1w	NWXyWXlURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkCyNlI4OzNpPkKwNlIzPzN\|PD;hQi=>
BA/F3	NWTpPVkzT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MYS5OkBpenN?	NILWdVRIem:5dHigbY5pcWKrdHnvckBw\iCvb4Xz[UBDSS:IMzDj[YxteyCneIDy[ZN{cW6pIFXHSnIhTGWuNTDteZRidnRiYX\0[ZIhQTZiaILzJIJ6KGOnbHygeIl1\XJvZ3zvJIF{e2G7LDDHTVUxKD1iMD61JO69VS5?	NHLXZ3Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEKyNlc{Oyd-MkCyNlI4OzN:L3G+
BA/F3	NEO2T3hIem:5dHigbY5pcWKrdHnvckBie3OjeR?=		M2jQclk3KGi{cx?=	NG[5[o1Iem:5dHigbY5pcWKrdHnvckBw\iCvb4Xz[UBDSS:IMzDj[YxteyCneIDy[ZN{cW6pIFXHSnIhVDh3OGKgcZV1[W62IHHmeIVzKDl4IHjyd{BjgSClZXzsJJRqfGW{LXfsc{Bie3OjeTygS2k2OCB;IECuOUDPxE1w	NV;Ec21KRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkCyNlI4OzNpPkKwNlIzPzN\|PD;hQi=>
WM266.4	NV7Ed3BJT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NWfGdXFTOjRiaILz	MVHHdo94fGhiaX7obYJqfGmxbjDpckBpfW2jbjDXUVI3Pi52IHPlcIx{KGGodHXyJFI1KGi{czDifUBOXFRicnXkeYN1cW:wIHHzd4F6NCCJSUWwJF0hQC5zMjFOwG0v	M4TsflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{OUi1PVYzLz5{Mkm4OVk3OjxxYU6=
A549	M{foT2FvfGmycn;sbYZmemG2aY\lJIF{e2G7		NVPj[JV6OjRiaILz	NVLhOGF[SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDBOVQ6KGOnbHzzJIFnfGW{IEK0JIhzeyCkeTDNWHQh[XO\|YYmsJGdKPTBiPTCwMlA{KM7:TT6=	M2KwW\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|M{mxN\|Y1Lz5{M{O5NVM3PDxxYU6=
MCF7	M2PNTGFvfGmycn;sbYZmemG2aY\lJIF{e2G7		NULCZm15OjRiaILz	MnS5RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCPQ1[3JINmdGy\|IHHmeIVzKDJ2IHjyd{BjgSCPVGSgZZN{[XluIFfJOVAhRSByLkC4JO69VS5?	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzN7MUO2OEc,OjN\|OUGzOlQ9N2F-
WM266.4	MnnMRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		MkGwNlQhcHK\|	NXvGb3duSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDXUVI3Pi52IHPlcIx{KGG\|c3Xzd4VlKGG\|IHPlcIwhfmmjYnnsbZR6KGGodHXyJFI1KGi{czDifUBOXFRiYYPzZZktKEeLNUCgQUA5NjF2IN88UU4>	M1XsR\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5MkO4PFQyLz5{N{KzPFg1OTxxYU6=
NIH3T3	MmjUSpVv[3Srb36gZZN{[Xl?			MYPJcohq[mm2aX;uJI9nKEWJRjDzeIlufWyjdHXkJIh2dWGwIHXyZmIyKGG3dH;wbI9{eGixconsZZRqd25iaX6gUmlJO1R\|IHPlcIx{NCCLQ{WwJF0hOC5yMUmzJO69VS5?	NYS2fWZDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMU[0PFAzQDRpPkG2OFgxOjh2PD;hQi=>
T24 NIH	MnT3SpVv[3Srb36gZZN{[Xl?			MVfJcohq[mm2aX;uJI9nKGyrZ3Hu[EB{fGmvdXzheIVlKGW{YlKyJIF2fG:yaH;zdIhwenmuYYTpc44hcW5iVEK0JG5KUCClZXzsd{whUUN3MDC9JFAvOjl7IN88UU4>	NH;R[Zo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNkS4NFI5PCd-MU[0PFAzQDR:L3G+
Jurkat	NUDYfJVYT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		MlT6NlQhcHK\|	M4\G[2dzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJGp2emujdDDj[YxteyCjZoTldkAzPCCqcoOsJGlEPTBiPTCyJO69VS5?	Ml32QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTdzN{i3NlIoRjF5MUe4O\|IzRC:jPh?=
erythroleukemia cells	MWnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NWXRR4hPOjRiaILz	NIDGXoxIem:5dHigbY5pcWKrdHnvckBw\iCMQVuyJHY3OTeIIH31eIFvfCCneIDy[ZN{cW6pIHj1cYFvKGW{eYTodo9t\XWtZX3pZUBk\WyuczDh[pRmeiB{NDDodpMtKEmFNUCgQUAzKM7:TT6=	MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzF5OEeyNkc,OTdzN{i3NlI9N2F-
erythroleukemia cells	M{fSfmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		Mm\jNlQhcHK\|	NEfyeVRIem:5dHigbY5pcWKrdHnvckBw\iCvb4Xz[UBmenm2aILvcIV2c2WvaXGgZ4VtdHNiYX\0[ZIhOjRiaILzMEBKSzVyIE2gNkDPxE1w	NHLuOJE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{G3PFczOid-MUexO\|g4OjJ:L3G+
COS7	NUjERYpPTnWwY4Tpc44h[XO\|YYm=			MWLJcohq[mm2aX;uJI9nKGi3bXHuJGpCUzJiVk[xO2YhdXW2YX70JIV5eHKnc4Pl[EBqdiCFT2O3JINmdGy\|LDDJR\|UxKD1iNDFOwG0v	NX33OlhKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUexO\|g4OjJpPkG3NVc5PzJ{PD;hQi=>
hematopoietic progenitor cells	NVfUXWE{T3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=			NIn0XpJIem:5dHigbY5pcWKrdHnvckBw\iCMQVuyJHY3OTeIIH31eIFvfCCneIDy[ZN{cW6pIHjlcYF1d3CxaXX0bYMheHKxZ3XubZRweiClZXzsd{Bqe2:uYYTl[EBnem:vIIDvcJlkgXSqZX3pZUB3\XKjIIDheIlmdnRiYomgZ49td267IH\vdo1qdmdiYYPzZZktKEmFNUCgQUA2KM7:TT6=	MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzF5OEeyNkc,OTdzN{i3NlI9N2F-
BA/F3	M3:zeGN6fG:2b4jpZ4l1gSCjc4PhfS=>			NFex[WJEgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBDSS:IMzDj[YxteyCneIDy[ZN{cW6pIFXHSnIhVDh3OGKgcZV1[W62LDDJR\|UxKD1iMD6wNVI2KM7:TT6=	M1TNd\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7MkO5NlI6Lz5zOUKzPVIzQTxxYU6=
A431	MojVR5l1d3SxeHnjbZR6KGG\|c3H5		MVe3NkBpenN?	MYDDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDBOFMyKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDTVmIh[XO\|YYmsJGlEPTBiPTCwMlA6PiEQvF2u	Mn\4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl6OEi3OlEoRjF7OEi4O\|YyRC:jPh?=
MCF7	MlnXRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		NHL5UG81QCCqcoO=	M{fsNmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTVPGO{Bk\WyuczDh[pRmeiB2ODDodpMh[nliTWTUJIF{e2G7LDDJR\|UxKD1iMD6wNkDPxE1w	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTlzNEizOUc,OTl7MUS4N\|U9N2F-
Sf9	NIfmfnpHfW6ldHnvckBie3OjeR?=			Mnu4TY5pcWKrdHnvckBw\iClbH;u[YQhTUeIUjDheZRweGixc4Doc5J6dGG2aX;uJIV5eHKnc4Pl[EBqdiCkYXP1cI93cXK3cz3pcoZm[3SnZDDT[lkh[2WubIOgZpkhe2:uaXStdIhie2ViRVzJV2EtKEmFNUCgQUAxNjB\|IN88UU4>	NYLaXYxLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm5NVQ5OzVpPkG5PVE1QDN3PD;hQi=>
Sf9	M2TNN2Z2dmO2aX;uJIF{e2G7			NYrCUHkxUW6qaXLpeIlwdiCxZjDoeY1idiClbH;u[YQhUEWUMjDheZRweGixc4Doc5J6dGG2aX;uJIV5eHKnc4Pl[EBqdiCkYXP1cI93cXK3cz3pcoZm[3SnZDDT[lkh[2WubIOgZpkhe2:uaXStdIhie2ViRVzJV2EtKEmFNUCgQUAxNjF4IN88UU4>	NG\IdXY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUmxOFg{PSd-MUm5NVQ5OzV:L3G+
MCF7	NX:2W5loSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		NEPi[oQ1QCCqcoO=	NUO5N3BySW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNR2Y4KGOnbHzzJIFnfGW{IES4JIhzeyCkeTDNWHQh[XO\|YYmsJGlEPTBiPTCwMlAyKM7:TT6=	M3vkeFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7OUG0PFM4Lz5zOUmxOFg{PzxxYU6=
Sf9	MlzrSpVv[3Srb36gZZN{[Xl?			MY\Jcohq[mm2aX;uJI9nKGOub37l[EBGT0[UIHH1eI9xcG:\|cHjvdplt[XSrb36g[ZhxemW\|c3XkJIlvKGKjY4Xsc5ZqenW\|LXnu[oVkfGWmIGPmPUBk\WyuczDifUB{d2yrZD3wbIF{\SCHTFnTRUwhUUN3MDC9JFAvODJizszNMi=>	MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTlzNEizO{c,OTl7MUS4N\|c9N2F-
Sf9	NHfISIZHfW6ldHnvckBie3OjeR?=			NXrreYVkUW6qaXLpeIlwdiCxZjDoeY1idiClbH;u[YQhUEWUMjDheZRweGixc4Doc5J6dGG2aX;uJIV5eHKnc4Pl[EBqdiCkYXP1cI93cXK3cz3pcoZm[3SnZDDT[lkh[2WubIOgZpkhe2:uaXStdIhie2ViRVzJV2EtKEmFNUCgQUAxNjF{IN88UU4>	MkPHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl7MUS4N\|coRjF7OUG0PFM4RC:jPh?=
MCF7	MYLBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		MlnWOFghcHK\|	M4C3N2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTVPGO{Bk\WyuczDh[pRmeiB2ODDodpMh[nliTWTUJIF{e2G7LDDJR\|UxKD1iMD6wNkDPxE1w	NVH3PZFSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkCwNFUyOTZpPkKwNFA2OTF4PD;hQi=>
NCI-H2122	MnfJRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?			MXPBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE6FST3INlEzOiClZXzsd{whUUN3MDC9JFEh\|ryPLh?=	NIHVcoY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEG0N\|c4QCd-MkCxOFM4Pzh:L3G+
SK-BR-3	NEXlPFRCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=			NYH5Nm5FSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDTT{1DWi1\|IHPlcIx{KGGodHXyJIhzeyCkeTDBWHAh[2:wdHXueEBie3OjeTygTWM2OCB;IEGuOVYh\|ryPLh?=	M37GRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyMUSzO\|c5Lz5{MEG0N\|c4QDxxYU6=
SCC15	NFzocVFCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=			MkTqRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCVQ1OxOUBk\WyuczygTWM2OCB;IEGuPVQh\|ryPLh?=	NF\rO\|I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEG0N\|c4QCd-MkCxOFM4Pzh:L3G+
SCC25	MkCzRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?			MXfBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFOFQ{K1JINmdGy\|LDDJR\|UxKD1iMz6zOEDPxE1w	NVTCW5ZDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkCxOFM4PzhpPkKwNVQ{Pzd6PD;hQi=>
NCI-H358	MXrBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?			NI\jeJlCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF7DTU1JOzV6IHPlcIx{KGGodHXyJIhzeyCkeTDBWHAh[2:wdHXueEBie3OjeTygTWM2OCB;IE[g{txONg>?	NIrLTZA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEG0N\|c4QCd-MkCxOFM4Pzh:L3G+
HCC827	Mn;3RY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?			MlOwRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCKQ1O4Nlch[2WubIOgZYZ1\XJiaILzJIJ6KEGWUDDjc451\W62IHHzd4F6NCCLQ{WwJF0hPy53IN88UU4>	M{fJb\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyMUSzO\|c5Lz5{MEG0N\|c4QDxxYU6=
BxPC3	NEK0e29CdnSrcILvcIln\XKjdHn2[UBie3OjeR?=			NXXQbGxESW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDCfHBEOyClZXzsd{Bi\nSncjDodpMh[nliQWTQJINwdnSnboSgZZN{[XluIFnDOVAhRSB5Lk[g{txONg>?	M1\5WFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyMUSzO\|c5Lz5{MEG0N\|c4QDxxYU6=
H460	M{nTPWFvfGmycn;sbYZmemG2aY\lJIF{e2G7			M2\zUWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSES2NEBk\WyuczDh[pRmeiCqcoOgZpkhSVSSIHPvcpRmdnRiYYPzZZktKEmFNUCgQUA5NjJizszNMi=>	M3zuV\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyMUSzO\|c5Lz5{MEG0N\|c4QDxxYU6=
CAL27	M1rtS2FvfGmycn;sbYZmemG2aY\lJIF{e2G7			Mo[5RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCFQVyyO{Bk\WyuczygTWM2OCB;IEGwMlE2KM7:TT6=	NFzNS5I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEG0N\|c4QCd-MkCxOFM4Pzh:L3G+
SKHEP1	M2XwcWFvfGmycn;sbYZmemG2aY\lJIF{e2G7			NHjhUVRCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGPLTGVROSClZXzsd{Bi\nSncjDodpMh[nliQWTQJINwdnSnboSgZZN{[XluIFnDOVAhRSBzMD6zO{DPxE1w	MoC5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjBzNEO3O\|goRjJyMUSzO\|c5RC:jPh?=
MDA-MB-468	NFTzN21CdnSrcILvcIln\XKjdHn2[UBie3OjeR?=			M3vSdGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTVTBMW1DNTR4ODDj[YxteyxiSVO1NEA:KDFzLkSg{txONg>?	MlTJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjBzNEO3O\|goRjJyMUSzO\|c5RC:jPh?=
LNCAP	MnixRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?			NGfoTmRCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFzOR2FRKGOnbHzzMEBKSzVyIE2gNVgvOzVizszNMi=>	Mon6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjBzNEO3O\|goRjJyMUSzO\|c5RC:jPh?=
A431	MVrGeY5kfGmxbjDhd5NigQ>?			M3;QXGlvcGmkaYTpc44hd2ZiRVfGVkBqdnS{YXPlcIx2dGG{IIDoc5NxcG:{eXzheIlwdiCrbjDoeY1idiCDNEOxJINmdGy\|IHL5JGVNUVODLDDJR\|UxKD1iMD6wN\|Qh\|ryPLh?=	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODN2Nk[1OUc,OjB\|NE[2OVU9N2F-
N87	M{LD[mZ2dmO2aX;uJIF{e2G7			NXT3elZ7UW6qaXLpeIlwdiCxZjDFdoJDOiCrboTyZYNmdGy3bHHyJJBpd3OyaH;yfYxifGmxbjDpckBpfW2jbjDOPFch[2WubIOgZpkhTUyLU1GsJGlEPTBiPTC1MlIh\|ryPLh?=	NUPI[oRRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkCzOFY3PTVpPkKwN\|Q3PjV3PD;hQi=>
A431	MkL2SpVv[3Srb36gZZN{[Xl?		NUnHRVh2OTBibXnudy=>	NV7Sd\|UxUW6qaXLpeIlwdiCxZjDFS2ZTKHCqb4PwbI9zgWyjdHnvckBqdiCqdX3hckBCPDNzIHPlcIx{KGGodHXyJFExKG2rboOgZpkhTkyLU1GsJGlEPTBiPTCxMlIh\|ryPLh?=	MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODRyM{ewNEc,OjB2MEO3NFA9N2F-
NCI-H661	M1HLb2N6fG:2b4jpZ4l1gSCjc4PhfS=>		M4rsdFQhfG9iNTDkZZl{	MojpR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUmNKNUh4NkGgZ4VtdHNiYX\0[ZIhPCC2bzC1JIRigXNiYomgUXRVKGG\|c3H5MEBKSzVyIE2gNVIvPzFizszNMi=>	M3jidFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyNE[2OVU2Lz5{MES2OlU2PTxxYU6=
DU145	NH;ZWllEgXSxdH;4bYNqfHliYYPzZZk>		MXy0JJRwKDViZHH5dy=>	M{jweGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGRWOTR3IHPlcIx{KGGodHXyJFQhfG9iNTDkZZl{KGK7IF3UWEBie3OjeTygTWM2OCB;IEG5MlQh\|ryPLh?=	NXK4SmFRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC0OlY2PTVpPkKwOFY3PTV3PD;hQi=>
A549	M3Plc2N6fG:2b4jpZ4l1gSCjc4PhfS=>		NYnDdGRkPCC2bzC1JIRigXN?	MnziR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gRVU1QSClZXzsd{Bi\nSncjC0JJRwKDViZHH5d{BjgSCPVGSgZZN{[XluIFnDOVAhRSB\|Mz6wN{DPxE1w	M1jaN\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyNE[2OVU2Lz5{MES2OlU2PTxxYU6=
PC3	NEjiTHJEgXSxdH;4bYNqfHliYYPzZZk>		NHvTUIc1KHSxIEWg[IF6ew>?	NFfudZBEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBRSzNiY3XscJMh[W[2ZYKgOEB1dyB3IHThfZMh[nliTWTUJIF{e2G7LDDJR\|UxKD1iM{[uO\|Yh\|ryPLh?=	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODR4NkW1OUc,OjB2Nk[1OVU9N2F-
A431	NG\KR\|RHfW6ldHnvckBie3OjeR?=			M{jKfGlvcGmkaYTpc44hd2ZiRVfGVkBmgHC{ZYPz[YQhcW5iaIXtZY4hSTR\|MTDj[YxteyxiSVO1NEA:KDFwMjFOwG0v	M{HqRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyNUW4NFczLz5{MEW1PFA4OjxxYU6=
MCF7	MXvBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		MmDROFghcHK\|	M4DYVGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTVPGO{Bk\WyuczDh[pRmeiB2ODDodpMh[nliTWTUJIF{e2G7LDDJR\|UxKD1iMD6wNkDPxE1w	MkPrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB3OUS4OVkoRjJyNUm0PFU6RC:jPh?=
Sf9	Mor5SpVv[3Srb36gZZN{[Xl?		Ml7HNUBpeg>?	MoH1TY5pcWKrdHnvckBw\iCqdX3hckBz\WOxbXLpcoFvfCCKaYO2fE11[WepZXSgSWdHWiCjdYTvdIhwe3Cqb4L5cIF1cW:wIHX4dJJme3OnZDDpckBU\jliY3XscJMh[W[2ZYKgNUBpeiCkeTDFUGlUSSxiSVO1NEA:KDBwMEOg{txONg>?	M1[wN\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyNUm0PFU6Lz5{MEW5OFg2QTxxYU6=
Sf9	NEP2O4hHfW6ldHnvckBie3OjeR?=		M2DJ[\|EhcHJ?	MonUTY5pcWKrdHnvckBw\iCqdX3hckBz\WOxbXLpcoFvfCCKaYO2fE11[WepZXSgTGVTOiCjdYTvdIhwe3Cqb4L5cIF1cW:wIHX4dJJme3OnZDDpckBU\jliY3XscJMh[W[2ZYKgNUBpeiCkeTDFUGlUSSxiSVO1NEA:KDBwMU[g{txONg>?	MkPGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB3OUS4OVkoRjJyNUm0PFU6RC:jPh?=
MCF7	MVXDfZRwfG:6aXPpeJkh[XO\|YYm=		NGPGclY1QCCqcoO=	MV7DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNR2Y4KGOnbHzzJIFnfGW{IES4JIhzeyCkeTDNWHQh[XO\|YYmsJGlEPTBiPTCwMlAzKM7:TT6=	NXm0OoF3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC2Nlc2QTdpPkKwOlI4PTl5PD;hQi=>
Sf9	NGThZWtHfW6ldHnvckBie3OjeR?=			NXnSbpJ7UW6qaXLpeIlwdiCxZjDobZN1cWSrbnWteIFo\2WmIILlZ49u[mmwYX70JGVITlJiYYX0c5Bpd3OyaH;yfYxifGmxbjDlfJBz\XO\|ZXSgbY4hW2Z7IHPlcIx{KGK7IIPvcIllNXCqYYPlJGVNUVODLDDJR\|UxKD1iMD6wN{DPxE1w	MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODZ{N{W5O{c,OjB4Mke1PVc9N2F-
MIAPaCa	M1T3ZmZ2dmO2aX;uJIF{e2G7			M1npWmlvcGmkaYTpc44hd2ZiRVfGVkBxcG:\|cHjvdplt[XSrb36gbY4hcHWvYX6gUWlCWGGFYTDj[YxteyCkeTDFUGlUSSxiSVO1NEA:KDBwMEWxJO69VS5?	MlXsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB6MUe1NlMoRjJyOEG3OVI{RC:jPh?=
MIAPaCa	NFX4bohHfW6ldHnvckBie3OjeR?=			NUHoS5J{UW6qaXLpeIlwdiCxZjDFVmJjOiCyaH;zdIhwenmuYYTpc44hcW5iaIXtZY4hVUmDUHHDZUBk\WyuczDifUBGVEmVQTygTWM2OCB;IE[uO\|Mh\|ryPLh?=	NFzi[o09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEixO\|UzOyd-MkC4NVc2OjN:L3G+
Sf9	NEPyTIdHfW6ldHnvckBie3OjeR?=		NFi0UIsyKGi{	M{PuS2lvcGmkaYTpc44hd2ZicnXjc41jcW6jboSgSWdHWiCneIDy[ZN{\WRiaX6gZoFkfWyxdnnyeZMhcW6oZXP0[YQhW2Z7IHPlcIx{KGGodHXyJFEhcHJiYomgSGVNTkmDL4TpcYUuemW\|b3z2[YQh\my3b4LpcYV1enliYYPzZZktKEmFNUCgQUAxNjB\|IN88UU4>	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTd4M{G0PEc,OjF5NkOxOFg9N2F-
A549	M2rCXGFvfGmycn;sbYZmemG2aY\lJIF{e2G7		MVe0PEBpenN?	NUfzXZlLSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDBOVQ6KGOnbHzzJIV5eHKnc4PpcochTUeIUjDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIHLhd4FtKGOnbHyg[5Jwf3SqIHHmeIVzKDR6IHjyd{BjgSCPVGSgZZN{[XluIFnDOVAhRSByLkK3JO69VS5?	M4nZW\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzN{[zNVQ5Lz5{MUe2N\|E1QDxxYU6=
MCF7	Mke4R5l1d3SxeHnjbZR6KGG\|c3H5		MYO0PEBpenN?	M3r0U2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1ETjdiY3XscJMh[W[2ZYKgOFghcHK\|IHL5JG1VXCCjc4PhfUwhUUN3MDC9JFAvODJizszNMi=>	NVvaRmdYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG4NFIzQTBpPkKxPFAzOjlyPD;hQi=>
Sf9	NFPGRlZHfW6ldHnvckBie3OjeR?=		NVXhNXZVOSCqch?=	MYXJcohq[mm2aX;uJI9nKEircz30ZYdo\WRiRVfGVkBmgHC{ZYPz[YQhcW5iaX7z[YN1KFOoOTDj[YxteyCjZoTldkAyKGi{IHL5JJRqdWVvcnXzc4x3\WRiZnz1c5JqdWW2cnnjJIFv[Wy7c3nzMEBKSzVyIE2gNE4xOyEQvF2u	M4PoN\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzOEG2OVE4Lz5{MUixOlUyPzxxYU6=
HepG2	M4H2RWFvfGmycn;sbYZmemG2aY\lJIF{e2G7		NVnsUINmPDhiaILz	NG\GWnJCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjldGczKGOnbHzzJIFnfGW{IES4JIhzeyCkeTDNWHQh[XO\|YYmsJGlEPTBiPTCwMlA5KM7:TT6=	NYHrZ2VGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG4NVY2OTdpPkKxPFE3PTF5PD;hQi=>
A16-F10	M1\OfWFvfGmycn;sbYZmemG2aY\lJIF{e2G7		NYSy[2JQPDhiaILz	M3vYNWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iQUG2MWYyOCClZXzsd{Bi\nSncjC0PEBpenNiYomgUXRVKGG\|c3H5MEBKSzVyIE2gNE4xOiEQvF2u	MmrPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJzMUK1OFEoRjJ{MUGyOVQyRC:jPh?=
Sf9	M1vRTGZ2dmO2aX;uJIF{e2G7		MYSxNEBucW6\|	MoT6TY5pcWKrdHnvckBw\iCHR1\SJIV5eHKnc4Pl[EBqdiCkYXP1cI93cXK3czDpcoZm[3SnZDDT[lkh[2WubIOgZZN{\XO\|ZXSgZZMhcW6qaXLpeIlwdiCxZjDheZRweGixc4Doc5J6dGG2aX;uJJBz\WmwY4XiZZRm\CCob4KgNVAhdWmwczDt[YF{fXKnZDDh[pRmeiBzIHjyJIJ6KESHTF\JRU9VcW2nLWLld49tfmWmIF\seY9zd22ndIL5MEBKSzVyIE2gNE4xOyEQvF2u	MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjFzMkW0NUc,OjJzMUK1OFE9N2F-
HepG2	MUfBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		MlPwOFghcHK\|	MXjBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEincFeyJINmdGy\|IHHmeIVzKDR6IHjyd{BjgSCPVGSgZZN{[XluIFnDOVAhRSByLkGyJO69VS5?	NFu0OIM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkGxNlU1OSd-MkKxNVI2PDF:L3G+
DIFI	NYjpNot3S3m2b4TvfIlkcXS7IHHzd4F6		NV3lVFhsPCCmYYnz	NFzkUGZEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBFUU[LIHPlcIx{KGGodHXyJFQh\GG7czDifUBxem:yaXTpeY0hcW:maXTlJJN1[WmwaX7nMYJie2WmIH\seY9zd22ndILpZ{BidmGueYPpd{whUUN3MDC9JFAvOTRizszNMi=>	MmrLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJzNkm2NFEoRjJ{MU[5OlAyRC:jPh?=
CAL27	NXTKe2Q{S3m2b4TvfIlkcXS7IHHzd4F6		MlvEOEBl[Xm\|	M17semN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGNCVDJ5IHPlcIx{KGGodHXyJFQh\GG7czDifUBxem:yaXTpeY0hcW:maXTlJJN1[WmwaX7nMYJie2WmIH\seY9zd22ndILpZ{BidmGueYPpd{whUUN3MDC9JFAvOjN7IN88UU4>	Mkm0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJzNkm2NFEoRjJ{MU[5OlAyRC:jPh?=
GXF251L	NHruVVhEgXSxdH;4bYNqfHliYYPzZZk>		MVm0JIRigXN?	NUjQNo1LS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hT1iIMkWxUEBk\WyuczDh[pRmeiB2IHThfZMh[nlicILvdIllcXWvIHnv[Ill\SC\|dHHpcolv\y2kYYPl[EBndHWxcn;t[ZRzcWNiYX7hcJl{cXNuIFnDOVAhRSByLkO2PUDPxE1w	M17sWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{MU[5OlAyLz5{MkG2PVYxOTxxYU6=
LXFA 629L	MVHDfZRwfG:6aXPpeJkh[XO\|YYm=		M4ftblQh\GG7cx?=	M2LXXmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGxZTkFiNkK5UEBk\WyuczDh[pRmeiB2IHThfZMh[nlicILvdIllcXWvIHnv[Ill\SC\|dHHpcolv\y2kYYPl[EBndHWxcn;t[ZRzcWNiYX7hcJl{cXNuIFnDOVAhRSByLk[2JO69VS5?	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjF4OU[wNUc,OjJzNkm2NFE9N2F-
DU145	M{HueGN6fG:2b4jpZ4l1gSCjc4PhfS=>		NF;JdZg1KGSjeYO=	NYfmeIc6S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hTFVzNEWgZ4VtdHNiYX\0[ZIhPCCmYYnzJIJ6KHC{b4Dp[Il2dSCrb3Tp[IUhe3SjaX7pcocu[mG\|ZXSg[ox2d3KxbXX0dolkKGGwYXz5d4l{NCCLQ{WwJF0hOC57Nk[g{txONg>?	MmW5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJzNkm2NFEoRjJ{MU[5OlAyRC:jPh?=
LXFA 289L	MY\DfZRwfG:6aXPpeJkh[XO\|YYm=		NEXVNWQ1KGSjeYO=	NX;nUGFtS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVFiIQTCyPFlNKGOnbHzzJIFnfGW{IESg[IF6eyCkeTDwdo9xcWSrdX2gbY9lcWSnIIP0ZYlvcW6pLXLhd4VlKG[udX;yc41mfHKrYzDhcoFtgXOrczygTWM2OCB;IEGuO\|gh\|ryPLh?=	NXjqTmFXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKxOlk3ODFpPkKyNVY6PjBzPD;hQi=>
LNCAP	M3LR[mN6fG:2b4jpZ4l1gSCjc4PhfS=>		NV\uVYUzPCCmYYnz	NFTLZodEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBNVkODUDDj[YxteyCjZoTldkA1KGSjeYOgZpkheHKxcHnkbZVuKGmxZHnk[UB{fGGrbnnu[{1j[XOnZDDmcJVwem:vZYTybYMh[W6jbInzbZMtKEmFNUCgQUA3NjZ\|IN88UU4>	MnjPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJzNkm2NFEoRjJ{MU[5OlAyRC:jPh?=
OVXF 899L	NYfHVY9zS3m2b4TvfIlkcXS7IHHzd4F6		NH\EUXk1KGSjeYO=	MlTTR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gU3ZZTiB6OUnMJINmdGy\|IHHmeIVzKDRiZHH5d{BjgSCycn;wbYRqfW1iaX;kbYRmKHO2YXnubY5oNWKjc3XkJIZtfW:{b33leJJq[yCjbnHsfZNqeyxiSVO1NEA:KDhwN{eg{txONg>?	NF\xTmI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkG2PVYxOSd-MkKxOlk3ODF:L3G+
PAXF 546L	NIP3W2ZEgXSxdH;4bYNqfHliYYPzZZk>		NUK3OZhmPCCmYYnz	NF3aT45EgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBRSViIIEW0Omwh[2WubIOgZYZ1\XJiNDDkZZl{KGK7IIDyc5Bq\Gm3bTDpc4Rq\GVic4ThbY5qdmdvYnHz[YQh\my3b4LvcYV1emmlIHHuZYx6e2m\|LDDJR\|UxKD1iMUCg{txONg>?	M2XWN\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{MU[5OlAyLz5{MkG2PVYxOTxxYU6=
RXF 486L	MYnDfZRwfG:6aXPpeJkh[XO\|YYm=		MlHjOEBl[Xm\|	NWLJZos2S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hWliIIES4Omwh[2WubIOgZYZ1\XJiNDDkZZl{KGK7IIDyc5Bq\Gm3bTDpc4Rq\GVic4ThbY5qdmdvYnHz[YQh\my3b4LvcYV1emmlIHHuZYx6e2m\|LDDJR\|UxKD1iMUCg{txONg>?	Mmn1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJzNkm2NFEoRjJ{MU[5OlAyRC:jPh?=
BXF T24	Mk\DR5l1d3SxeHnjbZR6KGG\|c3H5		M1G1WFQh\GG7cx?=	MX3DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDCXGYhXDJ2IHPlcIx{KGGodHXyJFQh\GG7czDifUBxem:yaXTpeY0hcW:maXTlJJN1[WmwaX7nMYJie2WmIH\seY9zd22ndILpZ{BidmGueYPpd{whUUN3MDC9JFE{NjlizszNMi=>	MmLoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJzNkm2NFEoRjJ{MU[5OlAyRC:jPh?=
CXF 269L	NH:3VIdEgXSxdH;4bYNqfHliYYPzZZk>		MX20JIRigXN?	MUjDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDDXGYhOjZ7TDDj[YxteyCjZoTldkA1KGSjeYOgZpkheHKxcHnkbZVuKGmxZHnk[UB{fGGrbnnu[{1j[XOnZDDmcJVwem:vZYTybYMh[W6jbInzbZMtKEmFNUCgQUAyPiEQvF2u	MlW1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJzNkm2NFEoRjJ{MU[5OlAyRC:jPh?=
PC3M	M3XkTmN6fG:2b4jpZ4l1gSCjc4PhfS=>		NXPibmNQPCCmYYnz	MoDNR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gVGM{VSClZXzsd{Bi\nSncjC0JIRigXNiYomgdJJweGmmaYXtJIlw\GmmZTDzeIFqdmmwZz3iZZNm\CCobIXvdo9u\XS{aXOgZY5idHm\|aYOsJGlEPTBiPTCxO{4zKM7:TT6=	NIW1dHk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkG2PVYxOSd-MkKxOlk3ODF:L3G+
LXFL 529L	NIi0TWpEgXSxdH;4bYNqfHliYYPzZZk>		M1j5T\|Qh\GG7cx?=	MnrDR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUHhHVCB3MknMJINmdGy\|IHHmeIVzKDRiZHH5d{BjgSCycn;wbYRqfW1iaX;kbYRmKHO2YXnubY5oNWKjc3XkJIZtfW:{b33leJJq[yCjbnHsfZNqeyxiSVO1NEA:KDF5LkSg{txONg>?	NW\RUJFnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKxOlk3ODFpPkKyNVY6PjBzPD;hQi=>
MEXF 276L	NYDyXHo1S3m2b4TvfIlkcXS7IHHzd4F6		NXS4VZp7PCCmYYnz	NHey[lFEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBOTViIIEK3Omwh[2WubIOgZYZ1\XJiNDDkZZl{KGK7IIDyc5Bq\Gm3bTDpc4Rq\GVic4ThbY5qdmdvYnHz[YQh\my3b4LvcYV1emmlIHHuZYx6e2m\|LDDJR\|UxKD1iMUiuOkDPxE1w	NV\WPFNERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKxOlk3ODFpPkKyNVY6PjBzPD;hQi=>
Saos2	NHfO[pNEgXSxdH;4bYNqfHliYYPzZZk>		M3S3VFQh\GG7cx?=	NFfuUm1EgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBU[W:\|MjDj[YxteyCjZoTldkA1KGSjeYOgZpkheHKxcHnkbZVuKGmxZHnk[UB{fGGrbnnu[{1j[XOnZDDmcJVwem:vZYTybYMh[W6jbInzbZMtKEmFNUCgQUAzOSEQvF2u	NEnEVFM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkG2PVYxOSd-MkKxOlk3ODF:L3G+
UXF 1138L	NEnx[JBEgXSxdH;4bYNqfHliYYPzZZk>		MYm0JIRigXN?	MV;DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDVXGYhOTF\|OFygZ4VtdHNiYX\0[ZIhPCCmYYnzJIJ6KHC{b4Dp[Il2dSCrb3Tp[IUhe3SjaX7pcocu[mG\|ZXSg[ox2d3KxbXX0dolkKGGwYXz5d4l{NCCLQ{WwJF0hOjRwNTFOwG0v	MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjF4OU[wNUc,OjJzNkm2NFE9N2F-
MAXF 401NL	M1W1SmN6fG:2b4jpZ4l1gSCjc4PhfS=>		NUXQU3M2PCCmYYnz	MkDxR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUWFZTiB2MEHOUEBk\WyuczDh[pRmeiB2IHThfZMh[nlicILvdIllcXWvIHnv[Ill\SC\|dHHpcolv\y2kYYPl[EBndHWxcn;t[ZRzcWNiYX7hcJl{cXNuIFnDOVAhRSB{NTFOwG0v	NXXoWVJiRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKxOlk3ODFpPkKyNVY6PjBzPD;hQi=>
MEXF 1341L	MoTYR5l1d3SxeHnjbZR6KGG\|c3H5		M{fwN\|Qh\GG7cx?=	NITObXFEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBOTViIIEGzOFFNKGOnbHzzJIFnfGW{IESg[IF6eyCkeTDwdo9xcWSrdX2gbY9lcWSnIIP0ZYlvcW6pLXLhd4VlKG[udX;yc41mfHKrYzDhcoFtgXOrczygTWM2OCB;IEOwMlEh\|ryPLh?=	MoDjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJzNkm2NFEoRjJ{MU[5OlAyRC:jPh?=
PXF 1752L	Mn3SR5l1d3SxeHnjbZR6KGG\|c3H5		M3zpNlQh\GG7cx?=	M2\MUmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHBZTiBzN{WyUEBk\WyuczDh[pRmeiB2IHThfZMh[nlicILvdIllcXWvIHnv[Ill\SC\|dHHpcolv\y2kYYPl[EBndHWxcn;t[ZRzcWNiYX7hcJl{cXNuIFnDOVAhRSB\|MT62JO69VS5?	NGD3Wos9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkG2PVYxOSd-MkKxOlk3ODF:L3G+
MDA231	M1PjN2N6fG:2b4jpZ4l1gSCjc4PhfS=>		Ml7EOEBl[Xm\|	NYHPfW1SS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVUSDMkOxJINmdGy\|IHHmeIVzKDRiZHH5d{BjgSCycn;wbYRqfW1iaX;kbYRmKHO2YXnubY5oNWKjc3XkJIZtfW:{b33leJJq[yCjbnHsfZNqeyxiSVO1NEA:KDN2LkWg{txONg>?	NYLuOoRmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKxOlk3ODFpPkKyNVY6PjBzPD;hQi=>
LXFL 1121L	MYTDfZRwfG:6aXPpeJkh[XO\|YYm=		NVfnZZZHPCCmYYnz	NXPaeXlCS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVFiITDCxNVIyVCClZXzsd{Bi\nSncjC0JIRigXNiYomgdJJweGmmaYXtJIlw\GmmZTDzeIFqdmmwZz3iZZNm\CCobIXvdo9u\XS{aXOgZY5idHm\|aYOsJGlEPTBiPTCzOE43KM7:TT6=	MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjF4OU[wNUc,OjJzNkm2NFE9N2F-
PXF 698L	NYX4RY1[S3m2b4TvfIlkcXS7IHHzd4F6		MlLlOEBl[Xm\|	MoLXR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gVHhHKDZ7OFygZ4VtdHNiYX\0[ZIhPCCmYYnzJIJ6KHC{b4Dp[Il2dSCrb3Tp[IUhe3SjaX7pcocu[mG\|ZXSg[ox2d3KxbXX0dolkKGGwYXz5d4l{NCCLQ{WwJF0hOzZwNDFOwG0v	M{GxVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{MU[5OlAyLz5{MkG2PVYxOTxxYU6=
RXF 393NL	M4\yWWN6fG:2b4jpZ4l1gSCjc4PhfS=>		NYntcGJmPCCmYYnz	NWDrPWFpS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hWliIIEO5N25NKGOnbHzzJIFnfGW{IESg[IF6eyCkeTDwdo9xcWSrdX2gbY9lcWSnIIP0ZYlvcW6pLXLhd4VlKG[udX;yc41mfHKrYzDhcoFtgXOrczygTWM2OCB;IES1MlYh\|ryPLh?=	NW[3R49IRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKxOlk3ODFpPkKyNVY6PjBzPD;hQi=>
LIXF 575L	NWfX[2hFS3m2b4TvfIlkcXS7IHHzd4F6		MWC0JIRigXN?	Ml\YR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUGlZTiB3N{XMJINmdGy\|IHHmeIVzKDRiZHH5d{BjgSCycn;wbYRqfW1iaX;kbYRmKHO2YXnubY5oNWKjc3XkJIZtfW:{b33leJJq[yCjbnHsfZNqeyxiSVO1NEA:KDR5LkKg{txONg>?	NEDzWII9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkG2PVYxOSd-MkKxOlk3ODF:L3G+
A431	MmLvSpVv[3Srb36gZZN{[Xl?		MVS2NEBucW6\|	M4LRbmlvcGmkaYTpc44hd2ZiRVfGVkB1gXKxc3nu[UBscW6jc3WgZYN1cX[rdImgbY4hTUeILYP0bY12dGG2ZXSgbJVu[W5iQUSzNUBk\WyuczDh[pRmeiB4MDDtbY5{KGK7IFXMTXNCNCCLQ{WwJF0hOS5{IN88UU4>	MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjJyNEe0NUc,OjJ{MES3OFE9N2F-
MCF7	NX\xS3BTSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		MnfpOFghcHK\|	NUC3PZNMSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNR2Y4KGOnbHzzJIFnfGW{IES4JIhzeyCkeTDNWHQh[XO\|YYmsJGlEPTBiPTCwMlAzKM7:TT6=	NFPzXVk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkK3O\|U5QCd-MkKyO\|c2QDh:L3G+
Sf9	NYq5VXhqTnWwY4Tpc44h[XO\|YYm=		M4LEWFEhcHJ?	MlLwTY5pcWKrdHnvckBw\iCjdYTvdIhwe3Cqb4L5cIF1cW:wIH;mJJJm[2:vYnnuZY51KEircz30ZYdo\WRiRVfGVkBmgHC{ZYPz[YQhcW5iYnHjeYxwfmm{dYOgbY5n\WO2ZXSgV4Y6KGOnbHzzJIFnfGW{IEGgbJIh[nliRFXMSmlCN3SrbXWtdoV{d2y4ZXSg[ox2d3KrbXX0dpkh[XO\|YYmsJGlEPTBiPTCwMlA{KM7:TT6=	MlzlQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ{N{e1PFgoRjJ{Mke3OVg5RC:jPh?=
Sf9	MmHhSpVv[3Srb36gZZN{[Xl?		Mnq4NUBpeg>?	MomwTY5pcWKrdHnvckBw\iCqaYP0bYRqdmVvdHHn[4VlKGi3bXHuJJJm[2:vYnnuZY51KGO7dH;wcIF{dWmlIHTvcYFqdiCxZjDFS2ZTKGW6cILld5Nm\CCrbjDiZYN2dG:4aYL1d{Bqdm[nY4Tl[EBqdnOnY4SgV4Y6KGOnbHzzJIFnfGW{IEGgbJIh[nliRFXMSmlCN3SrbXWtdoV{d2y4ZXSg[ox2d3KxbXX0dolkKGGwYXz5d4l{NCCLQ{WwJF0hOC5yMzFOwG0v	NYi5ZYllRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKzOlEzPzJpPkKyN\|YyOjd{PD;hQi=>
MCF7	Mn7kRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		NGnrTnk1QCCqcoO=	M2X2cWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTVPGO{Bk\WyuczDh[pRmeiB2ODDodpMh[nliTWTUJIF{e2G7LDDJR\|UxKD1iMD6wO{DPxE1w	NV3DSGhYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKzOlEzPzJpPkKyN\|YyOjd{PD;hQi=>
B16F10	M{DMfWFvfGmycn;sbYZmemG2aY\lJIF{e2G7		MkK1OFghcHK\|	MVXBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IH3veZNmKEJzNl[xNEBk\WyuczDh[pRmeiB2ODDodpMh[nliTWTUJIF{e2G7LDDJR\|UxKD1iMD6xJO69VS5?	NX7JSJU3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKzOlEzPzJpPkKyN\|YyOjd{PD;hQi=>
HCT116	NIHG[mFCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		M1q4XVQ5KGi{cx?=	MVnBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEiFVEGxOkBk\WyuczDh[pRmeiB2ODDodpMh[nliTWTUJIF{e2G7LDDJR\|UxKD1iMD6xOEDPxE1w	MmPMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ\|NkGyO\|IoRjJ{M{[xNlczRC:jPh?=
Sf9	NFrDfXlHfW6ldHnvckBie3OjeR?=		M3rw[lEhcHJ?	NYfvdFhrUW6qaXLpeIlwdiCxZjDobZN1cWSrbnWteIFo\2WmIHj1cYFvKHKnY3;tZolv[W62IHP5eI9xdGG\|bXnjJIRwdWGrbjDv[kBJTVJ{IHX4dJJme3OnZDDpckBj[WO3bH;2bZJ2eyCrbn\lZ5Rm\CCrboPlZ5QhW2Z7IHPlcIx{KGGodHXyJFEhcHJiYomgSGVNTkmDL4TpcYUuemW\|b3z2[YQh\my3b4LvcYV1emmlIHHuZYx6e2m\|LDDJR\|UxKD1iMD6xOEDPxE1w	NXvWW4ZoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKzOlEzPzJpPkKyN\|YyOjd{PD;hQi=>
A431	MVzDfZRwfG:6aXPpeJkh[XO\|YYm=		Ml22OFghcHK\|	NYPrRmtmS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hSTR\|MTDj[YxteyCxdnXyJIV5eHKnc4PpcochTUeIUjDh[pRmeiB2ODDodpMh[nliTWTUJIF{e2G7LDDJR\|UxKD1iMD6wOVUh\|ryPLh?=	MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjRzNE[xNkc,OjJ2MUS2NVI9N2F-
HEK293 Flp-In	NFP2T2hHfW6ldHnvckBie3OjeR?=		MoTqOUBucW6\|	M1\VXGlvcGmkaYTpc44hd2ZiaIXtZY4hdGm4ZYKgU2FVWDKEMTDlfJBz\XO\|ZXSgbY4hUEWNMkmzJGZteC2LbjDj[YxteyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gbY4hYzOKXVWzV{B2eHSja3WgbY5kfWKjdHXkJIZweiB3IH3pcpMh[nlic3PpcpRqdGyjdHnvckBkd3WwdHnu[{whUUN3MDC9JFAvPTVizszNMi=>	M{Xk[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{NUSxNFY5Lz5{MkW0NVA3QDxxYU6=
HEK293 Flp-In	NGnyeplHfW6ldHnvckBie3OjeR?=			MlXoTY5pcWKrdHnvckBw\iCqdX3hckBtcX[ncjDPRXRROUJzIHX4dJJme3OnZDDpckBJTUt{OUOgSoxxNUmwIHPlcIx{KGG\|c3Xzd4VlKGG\|IILl[JVkfGmxbjDpckBGOTdvYnX0ZWchfXC2YXvlJIJ6KHOlaX70bYxt[XSrb36gZ492dnSrbnesJGlEPTBiPTCyNUDPxE1w	M17DXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{NUSxNFY5Lz5{MkW0NVA3QDxxYU6=
HEK293 Flp-In	M1PqWmZ2dmO2aX;uJIF{e2G7		NGK2RpQ2KG2rboO=	MXTJcohq[mm2aX;uJI9nKGi3bXHuJIxqfmW{IF;BWHAySjNiZYjwdoV{e2WmIHnuJGhGUzJ7MzDGcJAuUW5iY3XscJMh[XO\|ZYPz[YQh[XNicnXkeYN1cW:wIHnuJHs{UF2HMUetZoV1[UdidYD0ZYtmKGmwY4XiZZRm\CCob4KgOUBucW6\|IHL5JJNkcW62aXzsZZRqd25iY3;1cpRqdmduIFnDOVAhRSB2NDFOwG0v	NGqwWJY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkW0NVA3QCd-MkK1OFExPjh:L3G+
A431	MXzGeY5kfGmxbjDhd5NigQ>?		M{i4dlYxKG2rboO=	M1jvRmlvcGmkaYTpc44hd2ZiRVfGVkBqdiCqdX3hckBCPDNzIHPlcIx{KHC{ZYTy[YF1\WRiZn;yJFYxKG2rboOgcYVie3W{ZXSgZYZ1\XJiMTDodkBjgSCHTFnTRUwhUUN3MDC9JFEvOiEQvF2u	NV[wdlVsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK3N\|kxQTBpPkKyO\|M6ODlyPD;hQi=>
SF539	Mn;ISpVv[3Srb36gZZN{[Xl?		MV[2NEBucW6\|	M2fEdmlvcGmkaYTpc44hd2ZiUFTHSnJj\XSjIHnuJIh2dWGwIGPGOVM6KGOnbHzzJJBz\XS{ZXH0[YQh\m:{IE[wJI1qdnNibXXhd5Vz\WRiYX\0[ZIhOSCqcjDifUBGVEmVQTygTWM2OCB;IEGyMlIh\|ryPLh?=	MlzOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ5M{mwPVAoRjJ{N{O5NFkxRC:jPh?=
PC9	NYjTe3B{TnWwY4Tpc44h[XO\|YYm=		MoXuNlQhcHK\|	NYTjd3ZjUW6qaXLpeIlwdiCxZjDFS2ZTKHCqb4PwbI9zgWyjdHnvckBqdiCqdX3hckBRSzliY3XscJMh[W[2ZYKgNlQhcHK\|IHL5JIJ6KFenc4Tldo4h[myxdDDhcoFtgXOrczygTWM2OCB;IEGuN\|Yh\|ryPLh?=	NIH6Spc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Mkm4NFIyQCd-MkK5PFAzOTh:L3G+
WM266.4	NX3kTm5tSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		NF73cWYzPCCqcoO=	M{n3SmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iV12yOlYvPCClZXzsd{Bi\nSncjCyOEBpenNiYomgUXRVKGG\|c3H5MEBKSzVyIE2gPE4xQSEQvF2u	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjl6NUm1O{c,OjJ7OEW5OVc9N2F-
MCF7	Ml;PRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		M3f1SVI1KGi{cx?=	M33qV2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTVPGO{Bk\WyuczDh[pRmeiB{NDDodpMh[nliTWTUJIF{e2G7LDDJR\|UxKD1iOD65O{DPxE1w	NX7OeG1KRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK5PFU6PTdpPkKyPVg2QTV5PD;hQi=>
Sf9	MlzmSpVv[3Srb36gZZN{[Xl?			MlrHTY5pcWKrdHnvckBw\iCHR1\SJIN6fG:ybHHzcYlkKGSxbXHpckAp[W2rbn:gZYNq\HNiNkS1JJRwKDFzOE[pJEh2dmuwb4fuJI9zcWerbjmg[ZhxemW\|c3XkJIlvKFOoOTDj[YxteyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gbY4h\W68eX3lJIF2fG:yaH;zdIhwenmuYYTpc44h[nliRFXMSmlCKHSrbXWgdoV{d2y4ZXSg[ox2d3KxbXX0dpktKEmFNUCgQUAxNjB\|IN88UU4>	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzJ2NUW3NEc,OjN{NEW1O\|A9N2F-
HepG2	MVjBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		Mn\oOFghcHK\|	MX;BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEincFeyJINmdGy\|IHHmeIVzKDR6IHjyd{BjgSCPVGSgZZN{[XluIFnDOVAhRSByLkGyJO69VS5?	MoDlQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN{NEW1O\|AoRjJ\|MkS1OVcxRC:jPh?=
A16-F10	M3ftfWFvfGmycn;sbYZmemG2aY\lJIF{e2G7		NXjId2pyPDhiaILz	MY\BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEFzNj3GNVAh[2WubIOgZYZ1\XJiNEigbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IECuNkDPxE1w	NIH3emc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{K0OVU4OCd-MkOyOFU2PzB:L3G+
MCF7	MmLDRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		M33GT\|Q5KGi{cx?=	NXnoeYRZSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNR2Y4KGOnbHzzJIFnfGW{IES4JIhzeyCkeTDNWHQh[XO\|YYmsJGlEPTBiPTCwMlAzKM7:TT6=	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzJ2NUiwNkc,OjN{NEW4NFI9N2F-
B16/F10	M4q5d2FvfGmycn;sbYZmemG2aY\lJIF{e2G7		MWW0PEBpenN?	M2SxbWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgcY92e2ViQkG2M2YyOCClZXzsd{Bi\nSncjC0PEBpenNiYomgUXRVKGG\|c3H5MEBKSzVyIE2gNE4xPSEQvF2u	MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzJ2NUiwNkc,OjN{NEW4NFI9N2F-
Sf9	Mnz5SpVv[3Srb36gZZN{[Xl?			NUTMNZF[UW6qaXLpeIlwdiCxZjDoeY1idiCKRWKyJIN6fG:ybHHzcYlkKGSxbXHpckAp[W2rbn:gZYNq\HNiNke2JJRwKDF{NEWpJIV5eHKnc4Pl[EBqdiCVZkmgZ4VtdHNiYomgSGVNTkmDIITpcYUhemW\|b3z2[YQh\my3b4LvcYV1enluIFnDOVAhRSByLkG2JO69VS5?	NF3URpg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{K0OVgxOid-MkOyOFU5ODJ:L3G+
A431	NIjyUlJHfW6ldHnvckBie3OjeR?=		M1S3U\|YxKG2rboO=	MVTJcohq[mm2aX;uJI9nKEWJRj3pcoR2[2WmIFXHSnIheGixc4Doc5J6dGG2aX;uJIlvKGi3bXHuJGE1OzFiY3XscJMhd3[ncnX4dJJme3OrbnegSWdHWiCycnX0doVifGWmIH\vdkA3OCCvaX7zJJBzcW:{IITvJGVITiCjZHTpeIlwdiCvZXHzeZJm\CCjZoTldkAyOCCvaX7zJIJ6KHCqb4PwbI91gXKxc3nu[UBGVEmVQTDjfZRw[myxdDDhcoFtgXOrczygTWM2OCB;IEGuNkDPxE1w	NVrlZoVyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOzO\|UxQTBpPkKzN\|c2ODlyPD;hQi=>
SF539	NEC3[3VHfW6ldHnvckBie3OjeR?=		NWnrWIV6PjBibXnudy=>	MUXJcohq[mm2aX;uJI9nKFCGR1[tRmIucW6mdXPl[EBRTEeIUjDi[ZRiKHCqb4PwbI9zgWyjdHnvckBqdiCqdX3hckBUTjV\|OTDj[YxteyCxdnXy[ZhxemW\|c3nu[{BRTEeIUjDi[ZRiKHC{ZYTy[YF1\WRiZn;yJFYxKG2rboOgdJJqd3JidH:gVGRITi2EQjDh[IRqfGmxbjDt[YF{fXKnZDDh[pRmeiBzMDDtbY5{KGK7IIDoc5NxcG:2eYLvd4lv\SCHTFnTRUBkgXSxYnzveEBidmGueYPpd{whUUN3MDC9JFEzNjJizszNMi=>	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzN5NUC5NEc,OjN\|N{WwPVA9N2F-
A431	M1\BTWZ2dmO2aX;uJIF{e2G7		M2fMdVYxKG2rboO=	MlvvTY5pcWKrdHnvckBw\iCHR1\SJIlvKGi3bXHuJGE1OzFiY3XscJMh[XO\|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBGT0ZvaX7keYNm\CC2eYLvd4lv\SCyaH;zdIhwenmuYYTpc44hcW6ldXLheIVlKG[xcjC2NEBucW6\|IIDybY9zKHSxIFXHSk1i[3SrdnH0bY9vKG2nYYP1doVlKDFyIH3pcpMh[nliRVzJV2EtKEmFNUCgQUAyNjJizszNMi=>	MlnNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN2M{SxN\|koRjJ\|NEO0NVM6RC:jPh?=
SF539	NHvoTYRHfW6ldHnvckBie3OjeR?=		NIjLO4c3OCCvaX7z	NVHXWFRqUW6qaXLpeIlwdiCxZjDQSGdHWmKndHGgbY4hcHWvYX6gV2Y2OzliY3XscJMh[XO\|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBRTEeIUj3CRk1qdmS3Y3XkJJR6em:\|aX7lJJBpd3OyaH;yfYxifGmxbjDpcoN2[mG2ZXSg[o9zKDZyIH3pcpMheHKrb4KgeI8hTUeILXHjeIl3[XSrb36gcYVie3W{ZXSgNVAhdWmwczDifUBGVEmVQTygTWM2OCB;IEGyMlIh\|ryPLh?=	NYPEdpk{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO0N\|QyOzlpPkKzOFM1OTN7PD;hQi=>
PC9	NFj2dZVHfW6ldHnvckBie3OjeR?=		MkjXNkBpenN?	M3e4eWlvcGmkaYTpc44hd2ZiRVfGVkBmgG:wIEG5JIRmdGW2aX;uJIFkfGm4YYTpcochdXW2YX70JJBpd3OyaH;yfYxifGmxbjDpckBpfW2jbjDQR\|kh[2WubIOgZYZ1\XJiMjDodpMh[nliZnz1c5Jme2OnbnPlJIF{e2G7LDDJR\|UxKD1iMD6wNFU6KM7:TT6=	M4rF[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OUOwPVk1Lz5{M{mzNFk6PDxxYU6=
LoVo	NXvMPWl2TnWwY4Tpc44h[XO\|YYm=		NV7rS41VOiCqcoO=	MXjJcohq[mm2aX;uJI9nKHerbHSgeJlx\SCHR1\SJJBpd3OyaH;yfYxifGmxbjDpckBpfW2jbjDMc3ZwKGOnbHzzJIFnfGW{IEKgbJJ{KGK7IH\seY9z\XOlZX7j[UBie3OjeTygTWM2OCB;IECuNFc4KM7:TT6=	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzl\|MEm5OEc,OjN7M{C5PVQ9N2F-
NCI-H1975	MVPGeY5kfGmxbjDhd5NigQ>?		M3HZVlIhcHK\|	NFnaWIVKdmirYnn0bY9vKG:oIFXHSnIhVDh3OGKvWFk4OE1iZH;1ZoxmKG23dHHueEBxcG:\|cHjvdplt[XSrb36gbY4hcHWvYX6gUmNKNUhzOUe1JINmdGy\|IHHmeIVzKDJiaILzJIJ6KG[udX;y[ZNk\W6lZTDhd5NigSxiSVO1NEA:KDdwNjFOwG0v	Mof4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN7M{C5PVQoRjJ\|OUOwPVk1RC:jPh?=
Sf9	M3rRWWZ2dmO2aX;uJIF{e2G7		NGjmWVgyOCCvaX7z	NIHmXFNKdmirYnn0bY9vKG:oIILlZ49u[mmwYX70JGVITlJia3nuZZNmKGO7dH;wcIF{dWmlIHTvcYFqdiBqdX7rco94diCxcnnnbY4qKGW6cILld5Nm\CCrbjDiZYN2dG:4aYL1d{BmgHC{ZYPzbY9vKH[nY4Tvdk1qdm[nY4Tl[EBqdnOnY4Sgd4Y6KGOnbHzzJIF{e2W\|c3XkJIF{KGyndnXsJI9nKGG3dH;wbI9{eGixconsZZRqd25iYX\0[ZIhOTBibXnud{BjgSCGRVzGTWEwfGmvZT3y[ZNwdH[nZDDmcJVwem:vZYTyfUwhUUN3MDC9JFAvODNizszNMi=>	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzl4Mk[2NEc,OjN7NkK2OlA9N2F-
HepG2	NILtVndCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		MlLBOFghcHK\|	Mo\vRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCKZYDHNkBk\WyuczDh[pRmeiB2ODDodpMh[nliTWTUJIF{e2G7LDDJR\|UxKD1iMD6xNkDPxE1w	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzl4Mk[2NEc,OjN7NkK2OlA9N2F-
A549	MkTyRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		M{T1W\|Q5KGi{cx?=	NXjtVol4SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDBOVQ6KGOnbHzzJIFnfGW{IES4JIhzeyCkeTDNWHQh[XO\|YYmsJGlEPTBiPTCwMlE{KM7:TT6=	NV\nclAzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO5OlI3PjBpPkKzPVYzPjZyPD;hQi=>
Sf9	NF7JWodHfW6ldHnvckBie3OjeR?=		MnftNVAhdWmwcx?=	MULJcohq[mm2aX;uJI9nKHKnY3;tZolv[W62IFXHSnIh[3m2b4DsZZNucWNiZH;tZYlvKCh4NEWgeI8hOTF6NjmgLJVvc26xd36gc5Jq\2mwKTDheZRweGixc4Doc5J6dGG2aX;uJIV5eHKnc4Pl[EBqdiCkYXP1cI93cXK3czDpcoZm[3SnZDDpcpNm[3RiU3[5JINmdGy\|IIDy[Ylv[3WkYYTl[EBnd3JiMUCgcYlveyCob3zsc5dm\CCkeTDBWHAuVWeFbEKgZYRlcXSrb36gcYVie3W{ZXSgZYZ1\XJiMTDodkBjgSCobIXvdo9u\XS{aXOgZY5idHm\|aYOsJGlEPTBiPTCwMlA{OiEQvF2u	NV;pelZRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSxOFQ5PTRpPkK0NVQ1QDV2PD;hQi=>
HepG2	NXjp[XdxS3m2b4TvfIlkcXS7IHHzd4F6		M3Pic\|Q5KGi{cx?=	MnuxR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTIVxTzJiY3XscJMh[XO\|ZYPz[YQh[XNiZ4Lve5RpKGmwaHnibZRqd25iYX\0[ZIhPDhiaILzJIJ6KE2WVDDhd5NigSxiSVO1NEA:KDBwMUKg{txONg>?	NYDvTWJWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSxOFQ5PTRpPkK0NVQ1QDV2PD;hQi=>
A549	MUHDfZRwfG:6aXPpeJkh[XO\|YYm=		NXHwdFRKPDhiaILz	NVjmbmtzS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hSTV2OTDj[YxteyCjc4Pld5Nm\CCjczDndo94fGhiaX7obYJqfGmxbjDh[pRmeiB2ODDodpMh[nliTWTUJIF{e2G7LDDJR\|UxKD1iMD6xN{DPxE1w	NGjQN4M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEG0OFg2PCd-MkSxOFQ5PTR:L3G+
A431	NHq3fI5CdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		M{n5OFczKGi{cx?=	MkK0RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCDNEOxJINmdGy\|IHHmeIVzKDd{IHjyd{BjgSCVUlKgZZN{[XluIFnDOVAhRSByLkSwPUDPxE1w	MlnBQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRzOEO3OFIoRjJ2MUizO\|QzRC:jPh?=
NCI-H1975	NXfqO\|BwSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		MoKzO\|IhcHK\|	MlfkRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCQQ1mtTFE6PzViY3XscJMh\XiycnXzd4lv\yCHR1\SJHQ4QTCPIH31eIFvfCCjZoTldkA4OiCqcoOgZpkhW1KEIHHzd4F6NCCLQ{WwJF0hPi57IN88UU4>	Mln4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRzOEO3OFIoRjJ2MUizO\|QzRC:jPh?=
KB	M1XmbGZ2dmO2aX;uJIF{e2G7		M3L3UVEhcHJ?	NGnI[nVKdmirYnn0bY9vKG:oIFXHSk1{fGmvdXzheIVlKGG3dH;wbI9{eGixconsZZRqd25ib3[gSWdHWiCrbjDoeY1idiCNQjDj[YxteyCrbnP1ZoF1\WRiZn;yJFEhcHJicILpc5IhfG9iRVfGJINp[WyuZX7n[UBu\WG\|dYLl[EBi\nSncjC2JI1qdnNiYomgSWxKW0FuIFnDOVAhRSByLkCxPUDPxE1w	NYHNW2xtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS0NVEyOjNpPkK0OFEyOTJ\|PD;hQi=>
A431	NF7ZRVVEgXSxdH;4bYNqfHliYYPzZZk>		MnjLO\|IhcHK\|	M1fHeWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGE1OzFiY3XscJMh\XiycnXzd4lv\yCHR1\SJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO\|YYmsJGlEPTBiPTCwMlc2KM7:TT6=	MnnHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR2MUGxNlMoRjJ2NEGxNVI{RC:jPh?=
Calu3	MmflR5l1d3SxeHnjbZR6KGG\|c3H5		NXXBN29ZPzJiaILz	NHHxc3JEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBE[Wy3MzDj[YxteyCneIDy[ZN{cW6pIFjFVlIh[W[2ZYKgO\|IhcHK\|IHL5JG1VXCCjc4PhfUwhUUN3MDC9JFAvQTNizszNMi=>	M3HFNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NEGxNVI{Lz5{NESxNVEzOzxxYU6=
NCI-H1975	MnntR5l1d3SxeHnjbZR6KGG\|c3H5		NHrhPIg4OiCqcoO=	M4K0NGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG5EUS2KMUm3OUBk\WyuczDlfJBz\XO\|aX7nJGVITlJiTEi1PHIwXDd7MF2gcZV1[W62IHHmeIVzKDd{IHjyd{BjgSCPVGSgZZN{[XluIFnDOVAhRSB3LkWxJO69VS5?	MnTSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR2MUGxNlMoRjJ2NEGxNVI{RC:jPh?=
A431	MX7BcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		MVe3NkBpenN?	M3TMTWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iQUSzNUBk\WyuczDhd5Nme3OnZDDhd{Boem:5dHigbY5pcWKrdHnvckBi\nSncjC3NkBpenNiYomgV3JDKGG\|c3H5MEBKSzVyIE2gNE42PiEQvF2u	NHH5[pU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEW2OVk3QSd-MkS1OlU6Pjl:L3G+
NCI-H1975	M1fhRmFvfGmycn;sbYZmemG2aY\lJIF{e2G7		NUGy[JdsPzJiaILz	M3LkbWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4Sg[4VncXSrbnniMZJme2m\|dHHueEBpfW2jbjDOR2kuUDF7N{WgZ4VtdHNiYYPz[ZN{\WRiYYOg[5Jwf3SqIHnubIljcXSrb36gZYZ1\XJiN{KgbJJ{KGK7IGPSRkBie3OjeTygTWM2OCB;IEeuNFYh\|ryPLh?=	NUSzS\|JURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS1OlU6PjlpPkK0OVY2QTZ7PD;hQi=>
Sf9	NYPue3d5TnWwY4Tpc44h[XO\|YYm=		M1;jUFEhcHJ?	M3T0fGlvcGmkaYTpc44hd2ZiYYX0c5Bpd3OyaH;yfYxifGmxbjDv[kBz\WOxbXLpcoFvfCCHR1\SJIN6fG:ybHHzcYlkKGSxbXHpckApPjR3IITvJFEyQDZrIDj1cotvd3ewIH;ybYdqdiliZYjwdoV{e2WmIHnuJHNnQSClZXzsd{Bi\nSncjCxJIhzKGK7IFTFUGZKSS:2aX3lMZJme2:udnXkJIZtfW:{b33leJJq[yCjbnHsfZNqeyxiSVO1NEA:KDBwMEOyJO69VS5?	MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDZyN{m5PEc,OjR4MEe5PVg9N2F-
HepG2	MVrBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		MonDOFghcHK\|	Mkm1RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCKZYDHNkBk\WyuczDh[pRmeiB2ODDodpMh[nliTWTUJIF{e2G7LDDJR\|UxKD1iMD6xNkDPxE1w	MoC5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR4MEe5PVgoRjJ2NkC3PVk5RC:jPh?=
A549	MmfGRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		MonCOFghcHK\|	NGLxO4tCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFG1OFkh[2WubIOgZYZ1\XJiNEigbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IECuNVMh\|ryPLh?=	M1\mUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NkC3PVk5Lz5{NE[wO\|k6QDxxYU6=
Sf9	MWrGeY5kfGmxbjDhd5NigQ>?		MYOxJIhz	MlrUTY5pcWKrdHnvckBw\iCjdYTvdIhwe3Cqb4L5cIF1cW:wIH;mJGVITlJiY4n0c5Bt[XOvaXOg[I9u[WmwIDjhcYlvdyCjY3nkd{A3PDVidH:gNVE5PiliKIXub45wf25ib4Lp[4lvMSCneIDy[ZN{\WRiaX6gV4Y6KGOnbHzzJIFnfGW{IEGgbJIh[nlidHnt[U1z\XOxbI\l[EBndHWxcn;t[ZRzgSxiSVO1NEA:KDBwMEOyJO69VS5?	M2j0OVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NkOwOFEzLz5{NE[zNFQyOjxxYU6=
HepG2	NWfFeoU2SW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		NGHIeYk1QCCqcoO=	NEKyN3pCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjldGczKGOnbHzzJIFnfGW{IES4JIhzeyCkeTDNWHQh[XO\|YYmsJGlEPTBiPTCwMlEzKM7:TT6=	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDZ\|MESxNkc,OjR4M{C0NVI9N2F-
A549	MXfBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		Mn72OFghcHK\|	M12zU2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iQUW0PUBk\WyuczDh[pRmeiB2ODDodpMh[nliTWTUJIF{e2G7LDDJR\|UxKD1iMD6xN{DPxE1w	M{fD[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NkOwOFEzLz5{NE[zNFQyOjxxYU6=
Sf9	MkfKSpVv[3Srb36gZZN{[Xl?		NHzaPZoyKGi{	NVvIZVB3UW6qaXLpeIlwdiCxZjDheZRweGixc4Doc5J6dGG2aX;uJI9nKGi3bXHuJGhGWjJiY4n0c5Bt[XOvaXOg[I9u[WmwIDjhcYlvdyCjY3nkd{A3PzZidH:gNVI1PSliKIXub45wf25ib4Lp[4lvMSCneIDy[ZN{\WRiaX6gV4Y6KGOnbHzzJIFnfGW{IEGgbJIh[nlidHnt[U1z\XOxbI\l[EBndHWxcn;t[ZRzgSxiSVO1NEA:KDBwMU[g{txONg>?	NHy4XJc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NE[zNFQyOid-MkS2N\|A1OTJ:L3G+
A431	NGHnO3JHfW6ldHnvckBie3OjeR?=			NXTkZoxCUW6qaXLpeIlwdiCxZjDFS2ZTKGmwIHj1cYFvKEF2M{GgZ4VtdHNiYomgdIhwe3Cqb4T5do9{cW6nIFXMTXNCKGG\|c3H5MEBKSzVyIE2gNE4xODF{IN88UU4>	NIWxRo49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEi5NFY2Oid-MkS4PVA3PTJ:L3G+
MCF7	MXPDfZRwfG:6aXPpeJkh[XO\|YYm=			M3;NOmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGVTNXCxc3n0bZZmKE2FRkegZ4VtdHNuIFnDOVAhRSByLkCwNVIh\|ryPLh?=	NULYUJhGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4PVA3PTJpPkK0PFkxPjV{PD;hQi=>
U251	M2DLcWZ2dmO2aX;uJIF{e2G7			M1rIVGlvcGmkaYTpc44hd2ZiVlXHSnIzKGmwIHj1cYFvKFV{NUGgZ4VtdHNiYomgdIhwe3Cqb4T5do9{cW6nIFXMTXNCKGG\|c3H5MEBKSzVyIE2gNE4yOjR5IN88UU4>	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh7ME[1Nkc,OjR6OUC2OVI9N2F-
MDA-MB-468	MULDfZRwfG:6aXPpeJkh[XO\|YYm=			NX7qR2xqS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hfHKrcHzlJI5m\2G2aY\lJG1FSS2PQj20Olgh[2WubIOsJGlEPTBiPTCwMlI{PTJizszNMi=>	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh7ME[1Nkc,OjR6OUC2OVI9N2F-
MDA-MB-231	NFXIPGZEgXSxdH;4bYNqfHliYYPzZZk>			NV7FemVGS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hfHKrcHzlJI5m\2G2aY\lJG1FSS2PQj2yN\|Eh[2WubIOsJGlEPTBiPTCwMlQ{QDVizszNMi=>	MmfLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6OUC2OVIoRjJ2OEmwOlUzRC:jPh?=
MDA-MB-435	MnnkR5l1d3SxeHnjbZR6KGG\|c3H5			M1HQS2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1FSS2PQj20N\|Uh[2WubIOsJGlEPTBiPTCwMlYzOjFizszNMi=>	NUHpRZdNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS4PVA3PTJpPkK0PFkxPjV{PD;hQi=>
HCC827	M1v0cWN6fG:2b4jpZ4l1gSCjc4PhfS=>		NFjqTlA1QCCqcoO=	M2LyVWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGhESzh{NzDj[YxteyCjZoTldkA1QCCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwJF0hOC5yMEKg{txONg>?	M1XHRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUCwPFMxLz5{NEmwNFg{ODxxYU6=
NCI-H1993	MXjDfZRwfG:6aXPpeJkh[XO\|YYm=		M4raPVQ5KGi{cx?=	MmrzR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUmNKNUhzOUmzJINmdGy\|IHHmeIVzKDR6IHjyd{BjgSCPVGSgZZN{[XluIFnDOVAhRSB{LkC0N{DPxE1w	NUnjfnZyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5NFA5OzBpPkK0PVAxQDNyPD;hQi=>
A549	M1vTeGN6fG:2b4jpZ4l1gSCjc4PhfS=>		MXm0PEBpenN?	NX\UcIJwS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hSTV2OTDj[YxteyCjZoTldkA1QCCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwJF0hPy5yOUmg{txONg>?	NV3lWYZNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5NFA5OzBpPkK0PVAxQDNyPD;hQi=>
NCI-H1975	MVPDfZRwfG:6aXPpeJkh[XO\|YYm=		MVO0PEBpenN?	MnrZR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUmNKNUhzOUe1JINmdGy\|IHHmeIVzKDR6IHjyd{BjgSCPVGSgZZN{[XluIFnDOVAhRSB5LkS5PEDPxE1w	MnTNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7MEC4N\|AoRjJ2OUCwPFMxRC:jPh?=
Sf9	NYTBenB4TnWwY4Tpc44h[XO\|YYm=			MnXYTY5pcWKrdHnvckBw\iCqaYP0bYRqdmVvdHHn[4VlKHKnY3;tZolv[W62IFXHSnIh[3m2b4DsZZNucWNiZH;tZYlvKCijbXnuc{Bi[2mmczC2OFUuOTF6NjmgLJVvc26xd36gc5Jq\2mwKTDlfJBz\XO\|ZXSgbY4hW2Z7IHPlcIx{KGG\|c3Xzd4VlKGG\|IILl[JVkfGmxbjDpckBmdnq7bXWgZZV1d3Cqb4PwbI9zgWyjdHnvckBjgSCGRVzGTWEwfGmvZT3y[ZNwdH[nZDDmcJVwem:vZYTyfUwhUUN3MDC9JFAvODNizszNMi=>	MkPnQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVzN{K0NlEoRjJ3MUeyOFIyRC:jPh?=
A549	MUnBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		M3fzNVQ5KGi{cx?=	MnjIRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCDNUS5JINmdGy\|IHHmeIVzKDR6IHjyd{BjgSCPVGSgZZN{[XluIFnDOVAhRSByLkGg{txONg>?	M{jRclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MUeyOFIyLz5{NUG3NlQzOTxxYU6=
HepG2	M2XxT2FvfGmycn;sbYZmemG2aY\lJIF{e2G7		Mo\HOFghcHK\|	M4C4TWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSHXwS\|Ih[2WubIOgZYZ1\XJiNEigbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IECuNUDPxE1w	NHTXZWM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUG3NlQzOSd-MkWxO\|I1OjF:L3G+
Sf9	NEHVcHhHfW6ldHnvckBie3OjeR?=			M2TvUWlvcGmkaYTpc44hd2ZiaHnzeIllcW6nLYTh[4dm\CC{ZXPvcYJqdmGwdDDISXIzKCi3bnvuc5dvKG:{aXfpckkh\XiycnXzd4VlKGmwIGPmPUBk\WyuczDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hcW5iZX76fY1mKGG3dH;wbI9{eGixconsZZRqd25iYomgSGVNTkmDL4TpcYUuemW\|b3z2[YQh\my3b4LvcYV1enluIFnDOVAhRSByLkKg{txONg>?	MkX4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVzN{K0NlEoRjJ3MUeyOFIyRC:jPh?=
NCI-H292	NVjBbVJYS3m2b4TvfIlkcXS7IHHzd4F6		NUfrTVZzPzJiaILz	NGTLeoNEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBPS0lvSEK5NkBk\WyuczDh[pRmeiB5MjDodpMh[nliU2LCJIF{e2G7LDDJR\|UxKD1iMTFOwG0v	M{C1cVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MkG1PFU3Lz5{NUKxOVg2PjxxYU6=
H460	MmPNR5l1d3SxeHnjbZR6KGG\|c3H5		MkHjO\|IhcHK\|	MmWyR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTFQ3OCClZXzsd{Bi\nSncjC3NkBpenNiYomgV3JDKGG\|c3H5MEBKSzVyIE2gPU42KM7:TT6=	M1O3NFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MkG1PFU3Lz5{NUKxOVg2PjxxYU6=
H460/Vbl	MnnkR5l1d3SxeHnjbZR6KGG\|c3H5		MYi3NkBpenN?	NUjjOWxmS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUDR4MD;WZowh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IGPSRkBie3OjeTygTWM2OCB;IEKxMlUh\|ryPLh?=	NULYUJlxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyNVU5PTZpPkK1NlE2QDV4PD;hQi=>
HT-29	NUfyZotQSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		MWm3NkBpenN?	MnzYRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCKVD2yPUBk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIHPlcIwheHKxbHnm[ZJifGmxbjD1coRmeiCwb4Ltc5hq[SClb37kbZRqd26\|IHHmeIVzKDd{IHjyd{BjgSCVUlKgZZN{[XluIFnDOVAhRSB{Lkm4JO69VS5?	Mkf3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV2NkiwOFQoRjJ3NE[4NFQ1RC:jPh?=
HT-29	M13ZcGFvfGmycn;sbYZmemG2aY\lJIF{e2G7		NYrFe4xMPzJiaILz	NFzxPHRCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjUMVI6KGOnbHzzJIF{e2W\|c3XkJIF{KGmwaHnibZRqd25ib3[gZ4VtdCCycn;sbYZmemG2aX;uJJVv\GW{IHj5dI95cWFiY3;u[Il1cW:wczDh[pRmeiB5MjDodpMh[nliU2LCJIF{e2G7LDDJR\|UxKD1iND6zO{DPxE1w	Mon1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV2NkiwOFQoRjJ3NE[4NFQ1RC:jPh?=
A549	NF3obXVCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		M4r3SVczKGi{cx?=	MWHBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEF3NEmgZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iClZXzsJJBzd2yrZnXyZZRqd25idX7k[ZIhdm:{bX;4bYEh[2:wZHn0bY9veyCjZoTldkA4OiCqcoOgZpkhW1KEIHHzd4F6NCCLQ{WwJF0hPy53OTFOwG0v	M13QO\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NE[4NFQ1Lz5{NUS2PFA1PDxxYU6=
A549	MnTzRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		NWL5T\|lSPzJiaILz	Ml3WRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCDNUS5JINmdGy\|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZiY3XscEBxem:uaX\ldoF1cW:wIIXu[IVzKGi7cH;4bYEh[2:wZHn0bY9veyCjZoTldkA4OiCqcoOgZpkhW1KEIHHzd4F6NCCLQ{WwJF0hQS5zIN88UU4>	M1q4NFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NE[4NFQ1Lz5{NUS2PFA1PDxxYU6=
A431	NHXGSVJHfW6ldHnvckBie3OjeR?=		M4W1[lYxKG2rbh?=	NELxTlhKdmirYnn0bY9vKG:oIFXHSnIhcW5iaIXtZY4hSTR\|MTDj[YxteyClb33wc5Vv\CCycnX0doVifGWmIH\vdkA3OCCvaX6gZoVnd3KnIFXHSkB{fGmvdXzheIlwdiCob4KgNVAhdWmwczDifUBxcG:\|cHjveJlzd3OrbnWgSWxKW0FiY4n0c4Jtd3RibXX0bI9lNCCLQ{WwJF0hOC5yMEGyJO69VS5?	MnfFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV6OEK1NVkoRjJ3OEiyOVE6RC:jPh?=
U251	MU\GeY5kfGmxbjDhd5NigQ>?		NFS2Ulc3OCCvaX6=	NU[5[HdIUW6qaXLpeIlwdiCxZjDWSWdHWjJiaX6gbJVu[W5iVUK1NUBk\WyuczDjc41xd3WwZDDwdoV1emWjdHXkJIZweiB4MDDtbY4h[mWob4LlJHZGT0Zic4TpcZVt[XSrb36g[o9zKDFyIH3pcpMh[nlicHjvd5Bpd3S7cn;zbY5mKEWOSWPBJIN6fG:kbH;0JI1mfGixZDygTWM2OCB;IECuNVI1PyEQvF2u	NEXnSGk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUi4NlUyQSd-MkW4PFI2OTl:L3G+
KB	MYDBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		MoDuOFghcHK\|	M3O5NmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iS1KgZ4VtdHNiZYjwdoV{e2mwZzDFS2ZTKGGwZDDTdoMh[W[2ZYKgOFghcHK\|IHL5JHNTSiCjc4PhfUwhUUN3MDC9JFUh\|ryPLh?=	NU\iPW0yRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[xPFg3OjBpPkK2NVg5PjJyPD;hQi=>
A498	NFXFblBCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		NVH3NXk6PDhiaILz	MXzBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEF2OUigZ4VtdHNiZYjwdoV{e2mwZzDFS2ZTKGGwZDDTdoMh[W[2ZYKgOFghcHK\|IHL5JHNTSiCjc4PhfUwhUUN3MDC9JFI2NjZizszNMi=>	M4fqT\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MUi4OlIxLz5{NkG4PFYzODxxYU6=
NCI-H292	NHryfHFHfW6ldHnvckBie3OjeR?=		MXyxJIhz	MkjhTY5pcWKrdHnvckBw\iCHR1\SJJBpd3OyaH;yfYxifGmxbjDpckBpfW2jbjDOR2kuUDJ7MjDj[YxteyCycnXpcoN2[mG2ZXSg[o9zKDFiaIKg[o9tdG:5ZXSgZpkhe3SrbYXsZZRqd25id3n0bEBGT0ZiZn;yJFghdWmwczDifUBmdGWldILvZ4hmdWmudX3pcoV{[2WwdDDpcY12dm:jc4PhfUwhUUN3MDC9JFAvODB4MzFOwG0v	M325cFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NEW1PVE6Lz5{NkS1OVkyQTxxYU6=
HCC827	NEfiSJZCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		NGKzcI84OiCqcoO=	MkC3RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCKQ1O4Nlch[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IFPDT{05KGG\|c3H5MEBKSzVyIE2gNE4xOjlizszNMi=>	NHnsOoI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkS4O\|kyPyd-Mk[0PFc6OTd:L3G+
A431	Mor4RY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		NF[2SIk4OiCqcoO=	MkD3RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCDNEOxJINmdGy\|IHHmeIVzKDd{IHjyd{BjgSCFQ1utPEBie3OjeTygTWM2OCB;IECuPFQ1KM7:TT6=	MkPSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ2OEe5NVcoRjJ4NEi3PVE4RC:jPh?=
PANC1	MnfZS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		MYS3NkBpenN?	M4DaTWdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJHBCVkNzIHPlcIx{KGGodHXyJFczKGi{czDifUBES0tvODDhd5NigSxiSVO1NEA:KDNwMTFOwG0v	NWPwZ\|IzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[1OFc3QTBpPkK2OVQ4PjlyPD;hQi=>
L3.6PL	MYHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NFm1cYc4OiCqcoO=	MkPBS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gUFMvPlCOIHPlcIx{KGGodHXyJFczKGi{czDifUBES0tvODDhd5NigSxiSVO1NEA:KDRizszNMi=>	M372clxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NUS3OlkxLz5{NkW0O\|Y6ODxxYU6=
PCI35	MnjCS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?		NYTybopkPzJiaILz	NFP6VXhIem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBRS0l\|NTDj[YxteyCjZoTldkA4OiCqcoOgZpkhS0ONLUigZZN{[XluIFnDOVAhRSB5Lkeg{txONg>?	NWHFd\|FoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[1OFc3QTBpPkK2OVQ4PjlyPD;hQi=>
PC9	MVPBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		MnH3PVYhcHK\|	M3XKR2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iUFO5JINmdGy\|IHHmeIVzKDl4IHjyd{BjgSCVeYTvfEBoemWnbjDtZZJs\XJiYnHz[YQh\my3b4Lld4NmdmOnIHHuZYx6e2m\|LDDJR\|UxKD1iMD6wO{DPxE1w	NEPT[og9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkW5PVU{Oid-Mk[1PVk2OzJ:L3G+
H9	MoGzRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		MmXZO\|IhcHK\|	NH\FXWdCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFi5JINmdGy\|IHHmeIVzKDd{IHjyd{BjgSCFZXzsWIl1\XJvR3zvJIF{e2G7LDDJR\|UxKD1iMT6zJO69VS5?	MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjV7OUWzNkc,OjZ3OUm1N\|I9N2F-
OVCAR3	NVHzb5JZSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		MWm3NkBpenN?	MoOyRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCRVlPBVlMh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IFPlcIxVcXSncj3HcI8h[XO\|YYmsJGlEPTBiPTC0MlYh\|ryPLh?=	NFrMW3U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkW5PVU{Oid-Mk[1PVk2OzJ:L3G+
Calu3	Ml\tRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		Moe0O\|IhcHK\|	MXjBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEOjbIWzJINmdGy\|IHHmeIVzKDd{IHjyd{BjgSCFZXzsWIl1\XJiYnz1[UBie3OjeTygTWM2OCB;IESuO{DPxE1w	Mmn1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ3OUm1N\|IoRjJ4NUm5OVMzRC:jPh?=
MRC5	M{T4dmFvfGmycn;sbYZmemG2aY\lJIF{e2G7		MnzBO\|IhcHK\|	M3rLNmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTWLDOUBk\WyuczDh[pRmeiB5MjDodpMh[nliQ3XscHRqfGW{LVfsc{Bie3OjeTygTWM2OCB;IEWuPEDPxE1w	M1K4SFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NUm5OVMzLz5{NkW5PVU{OjxxYU6=
U937	MXPBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		MYK3NkBpenN?	NWqzdplWSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDVPVM4KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDD[YxtXGm2ZYKgZox2\SCjc4PhfUwhUUN3MDC9JFkvQSEQvF2u	NFvsZZE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkW5PVU{Oid-Mk[1PVk2OzJ:L3G+
BT474	MUPBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		NEfUeYc4OiCqcoO=	NEjhNYtCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFLUOFc1KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDD[YxtXGm2ZYKgZox2\SCjc4PhfUwhUUN3MDC9JFE{KM7:TT6=	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjV7OUWzNkc,OjZ3OUm1N\|I9N2F-
FADU	MYHBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?			MXPBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE[DRGWgZ4VtdHNuIFnDOVAhRSBzODFOwG0v	NFTZcWM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkW5PVU{Oid-Mk[1PVk2OzJ:L3G+
MCF7	NYrGdJp[SW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		MlflNVIhcHK\|	M1[zZ2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTVPGO{Bk\WyuczDh[pRmeiBzMjDodpMh[nliTWTUJIF{e2G7LDDJR\|UxKD1iMD6xJO69VS5?	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjZ3MkS4Nkc,OjZ4NUK0PFI9N2F-
HepG2	NX;UU\|JkSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		NInKUocyOiCqcoO=	M1fmWGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSHXwS\|Ih[2WubIOgZYZ1\XJiMUKgbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IECuNVIh\|ryPLh?=	M2i1SFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NkWyOFgzLz5{Nk[1NlQ5OjxxYU6=
B16F10	NIjHcFJCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		M1m2e\|EzKGi{cx?=	MmqyRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDtc5V{\SCEMU\GNVAh[2WubIOgZYZ1\XJiMUKgbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IECuNVch\|ryPLh?=	NUHSWIxTRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[2OVI1QDJpPkK2OlUzPDh{PD;hQi=>
HeLa	Mn\TRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		NH7Gc3gyOiCqcoO=	M1\EfGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSHXMZUBk\WyuczDh[pRmeiBzMjDodpMh[nliTWTUJIF{e2G7LDDJR\|UxKD1iMD6yJO69VS5?	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjZ3MkS4Nkc,OjZ4NUK0PFI9N2F-
HCC827	NFO5RoRHfW6ldHnvckBie3OjeR?=		MViyJIhzew>?	M3nHNWlvcGmkaYTpc44hd2ZiRVfGVkBl\WyndHnvckBufXSjboSgZZV1d3Cqb4PwbI9zgWyjdHnvckBqdiCqdX3hckBJS0N6MkegZ4VtdHNiYX\0[ZIhOiCqcoOgZpkhe2GwZIfpZ4ghTUyLU1GsJGlEPTBiPTCwMlAxQCEQvF2u	NHTYbHA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nke1OlIzOid-Mk[3OVYzOjJ:L3G+
H3255	M3W0R2Z2dmO2aX;uJIF{e2G7		NUftc2h{OiCqcoO=	MVnJcohq[mm2aX;uJI9nKEWJRmKgUFg2QFJibYX0ZY51KGG3dH;wbI9{eGixconsZZRqd25iaX6gbJVu[W5iSEOyOVUh[2WubIOgZYZ1\XJiMjDodpMh[nlic3Hu[Jdq[2hiRVzJV2EtKEmFNUCgQUAxNjBzIN88UU4>	MmDrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ5NU[yNlIoRjJ4N{W2NlIzRC:jPh?=
PC9	MmX6SpVv[3Srb36gZZN{[Xl?		NHTJcoMzKGi{cx?=	M3frXGlvcGmkaYTpc44hd2ZiRVfGVkBl\WyndHnvckBufXSjboSgZZV1d3Cqb4PwbI9zgWyjdHnvckBqdiCqdX3hckBRSzliY3XscJMh[W[2ZYKgNkBpenNiYomgd4Fv\HerY3igSWxKW0FuIFnDOVAhRSByLkCxNUDPxE1w	MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjd3NkKyNkc,OjZ5NU[yNlI9N2F-
A549	M1HUSmZ2dmO2aX;uJIF{e2G7			NWH1TlN1UW6qaXLpeIlwdiCxZjDFS2Yue3SrbYXsZZRm\CC5aXzkJJR6eGViRVfGVkBifXSxcHjvd5Bpd3K7bHH0bY9vKGW6cILld5Nm\CCrbjDoeY1idiCDNUS5JINmdGy\|IHL5JJNidmS5aXPoJGVNUVODLDDJR\|UxKD1iMD6wNVEh\|ryPLh?=	NIfpZnU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Nke1OlIzOid-Mk[3OVYzOjJ:L3G+
NCI-H1975	M1LhWWZ2dmO2aX;uJIF{e2G7		M1zBb\|IhcHK\|	M{P1TGlvcGmkaYTpc44hd2ZiRVfGVkBNQDV6Uj;UO\|kxVSCmb4XicIUhdXW2YX70JIF2fG:yaH;zdIhwenmuYYTpc44hcW5iaIXtZY4hVkOLLVixPVc2KGOnbHzzJIFnfGW{IEKgbJJ{KGK7IIPhcoR4cWOqIFXMTXNCNCCLQ{WwJF0hQSEQvF2u	MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjd3NkKyNkc,OjZ5NU[yNlI9N2F-
PC9-DRH	NFnGWpBHfW6ldHnvckBie3OjeR?=		M2XMNFIhcHK\|	MW\Jcohq[mm2aX;uJI9nKEWJRmKg[IVt\XSrb36vWFc6OE1ibYX0ZY51KGG3dH;wbI9{eGixconsZZRqd25iaX6gbJVu[W5iUFO5MWRTUCClZXzsd{Bi\nSncjCyJIhzeyCkeTDzZY5lf2mlaDDFUGlUSSxiSVO1NEA:KDlwNzFOwG0v	M2q0OFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4N{W2NlIzLz5{Nke1OlIzOjxxYU6=
A549	M4XVdmFvfGmycn;sbYZmemG2aY\lJIF{e2G7		M3jiZlQ5KGi{cx?=	NHrWRVZCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFG1OFkh[2WubIOgZZN{\XO\|ZXSgZZMhfmmjYnzlJINmdGy\|IHHmeIVzKDR6IHjyd{BjgSCFQ1u4JIF{e2G7LDDJR\|UxKD1iNj6yOkDPxE1w	M4DSfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4OEe5N\|E1Lz5{Nki3PVMyPDxxYU6=
NCI-H358	M3vVWWFvfGmycn;sbYZmemG2aY\lJIF{e2G7		MlLzOFghcHK\|	NWjHbo1HSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDOR2kuUDN3ODDj[YxteyCjc4Pld5Nm\CCjczD2bYFjdGViY3XscJMh[W[2ZYKgOFghcHK\|IHL5JGNEUzhiYYPzZZktKEmFNUCgQUA3Njh3IN88UU4>	M{DvNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4OEe5N\|E1Lz5{Nki3PVMyPDxxYU6=
HepG2	MUjBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		MUe0PEBpenN?	MVTBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEincFeyJINmdGy\|IHHmeIVzKDR6IHjyd{BjgSCPVGSgZZN{[XluIFnDOVAhRSB3Lkig{txONg>?	NX3hZZpxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[4PVY4ODhpPkK2PFk3PzB6PD;hQi=>
LO2	NIXZS5lEgXSxdH;4bYNqfHliYYPzZZk>		M4HXdlQ5KGi{cx?=	NGTxVo5EgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBNVzJiY3XscJMh[W[2ZYKgOFghcHK\|IHL5JG1VXCCjc4PhfUwhUUN3MDC9JFE5NjVizszNMi=>	MmLRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ6OU[3NFgoRjJ4OEm2O\|A5RC:jPh?=
NCI-H358	MXnBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		NU[w[o41PDhiaILz	M{\mR2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTlPJMWg{PThiY3XscJMh[XO\|ZYPz[YQh[XNicnXkeYN1cW:wIHnuJINmdGxidnnhZoltcXS7IHHmeIVzKDR6IHjyd{BjgSClY3u4JIF{e2G7LDDJR\|UxKD1iMz65NUDPxE1w	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzJ\|NEi4O{c,Ojd{M{S4PFc9N2F-
A549	M2rORWFvfGmycn;sbYZmemG2aY\lJIF{e2G7		NYLZZYhNPDhiaILz	M4DjRWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iQUW0PUBk\WyuczDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hcW5iY3XscEB3cWGkaXzpeJkh[W[2ZYKgOFghcHK\|IHL5JINkczhiYYPzZZktKEmFNUCgQUA4NjN3IN88UU4>	MorpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd{M{S4PFcoRjJ5MkO0PFg4RC:jPh?=
BA/F3	MlT1SpVv[3Srb36gZZN{[Xl?		MUC0PEBpenN?	NH7OfFdKdmirYnn0bY9vKG:oIFXHSnIhVDh3OGKgcZV1[W62IDj1cotvd3ewIH;ybYdqdiliZYjwdoV{e2WmIHnuJI1wfXOnIFLBM2Y{KGOnbHzzJIF{e2W\|c3XkJIF{KHKnZIXjeIlwdiCrbjDj[YxtKH[rYXLpcIl1gSCjZoTldkA1QCCqcoOgZpkhYFSWIHHzd4F6NCCLQ{WwJF0hOC5yOEeg{txONg>?	NXLWbVVNRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkeyN\|U5PDFpPkK3NlM2QDRzPD;hQi=>
A431	M{DHe2Z2dmO2aX;uJIF{e2G7		M4\jeVYxKG2rboO=	MYDJcohq[mm2aX;uJI9nKEWJRmKgbY4hcHWvYX6gRVQ{OSClZXzsd{Bie3Onc4Pl[EBieyC{ZXT1Z5Rqd25iaX6gSWdHKGmwZIXj[YQheGixc4Doc5J6dGG2aX;uJJBz\WmwY4XiZZRm\CCob4KgOlAhdWmwczDmc4xtd3enZDDifUBGT0ZiYXTkbZRqd25ibXXhd5Vz\WRiYX\0[ZIhOTBibXnud{BjgSCHTFnTRUBu\XSqb3SsJGlEPTBiPTCwMlAxOTJizszNMi=>	NYTwSGI4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMke4PVQ2QDlpPkK3PFk1PTh7PD;hQi=>
HEK293	Mon3SpVv[3Srb36gZZN{[Xl?		NFi3bHgzKG2rboO=	MUDJcohq[mm2aX;uJI9nKGi3bXHuJG9EXDFiZYjwdoV{e2WmIHnuJGhGUzJ7MzDj[YxteyCjc4Pld5Nm\CCjczDk[YNz\WG\|ZTDpckB2eHSja3Wgc4YhSVOSKzDh[pRmeiB{IH3pcpMh[nliZnz1c5Jme2OnbnPlJIF{e2G7LDDJR\|UxKD1iMU[uNkDPxE1w	M4PhOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MkOwPVg2Lz5{OEKzNFk5PTxxYU6=
H3255	MmnnSpVv[3Srb36gZZN{[Xl?		M{PDc\|IhcHK\|	MXfJcohq[mm2aX;uJI9nKEWJRmKgUFg2QFJibYX0ZY51KHCqb4PwbI9zgWyjdHnvckBqdiCqdX3hckBJOzJ3NTDj[YxteyCycnXpcoN2[mG2ZXSg[o9zKDJiaILzJIZwdGyxd3XkJIJ6KEWJRjDzeIlufWyjdHnvckBnd3JiMUCgcYlveyCkeTDzZY5lf2mlaDDFUGlUSSxiSVO1NEA:KDBwMEGg{txONg>?	Mm\rQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh{OEe3N\|AoRjJ6Mki3O\|MxRC:jPh?=
A549	NFHkcm9HfW6ldHnvckBie3OjeR?=		NIrXd2czKGi{cx?=	NEflOWRKdmirYnn0bY9vKG:oIFXHSk1{fGmvdXzheIVlKHerbHSteJlx\SCHR1\SJJBpd3OyaH;yfYxifGmxbjDpckBpfW2jbjDBOVQ6KGOnbHzzJJBz\WmwY4XiZZRm\CCob4KgNkBpenNiZn;scI94\WRiYomgSWdHKHO2aX31cIF1cW:wIH\vdkAyOCCvaX7zJIJ6KHOjbnT3bYNpKEWOSWPBMEBKSzVyIE2gNE4xOTFizszNMi=>	NYHxdpNWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiyPFc4OzBpPkK4Nlg4PzNyPD;hQi=>
PC9	M{Xnb2Z2dmO2aX;uJIF{e2G7		NV;GWpoyOiCqcoO=	NYL3fZFOUW6qaXLpeIlwdiCxZjDFS2ZTKGW6b36gNVkh\GWuZYTpc44hdXW2YX70JJBpd3OyaH;yfYxifGmxbjDpckBpfW2jbjDQR\|kh[2WubIOgdJJmcW6ldXLheIVlKG[xcjCyJIhzeyCob3zsc5dm\CCkeTDFS2Yhe3SrbYXsZZRqd25iZn;yJFExKG2rboOgZpkhe2GwZIfpZ4ghTUyLU1GsJGlEPTBiPTCwMlAyOSEQvF2u	NVTt[m9tRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiyPFc4OzBpPkK4Nlg4PzNyPD;hQi=>
H1975	MmXMSpVv[3Srb36gZZN{[Xl?		NFK2XYwzKGi{cx?=	MWXJcohq[mm2aX;uJI9nKEWJRmKgWFc6OE1xTEi1PHIh\G:3YnzlJI12fGGwdDDwbI9{eGixconsZZRqd25iaX6gbJVu[W5iSEG5O\|Uh[2WubIOgdJJmcW6ldXLheIVlKG[xcjCyJIhzeyCob3zsc5dm\CCkeTDFS2Yhe3SrbYXsZZRqd25iZn;yJFExKG2rboOgZpkhe2GwZIfpZ4ghTUyLU1GsJGlEPTBiPTC5MlAxOyEQvF2u	NYXBbpl3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkiyPFc4OzBpPkK4Nlg4PzNyPD;hQi=>
PC9-DRH	NV\BXY5oTnWwY4Tpc44h[XO\|YYm=		NEe1[mUzKGi{cx?=	MYHJcohq[mm2aX;uJI9nKEWJRmKgWFc6OE1xZYjvckAyQSCmZXzleIlwdiCvdYThcpQheGixc4Doc5J6dGG2aX;uJIlvKGi3bXHuJHBEQS2GUligZ4VtdHNicILlbY5kfWKjdHXkJIZweiB{IHjyd{Bnd2yub4fl[EBjgSCHR1[gd5RqdXWuYYTpc44h\m:{IEGwJI1qdnNiYomgd4Fv\HerY3igSWxKW0FuIFnDOVAhRSB7LkezOkDPxE1w	M3fRSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6Mki3O\|MxLz5{OEK4O\|c{ODxxYU6=
Sf9	MVfGeY5kfGmxbjDhd5NigQ>?		MonlNVAhdWmwcx?=	M2nXXWlvcGmkaYTpc44hd2ZiSHnzOk11[WepZXSgdoVkd22kaX7hcpQhTUeIUjDjfZRweGyjc33pZ{Bld22jaX6gLJVvc26xd36gc5Jq\2mwKTCoOlQ2KHSxIEGxPFYhemW\|aXT1[ZMqKGW6cILld5Nm\CCrbjDiZYN2dG:4aYL1d{Bqdm[nY4Tl[EBU\i17IHPlcIx{KHC{ZXnuZ5Vj[XSnZDDmc5IhOTBibXnud{Bnd2yub4fl[EBjgSCDVGCgZYRlcXSrb36gcYVie3W{ZXSgZYZ1\XJiMTDodkBjgSCGRVzGTWEwXGmvZT3S[ZNwdH[nZDDmcJVwem:vZYTyfUwhUUN3MDC9JFAvODZizszNMi=>	MUK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDR\|MUO1N{c,Ojh2M{GzOVM9N2F-
HepG2	M1L4OmN6fG:2b4jpZ4l1gSCjc4PhfS=>		MWSyOEBpenN?	M1q2e2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGhmeEd{IHPlcIx{KGG\|c3Xzd4VlKGG\|IHTlZ5Jm[XOnIHnuJINmdGxidnnhZoltcXS7IHHmeIVzKDJ2IHjyd{BjgSC\|cHXjeJJweGixdH;t[ZRzgSxiSVO1NEA:KDJ3IN88UU4>	M36wSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NEi3NVI4Lz5{OES4O\|EzPzxxYU6=
A549	M2KybWFvfGmycn;sbYZmemG2aY\lJIF{e2G7		NIi4Slk4OiCqcoO=	MVXBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEF3NEmgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KE2WVDDhd5NigSxiSVO1NEA:KDJzLkOg{txONg>?	NVTFfI1TRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki4PFY2ODlpPkK4PFg3PTB7PD;hQi=>
MDA-MB-231	MXzBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		MW[3NkBpenN?	MXrBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2GQT3NRk0zOzFiY3XscJMhcW6ldXLheIVlKG[xcjC3NkBpenNiYomgUXRVKGG\|c3H5MEBKSzVyIE2gN\|AvOTJizszNMi=>	M{\BSFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6OUKzN\|g{Lz5{OEmyN\|M5OzxxYU6=
MDA-MB-231	M2PySGFvfGmycn;sbYZmemG2aY\lJIF{e2G7		NIG5Z5I1QCCqcoO=	M1\XdmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTVTBMW1DNTJ\|MTDj[YxteyCrbnP1ZoF1\WRiZn;yJFQ5KGi{czDifUBOXFRiYYPzZZktKEmFNUCgQUA{Oy52NjFOwG0v	M3zJXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6OUKzN\|g{Lz5{OEmyN\|M5OzxxYU6=
MCF7	NV3POFRWSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		MYG0PEBpenN?	MnT5RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCPQ1[3JINmdGy\|IHHmeIVzKDR6IHjyd{BjgSCPVGSgZZN{[XluIFnDOVAhRSByLkC4JO69VS5?	NGr0NZg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEm4PFYzPCd-Mki5PFg3OjR:L3G+
B16F10	NIfJU3RCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		MVe0PEBpenN?	NInKS5BCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JI1wfXOnIFKxOmYyOCClZXzsd{Bi\nSncjC0PEBpenNiYomgUXRVKGG\|c3H5MEBKSzVyIE2gNE4yOiEQvF2u	MnnLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh7OEi2NlQoRjJ6OUi4OlI1RC:jPh?=
A549	MliwR5l1d3SxeHnjbZR6KGG\|c3H5		M13VflI1KGi{cx?=	M4jRN2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGE2PDliY3XscJMh[W[2ZYKgNlQhcHK\|IHL5JG1VXCCjc4PhfUwhUUN3MDC9JFAvPzNizszNMi=>	NV\yRnM1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkmwNlg2OzRpPkK5NFI5PTN2PD;hQi=>
A498	MlXqRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		NXrvV45KPDhiaILz	M4TQ[2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iQUS5PEBk\WyuczDh[pRmeiB2ODDodpMh[nliTWTUJIF{e2G7LDDJR\|UxKD1iMUKuOUDPxE1w	NGf2dWI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUC1O\|A1Oid-MkmwOVcxPDJ:L3G+
HuH7	Mne2RY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		NIXzN4Q1QCCqcoO=	MoWyRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCKdVi3JINmdGy\|IHHmeIVzKDR6IHjyd{BjgSCPVGSgZZN{[XluIFnDOVAhRSB{NTFOwG0v	NH\tfIg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUC1O\|A1Oid-MkmwOVcxPDJ:L3G+
NCI-H23	NFX0XllEgXSxdH;4bYNqfHliYYPzZZk>		MmjaOFYhcHK\|	NFvlWoxEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBPS0lvSEKzJINmdGy\|IHHzd4V{e2WmIHHzJJJm\HWldHnvckBqdiClZXzsJJZq[WKrbHn0fUBi\nSncjC0OkBpenNiYomgUXRVKGG\|c3H5MEBKSzVyIE2gOFkvOyEQvF2u	M{fpPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7MUO4NFI4Lz5{OUGzPFAzPzxxYU6=
HT-29	MXzBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		NUnPeJl3PDhiaILz	NIH4SVJCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBpfW2jbjDIWE0zQSClZXzsd{Bi\nSncjC0PEBpenNiYomgdJJweGmmaYXtJIlw\GmmZTDzeIFqdmmwZz3iZZNm\CCobIXvdoV{[2WwY3WgZZN{[XluIFnDOVAhRSByLkCyJO69VS5?	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTRyN{m1Okc,Ojl2MEe5OVY9N2F-
MIAPaCa2	MV7BcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		NHPOdZU1QCCqcoO=	MV\BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDoeY1idiCPSVHQZWNiOiClZXzsd{Bi\nSncjC0PEBpenNiYomgdJJweGmmaYXtJIlw\GmmZTDzeIFqdmmwZz3iZZNm\CCobIXvdoV{[2WwY3WgZZN{[XluIFnDOVAhRSByLkCzJO69VS5?	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTRyN{m1Okc,Ojl2MEe5OVY9N2F-
MCF7	NHHu[WhCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		NVfKeItxPDhiaILz	MWDBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDoeY1idiCPQ1[3JINmdGy\|IHHmeIVzKDR6IHjyd{BjgSCycn;wbYRqfW1iaX;kbYRmKHO2YXnubY5oNWKjc3XkJIZtfW:{ZYPj[Y5k\SCjc4PhfUwhUUN3MDC9JFAvODNizszNMi=>	MnmyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2MEe5OVYoRjJ7NEC3PVU3RC:jPh?=
PC3	NGHkb\|JCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		NWDoV4dQPDhiaILz	M4HpVWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIh2dWGwIGDDN{Bk\WyuczDh[pRmeiB2ODDodpMh[nlicILvdIllcXWvIHnv[Ill\SC\|dHHpcolv\y2kYYPl[EBndHWxcnXzZ4Vv[2ViYYPzZZktKEmFNUCgQUAxNjB\|IN88UU4>	MoGyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2MEe5OVYoRjJ7NEC3PVU3RC:jPh?=
A549	MYfBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		MYW0PEBpenN?	NVTWTI5rSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkhcHWvYX6gRVU1QSClZXzsd{Bi\nSncjC0PEBpenNiYomgdJJweGmmaYXtJIlw\GmmZTDzeIFqdmmwZz3iZZNm\CCobIXvdoV{[2WwY3WgZZN{[XluIFnDOVAhRSByLkC0JO69VS5?	NXrYb3BRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0NFc6PTZpPkK5OFA4QTV4PD;hQi=>
Sf9	MWXGeY5kfGmxbjDhd5NigQ>?		MX[xNEBucW6\|	M4nnc2lvcGmkaYTpc44hd2ZiSHnzOk11[WepZXSgSWdHWiBqdX7rco94diCxcnnnbY4qKGO7dH;wcIF{dWmlIHTvcYFqdiCneIDy[ZN{\WRiaX6gZoFkfWyxdnnyeZMhcW6oZXP0[YQhW2Z7IHnud4VkfCClZXzsd{Bi\nSncjCxNEBucW6\|IH\vcIxwf2WmIHL5JIFl\Gm2aX;uJI9nKEGWUD3N[2NtOiCjbnSgcYVie3W{ZXSgZYZ1\XJiMTDodkBjgSC2aX3lMZJme2:udnXkJIZtfW:{b33leJJq[yCjbnHsfZNqeyxiSVO1NEA:KDBwMEig{txONg>?	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTRyN{m1Okc,Ojl2MEe5OVY9N2F-
Sf9	NV;T[pFwTnWwY4Tpc44h[XO\|YYm=			M2qwbmlvcGmkaYTpc44hd2ZicnXjc41jcW6jboSg[pVtdC2uZX7neIghT1OWLYTh[4dm\CCqdX3hckBDNVKDRjDWOlAxTSCvdYThcpQhMDRzNzD0c{A4PjZicnXzbYR2\XNrIHX4dJJme3OnZDDpckBD[WO3bH;2bZJ2eyCrbn\lZ5Rm\CCVZkmgZ4VtdHNidYPpcochVi22ZYLtbY5idCCKaYOteIFo\2WmIHj1cYFvKE2HS{GgZZMhe3Wkc4TyZZRmKGK7IF71MZBi\2ViZ3XsMYJie2WmIIDoc5NxcG:{IIPjdoVmdiCjbnHsfZNqeyxiSVO1NEA:KDBwME[g{txONg>?	NYS4R\|lZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm1OFk5PDFpPkK5OVQ6QDRzPD;hQi=>
Sf9	Ml\oSpVv[3Srb36gZZN{[Xl?			M{HmdmlvcGmkaYTpc44hd2ZiSHnzMVYhfGGpZ3XkJJJm[2:vYnnuZY51KEWJRmKgZ5l1d3CuYYPtbYMh\G:vYXnuJEg3PDVidH:gNVE5PiC{ZYPp[JVmeyliKIXub45wf25ib4Lp[4lvMSCneIDy[ZN{\WRiaX6gRoFkfWyxdnnyeZMhcW6oZXP0[YQhW2Z7IHPlcIx{KGK7IHTpd5Nw[2mjdHnvck1mdmijbnPl[EBt[W62aHHubYRmKG[udX;y[ZNk\W6lZTDpcY12dm:jc4PhfU91cW2nLYLld49tfmWmIH\seY9zd22ndILpZ{BidmGueYPpd{whUUN3MDC9JFAvODhizszNMi=>	M1mwZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NUS5PFQyLz5{OUW0PVg1OTxxYU6=
A549	NYm3NIdxSW62aXPhcoNmeiCjc4PhfS=>		Mk\YPVYhcHK\|	MVPBcpRq[2GwY3XyJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iQUW0PUBk\WyuczDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hcW5iY3XscEB3cWGkaXzpeJkh[W[2ZYKgPVYhcHK\|IHL5JG1VXCCjc4PhfUwhUUN3MDC9JFE4NjN{IN88UU4>	M2TCVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NUS5PFQyLz5{OUW0PVg1OTxxYU6=
MCF7	MljjRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		NFnuOXM1QCCqcoO=	MnPURY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCPQ1[3JINmdGy\|IHHmeIVzKDR6IHjyd{BjgSCPVGSgZZN{[XluIFnDOVAhRSB{MDFOwG0v	MlPRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzByNEe0NVAoRjNyMES3OFExRC:jPh?=
HepG2	NHfsXJZCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		M{H6N\|Q5KGi{cx?=	NEjud41CdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjldGczKGOnbHzzJIFnfGW{IES4JIhzeyCkeTDNWHQh[XO\|YYmsJGlEPTBiPTCyOUDPxE1w	NVXGOnRiRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CwOFc1OTBpPkOwNFQ4PDFyPD;hQi=>
Sf9	Mnn3SpVv[3Srb36gZZN{[Xl?		NWjJZ5RuPSCvaX7z	MVzJcohq[mm2aX;uJI9nKHKnY3;tZolv[W62IHj1cYFvKEeVVD30ZYdo\WRiSFXSNkApPjd4LXXu[Ekh\XiycnXzd4VlKGmwIHLhZ5Vtd3[rcoXzJIlv\mWldHXkJHNnQSCrboPlZ5Qh[2WubIOgdJJmcW6ldXLheIVlKG[xcjC1JI1qdnNiZn;scI94\WRiYomgRXRRKGGmZHn0bY9vKGGwZDDt[YF{fXKnZDDh[pRmeiB\|MDDtbY5{KGK7IFjUVmYh[XO\|YYmsJGlEPTBiPTCwMlA6OSEQvF2u	NFzOTmI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9\|MEC5OlU5OCd-M{CwPVY2QDB:L3G+
Sf9	MX\GeY5kfGmxbjDhd5NigQ>?		NXOyb4hxPSCvaX7z	MWLJcohq[mm2aX;uJI9nKEeVVD30ZYdo\WRicnXjc41jcW6jboSgbJVu[W5iVlXHSnIhMDd6OT3lcoQqKGW6cILld5Nm\CCrbjDiZYN2dG:4aYL1d{Bqdm[nY4Tl[EBU\jliaX7z[YN1KGOnbHzzJJBz\WmwY4XiZZRm\CCob4KgOUBucW6\|IH\vcIxwf2WmIHL5JGFVWCCjZHTpeIlwdiCjbnSgcYVie3W{ZXSgZYZ1\XJiM{CgcYlveyCkeTDIWHJHKGG\|c3H5MEBKSzVyIE2gNE4zPSEQvF2u	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODB7NkW4NEc,OzByOU[1PFA9N2F-
A431	NEXSTIRHfW6ldHnvckBie3OjeR?=		NUXFSVh5PjBibXnudy=>	NXHDd3l4UW6qaXLpeIlwdiCxZjDFS2YucW6mdXPl[EBGT0[UIHHjeIl3[XSrb36gbY4hcHWvYX6gRVQ{OSClZXzsd{BxemW2cnXheIVlKG[xcjC2NEBucW6\|IH\vcIxwf2WmIHL5JGVITiCjZHTpeIlwdiCjbnSgcYVie3W{ZXSgZYZ1\XJiMUCgcYlveyCkeTDFUGlUSSxiSVO1NEA:KDBwMECxNkDPxE1w	MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODB7OEi2PUc,OzByOUi4Olk9N2F-
U251	NH:0RVhHfW6ldHnvckBie3OjeR?=		NYXHO5RiPjBibXnudy=>	NVrhd2xJUW6qaXLpeIlwdiCxZjDWSWdHNWmwZIXj[YQhXkWJRmKyJIFkfGm4YYTpc44hcW5iaIXtZY4hXTJ3MTDj[YxteyCycnX0doVifGWmIH\vdkA3OCCvaX7zJIZwdGyxd3XkJIJ6KF[HR1[gZYRlcXSrb36gZY5lKG2nYYP1doVlKGGodHXyJFExKG2rboOgZpkhTUyLU1GsJGlEPTBiPTCwMlEzPDdizszNMi=>	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODB7OEi2PUc,OzByOUi4Olk9N2F-
HEK293 Flp-In	M3jjOGZ2dmO2aX;uJIF{e2G7		MXW1JI1qdnN?	M1\2VGlvcGmkaYTpc44hd2ZiaIXtZY4hdGm4ZYKgU2FVWDKEMTDlfJBz\XO\|ZXSgbY4hUEWNMkmzJGZteC2LbjDj[YxteyCjc4Pld5Nm\CCjczDy[YR2[3Srb36gbY4hYzOKXVWzV{B2eHSja3WgbY5kfWKjdHXkJIZweiB3IH3pcpMh[nlic3PpcpRqdGyjdHnvckBkd3WwdHnu[{whU2liPTCwMlU{KM7:TT6=	MlrNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ3NEGwOlgoRjJ{NUSxNFY5RC:jPh?=
HEK293 Flp-In	M{\RcWZ2dmO2aX;uJIF{e2G7			NWjNbXVEUW6qaXLpeIlwdiCxZjDoeY1idiCuaY\ldkBQSVSSMVKxJIV5eHKnc4Pl[EBqdiCKRVuyPVMhTmyyLVnuJINmdGy\|IHHzd4V{e2WmIHHzJJJm\HWldHnvckBqdiCHMUetZoV1[UdidYD0ZYtmKGK7IIPjbY51cWyuYYTpc44h[2:3boTpcoctKEurIE2gNlEh\|ryPLh?=	MlzSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ3NEGwOlgoRjJ{NUSxNFY5RC:jPh?=
HEK293 Flp-In	M1e5PGZ2dmO2aX;uJIF{e2G7		M2PFdlUhdWmwcx?=	MX\Jcohq[mm2aX;uJI9nKGi3bXHuJIxqfmW{IF;BWHAySjNiZYjwdoV{e2WmIHnuJGhGUzJ7MzDGcJAuUW5iY3XscJMh[XO\|ZYPz[YQh[XNicnXkeYN1cW:wIHnuJHs{UF2HMUetZoV1[UdidYD0ZYtmKGmwY4XiZZRm\CCob4KgOUBucW6\|IHL5JJNkcW62aXzsZZRqd25iY3;1cpRqdmduIFvpJF0hPDFizszNMi=>	NF20Zlk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkW0NVA3QCd-MkK1OFExPjh:L3G+
hematopoietic progenitor cells	MWPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?	M{PBdlUhfU1?		M3LJeGdzd3e2aDDpcohq[mm2aX;uJI9nKEqDS{KgWlYyP0ZibYX0ZY51KGW6cILld5NqdmdiaIXtZY4heG:ueXP5eIhmdWmjII\ldoEhcGWvYYTvdI9q\XSrYzDwdo9o\W6rdH;yJINmdGy\|IHH0JFUhfU1iYomg[ZJ6fGi{b3nkJIJ2enO2LX\vdo1qdmdidX7peEBie3OjeR?=	MnTvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTdzN{i3NlIoRjF5MUe4O\|IzRC:jPh?=
A431	MnGxSpVv[3Srb36gZZN{[Xl?		NHXpd44yKGi{cx?=	NHTyTXRKdmirYnn0bY9vKG:oIFXHSk1qdmS3Y3XkJGVITlJicHjvd5Bpd3K7bHH0bY9vKGmwIHj1cYFvKEF2M{GgZ4VtdHNicILleJJm[XSnZDDmc5IhOSCqcoOg[o9tdG:5ZXSgZpkhTUeILYP0bY12dGG2aX;uJIJ6KGmvbYXuc4Jtd3RiYX7hcJl{cXN?	M4KzS\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7OU[5OFY2Lz5zOUm2PVQ3PTxxYU6=
PC9	MVrDfZRwfG:6aXPpeJkh[XO\|YYm=	M33Wd\|AvODBzIITvJFExKHWP		NHTrOIJEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBRSzliY3XscJMh\XiycnXzd4lv\yB5NE[tO\|UxKHOncYXlcoNmKGSnbHX0[YQhTUeIUjDhd5Nme3OnZDDhd{Bk\WyuII\pZYJqdGm2eTDheEAxNjByMTD0c{AyOCC3TTDh[pRmeiB7NjDodpMh[nliY3XscEB1cXSncj3ncI8h[XO\|YYm=	NYD0dlRzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkCyNlI4OzNpPkKwNlIzPzN\|PD;hQi=>
NCI-H1975	M4nZO2N6fG:2b4jpZ4l1gSCjc4PhfS=>	Mk\pNE4xODFidH:gNVAhfU1?		MonSR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUmNKNUhzOUe1JINmdGy\|IHX4dJJme3OrbnegSWdHWiCWN{mwUUBidmRiTEi1PHIhdXW2YX70JIF1KDBwMECxJJRwKDFyIIXNJIFnfGW{IEm2JIhzeyCkeTDj[YxtKHSrdHXyMYdtdyCjc4PhfS=>	NVHtOYQ4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkCyNlI4OzNpPkKwNlIzPzN\|PD;hQi=>
HCC827	MlXaRZBweHSxc3nzJIF{e2G7	M3\JVFEhfU1?		NY\ZbGg3UW6mdXP0bY9vKG:oIHHwc5B1d3OrczDpckBpfW2jbjDIR2M5OjdiY3XscJMh[XRiMTD1UUBi\nSncjCyOEBpenNidYPpcocheHKxcHnkbZVuKGmxZHnk[UBjgSCobH;3JIN6fG:vZYTyfS=>	NVfSRm9uRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5NFA5OzBpPkK0PVAxQDNyPD;hQi=>
LLC	NXe1b4VWSW62aYT1cY9zKGG\|c3H5	MmPZNVAxKG2pL3vn	Mnm0NVQh\GG7cx?=	M{PkN2FvfGm2dX3vdkBi[3Srdnn0fUBi\2GrboP0JI1wfXOnIFzMR{Bk\WyuczDhcIxw\3KjZoTl[EBqdiCVQ1nEJI1wfXOnIHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZidIXtc5Ih\3Kxd4ToJIF1KDFyMDDt[{9s\yxicH:gdYQh\m:{IEG0JIRigXN?	M1fzO\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4MUi4OlIxLz5{NkG4PFYzODxxYU6=
PC9	NYH2V\|hISW62aYT1cY9zKGG\|c3H5	MWmxOUBu\y:tZx?=	NHXYUpM1KHenZXvz	MlXDRY51cXS3bX;yJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iUFO5JINmdGy\|IHX4dJJme3OrbnegSWdHWiCneH;uNVkh\GWuZYTpc44hdXW2YX70JJhmdm:pcnHmeIVlKGmwIH3veZNmKGG\|c3Xzd4VlKGG\|IIT1cY9zKHKnZ4Lld5Nqd25iYYSgNVUhdWdxa3esJJFlKG2nYYP1doVlKGGodHXyJFQhf2Wna4O=	MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjNzM{K1Nkc,OjZ\|MUOyOVI9N2F-
PC9	MnG5RY51cXS3bX;yJIF{e2G7	M{DBNFE2KG2pL3vn	NHXmSJE1KHenZXvz	M3LyfmFvfGm2dX3vdkBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGDDPUBk\WyuczDlfJBz\XO\|aX7nJGVITlJiZYjvclE6KGSnbHX0bY9vKG23dHHueEB5\W6xZ4Lh[pRm\CCrbjDtc5V{\SCjdDCxOUBu\y:tZzygdYQhdWWjc4Xy[YQh[W[2ZYKgOEB4\WWtcx?=	MnjSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ\|MUOyOVIoRjJ4M{GzNlUzRC:jPh?=
A673	MXHxTHRUKGG\|c3H5			NVLMfmJleUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IFG2O\|Mh[2WubIO=	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
Saos-2	MYHxTHRUKGG\|c3H5			MWjxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhW2Gxcz2yJINmdGy\|	NVTZeYRWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
BT-37	NImyb4tyUFSVIHHzd4F6			M365cZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCEVD2zO{Bk\Wyucx?=	NIHHTZk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
BT-12	MWXxTHRUKGG\|c3H5			MoHxdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKEKWLUGyJINmdGy\|	M{ThelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
NB1643	MYTxTHRUKGG\|c3H5			MnXidWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKE6EMU[0N{Bk\Wyucx?=	NH\OcYE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
OHS-50	NWnXUm1UeUiWUzDhd5NigQ>?			MYXxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhV0iVLUWwJINmdGy\|	Mm\CQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
Rh41	MWfxTHRUKGG\|c3H5			MX7xTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhWmh2MTDj[Yxtew>?	M4i0XlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
BT-37	Mo\SdWhVWyCjc4PhfS=>			M3q5UJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJGJVNTN5IHPlcIx{	NILNco89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
MG 63 (6-TG R)	M4jldJFJXFNiYYPzZZk>			M4n1RZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJG1IKDZ\|IDi2MXRIKFJrIHPlcIx{	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
Rh41	NWTpb5hQeUiWUzDhd5NigQ>?			NWniSIVReUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhWmh2MTDj[Yxtew>?	MojYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
SJ-GBM2	MoD6dWhVWyCjc4PhfS=>			MVjxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhW0pvR1LNNkBk\Wyucx?=	NUG0[GV[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
SK-N-MC	MlS0dWhVWyCjc4PhfS=>			NUXQW2NoeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IGPLMW4uVUNiY3XscJM>	NXn4RmZbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
NB-EBc1	MnvPdWhVWyCjc4PhfS=>			MYTxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhVkJvRVLjNUBk\Wyucx?=	NYHJUY9bRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
LAN-5	NWTOfmdweUiWUzDhd5NigQ>?			NVT6dY85eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IFzBUk02KGOnbHzz	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
Rh18	Mly1dWhVWyCjc4PhfS=>			NX[xUGtCeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IGLoNVgh[2WubIO=	MnTpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
SK-N-MC	MmD5dWhVWyCjc4PhfS=>			NFWwT2xyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBUUy2QLV3DJINmdGy\|	NWS0fGJsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
TC32	M3PSOZFJXFNiYYPzZZk>			NIX5SIpyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBVSzN{IHPlcIx{	Mk\qQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
NCI-H1648	NGewSHVIem:5dHigTY5pcWKrdHnvckBie3OjeR?=			MVvJcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KMU[0PEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOC5yNECwNkDPxE1w	M2TGPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFU2Oy9pPmPBUmdGWjxxYU6=
TE-12	MojkS5Jwf3SqIFnubIljcXSrb36gZZN{[Xl?			NXvSUI9qUW6qaXLpeIlwdiCxZjDoeY1idiCWRT2xNkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOC5yNUS0NUDPxE1w	NWf5eZhtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTV\|Lze+V2FPT0WUPD;hQi=>
ECC12	M2\mfmdzd3e2aDDJcohq[mm2aX;uJIF{e2G7			Mn30TY5pcWKrdHnvckBw\iCqdX3hckBGS0NzMjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gNE4xQDB3MjFOwG0v	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1OVMwLz6VQV7HSXI9N2F-
BB30-HNC	NWLaemFkT3Kxd4ToJGlvcGmkaYTpc44h[XO\|YYm=			M1HKZmlvcGmkaYTpc44hd2ZiaIXtZY4hSkJ\|MD3IUmMh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDBwMUS3OlUh\|ryPLh?=	M{ezT\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFU2Oy9pPmPBUmdGWjxxYU6=
LB996-RCC	NWrIXmRNT3Kxd4ToJGlvcGmkaYTpc44h[XO\|YYm=			NFvpNHNKdmirYnn0bY9vKG:oIHj1cYFvKEyEOUm2MXJESyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxKD1iMD60NFE3OSEQvF2u	M2PHclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFU2Oy9pPmPBUmdGWjxxYU6=
EW-24	Mny4S5Jwf3SqIFnubIljcXSrb36gZZN{[Xl?			MoiyTY5pcWKrdHnvckBw\iCqdX3hckBGXy1{NDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gNE42QTR2MzFOwG0v	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1OVMwLz6VQV7HSXI9N2F-
LC-1F	MULHdo94fGhiSX7obYJqfGmxbjDhd5NigQ>?			NUe3[Wo5UW6qaXLpeIlwdiCxZjDoeY1idiCOQz2xSkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOC54ME[zNkDPxE1w	M3rHNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFU2Oy9pPmPBUmdGWjxxYU6=
TK10	NIrzWHZIem:5dHigTY5pcWKrdHnvckBie3OjeR?=			MljsTY5pcWKrdHnvckBw\iCqdX3hckBVUzFyIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTCwMlg2QDd6IN88UU4>	M4PpTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFU2Oy9pPmPBUmdGWjxxYU6=
A388	MXvHdo94fGhiSX7obYJqfGmxbjDhd5NigQ>?			M{XaemlvcGmkaYTpc44hd2ZiaIXtZY4hSTN6ODDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gNU4xQTN6IN88UU4>	NFyyc5M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2PTNxJ{7TRW5ITVJ:L3G+
EKVX	M13tdWdzd3e2aDDJcohq[mm2aX;uJIF{e2G7			M4LiW2lvcGmkaYTpc44hd2ZiaIXtZY4hTUuYWDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gNU4yOjN3NDFOwG0v	NVTGdWhXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTV\|Lze+V2FPT0WUPD;hQi=>
TE-9	MmDSS5Jwf3SqIFnubIljcXSrb36gZZN{[Xl?			MnzlTY5pcWKrdHnvckBw\iCqdX3hckBVTS17IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTCxMlIzPTFzIN88UU4>	MlrMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVU{Nyd-U1HOS2VTRC:jPh?=
TE-1	NHPnUmlIem:5dHigTY5pcWKrdHnvckBie3OjeR?=			Mn\uTY5pcWKrdHnvckBw\iCqdX3hckBVTS1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTCxMlQxPDhizszNMi=>	NHj4WpY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2PTNxJ{7TRW5ITVJ:L3G+
MOLT-16	MnrtS5Jwf3SqIFnubIljcXSrb36gZZN{[Xl?			M2LQT2lvcGmkaYTpc44hd2ZiaIXtZY4hVU:OVD2xOkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOS57MkmyOUDPxE1w	MXG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1OVMwLz6VQV7HSXI9N2F-
TE-6	NH\xTWtIem:5dHigTY5pcWKrdHnvckBie3OjeR?=			MX3Jcohq[mm2aX;uJI9nKGi3bXHuJHRGNTZiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OCB;IEKuOVY4QCEQvF2u	M2OwcFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFU2Oy9pPmPBUmdGWjxxYU6=
697	NWjNdVNiT3Kxd4ToJGlvcGmkaYTpc44h[XO\|YYm=			M13iOGlvcGmkaYTpc44hd2ZiaIXtZY4hPjl5IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTCyMlY2OzB3IN88UU4>	MkTUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVU{Nyd-U1HOS2VTRC:jPh?=
A253	M3v2RWdzd3e2aDDJcohq[mm2aX;uJIF{e2G7			MWLJcohq[mm2aX;uJI9nKGi3bXHuJGEzPTNiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OCB;IEKuO\|UyPiEQvF2u	MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1OVMwLz6VQV7HSXI9N2F-
OS-RC-2	M3XVWmdzd3e2aDDJcohq[mm2aX;uJIF{e2G7			NWPFNWNkUW6qaXLpeIlwdiCxZjDoeY1idiCRUz3SR{0zKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSB{Lkm0NFI{KM7:TT6=	M4DwVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFU2Oy9pPmPBUmdGWjxxYU6=
KS-1	NEHyN2xIem:5dHigTY5pcWKrdHnvckBie3OjeR?=			M2C5emlvcGmkaYTpc44hd2ZiaIXtZY4hU1NvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gNk46PDV2MjFOwG0v	NGnpSVE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2PTNxJ{7TRW5ITVJ:L3G+
MC116	MnyzS5Jwf3SqIFnubIljcXSrb36gZZN{[Xl?			NYe0U3hmUW6qaXLpeIlwdiCxZjDoeY1idiCPQ{GxOkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOy54MkC0PUDPxE1w	MmLvQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVU{Nyd-U1HOS2VTRC:jPh?=
LB2241-RCC	M1PCUGdzd3e2aDDJcohq[mm2aX;uJIF{e2G7			MmOxTY5pcWKrdHnvckBw\iCqdX3hckBNSjJ{NEGtVmNEKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSB\|LkixO\|I6KM7:TT6=	MkjYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVU{Nyd-U1HOS2VTRC:jPh?=
RL95-2	NVPpS21nT3Kxd4ToJGlvcGmkaYTpc44h[XO\|YYm=			NUHDUIpQUW6qaXLpeIlwdiCxZjDoeY1idiCUTEm1MVIh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDRwMEOzNkDPxE1w	M2fvVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFU2Oy9pPmPBUmdGWjxxYU6=
HCE-T	MVjHdo94fGhiSX7obYJqfGmxbjDhd5NigQ>?			MlXXTY5pcWKrdHnvckBw\iCqdX3hckBJS0VvVDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gOE4yODF6ODFOwG0v	NVzWW21DRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTV\|Lze+V2FPT0WUPD;hQi=>
NCCIT	NXLCVZpiT3Kxd4ToJGlvcGmkaYTpc44h[XO\|YYm=			NWfVfHZiUW6qaXLpeIlwdiCxZjDoeY1idiCQQ1PJWEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hPC5\|OES5O{DPxE1w	NIjodG89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2PTNxJ{7TRW5ITVJ:L3G+
GCIY	M4jFU2dzd3e2aDDJcohq[mm2aX;uJIF{e2G7			MXrJcohq[mm2aX;uJI9nKGi3bXHuJGdEUVliY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OCB;IESuOlM2OzJizszNMi=>	MmfDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVU{Nyd-U1HOS2VTRC:jPh?=
LB1047-RCC	MXzHdo94fGhiSX7obYJqfGmxbjDhd5NigQ>?			Ml\jTY5pcWKrdHnvckBw\iCqdX3hckBNSjFyNEetVmNEKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSB2Lkm4N\|c6KM7:TT6=	NFTGT409[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2PTNxJ{7TRW5ITVJ:L3G+
A3-KAW	NEe3OGxIem:5dHigTY5pcWKrdHnvckBie3OjeR?=			MmXtTY5pcWKrdHnvckBw\iCqdX3hckBCOy2NQWegZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFUvPDN7NE[g{txONg>?	NV60eZR7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTV\|Lze+V2FPT0WUPD;hQi=>
TE-15	NV\JdXM5T3Kxd4ToJGlvcGmkaYTpc44h[XO\|YYm=			MYXJcohq[mm2aX;uJI9nKGi3bXHuJHRGNTF3IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTC1MlQ4OjdizszNMi=>	NGjtTZg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2PTNxJ{7TRW5ITVJ:L3G+
NOS-1	NFH6eG1Iem:5dHigTY5pcWKrdHnvckBie3OjeR?=			MVvJcohq[mm2aX;uJI9nKGi3bXHuJG5QWy1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTC1MlQ6Ozh4IN88UU4>	NWr0U2lWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTV\|Lze+V2FPT0WUPD;hQi=>
EW-16	M1jSNWdzd3e2aDDJcohq[mm2aX;uJIF{e2G7			NHHaZpBKdmirYnn0bY9vKG:oIHj1cYFvKEWZLUG2JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUA3NjJ3M{i3JO69VS5?	M4nucVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFU2Oy9pPmPBUmdGWjxxYU6=
LAMA-84	NEXSZ4xIem:5dHigTY5pcWKrdHnvckBie3OjeR?=			NFzwOmpKdmirYnn0bY9vKG:oIHj1cYFvKEyDTVGtPFQh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDdwMEC3O\|Ih\|ryPLh?=	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1OVMwLz6VQV7HSXI9N2F-
TE-5	M4fzVmdzd3e2aDDJcohq[mm2aX;uJIF{e2G7			MV7Jcohq[mm2aX;uJI9nKGi3bXHuJHRGNTViY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OCB;IEeuNFQzPDdizszNMi=>	MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1OVMwLz6VQV7HSXI9N2F-
HEL	M4nHTWdzd3e2aDDJcohq[mm2aX;uJIF{e2G7			NUnTNFdsUW6qaXLpeIlwdiCxZjDoeY1idiCKRVygZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFcvOzN3NkSg{txONg>?	M2ju[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFU2Oy9pPmPBUmdGWjxxYU6=
NCI-H209	MVPHdo94fGhiSX7obYJqfGmxbjDhd5NigQ>?			NWTPVHQ3UW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFIxQSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxKD1iOD6wOFQyOiEQvF2u	NWHaXVI3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTV\|Lze+V2FPT0WUPD;hQi=>
DJM-1	M1LwbWdzd3e2aDDJcohq[mm2aX;uJIF{e2G7			MmjFTY5pcWKrdHnvckBw\iCqdX3hckBFUk1vMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gPE42Ojl4NDFOwG0v	Mo\lQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVU{Nyd-U1HOS2VTRC:jPh?=
OVCAR-4	NW\UWZByT3Kxd4ToJGlvcGmkaYTpc44h[XO\|YYm=			MWnJcohq[mm2aX;uJI9nKGi3bXHuJG9XS0GULUSgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFgvQDR{MUmg{txONg>?	M1j1NFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFU2Oy9pPmPBUmdGWjxxYU6=
NB17	M4GzNGdzd3e2aDDJcohq[mm2aX;uJIF{e2G7			M{DQWGlvcGmkaYTpc44hd2ZiaIXtZY4hVkJzNzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gPU4zPTl7MTFOwG0v	M3LyZ\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFU2Oy9pPmPBUmdGWjxxYU6=
SK-NEP-1	M4m3OWdzd3e2aDDJcohq[mm2aX;uJIF{e2G7			MYnJcohq[mm2aX;uJI9nKGi3bXHuJHNMNU6HUD2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUA6NjN3N{e2JO69VS5?	Mlj6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVU{Nyd-U1HOS2VTRC:jPh?=
NB5	MmnUS5Jwf3SqIFnubIljcXSrb36gZZN{[Xl?			NIHqfplKdmirYnn0bY9vKG:oIHj1cYFvKE6ENTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gNVAvOjlizszNMi=>	MlHQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVU{Nyd-U1HOS2VTRC:jPh?=
BV-173	NF7pVnBIem:5dHigTY5pcWKrdHnvckBie3OjeR?=			NVq3cYNHUW6qaXLpeIlwdiCxZjDoeY1idiCEVj2xO\|Mh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDFyLkOyO\|Ih\|ryPLh?=	MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1OVMwLz6VQV7HSXI9N2F-
MPP-89	M1zKc2dzd3e2aDDJcohq[mm2aX;uJIF{e2G7			MUDJcohq[mm2aX;uJI9nKGi3bXHuJG1RWC16OTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gNVAvPDR{IN88UU4>	M{HyWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFU2Oy9pPmPBUmdGWjxxYU6=
RPMI-6666	NEHXR4JIem:5dHigTY5pcWKrdHnvckBie3OjeR?=			M{XUOmlvcGmkaYTpc44hd2ZiaIXtZY4hWlCPST22OlY3KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSBzMD60PVY6KM7:TT6=	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1OVMwLz6VQV7HSXI9N2F-
MS-1	MV\Hdo94fGhiSX7obYJqfGmxbjDhd5NigQ>?			MYjJcohq[mm2aX;uJI9nKGi3bXHuJG1UNTFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OCB;IEGxMlQ3PThizszNMi=>	NVTqblJuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTV\|Lze+V2FPT0WUPD;hQi=>
ALL-PO	MVvHdo94fGhiSX7obYJqfGmxbjDhd5NigQ>?			MXfJcohq[mm2aX;uJI9nKGi3bXHuJGFNVC2STzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gNVEvPTF5OTFOwG0v	NGLsd5E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2PTNxJ{7TRW5ITVJ:L3G+
NB10	MUTHdo94fGhiSX7obYJqfGmxbjDhd5NigQ>?			NV;kfoE{UW6qaXLpeIlwdiCxZjDoeY1idiCQQkGwJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAyOS55NUi3JO69VS5?	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1OVMwLz6VQV7HSXI9N2F-
NB13	M2TPVGdzd3e2aDDJcohq[mm2aX;uJIF{e2G7			NVjnTpFRUW6qaXLpeIlwdiCxZjDoeY1idiCQQkGzJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAyOS57OUG0JO69VS5?	NUPVWZVtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTV\|Lze+V2FPT0WUPD;hQi=>
SCH	NVrKemdNT3Kxd4ToJGlvcGmkaYTpc44h[XO\|YYm=			MWXJcohq[mm2aX;uJI9nKGi3bXHuJHNEUCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxKD1iMUKuNVg6OSEQvF2u	NEXmc\|M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2PTNxJ{7TRW5ITVJ:L3G+
ES6	MkDGS5Jwf3SqIFnubIljcXSrb36gZZN{[Xl?			NEf6NJNKdmirYnn0bY9vKG:oIHj1cYFvKEWVNjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gNVIvPDd3IN88UU4>	MnrIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVU{Nyd-U1HOS2VTRC:jPh?=
ETK-1	NVvSNmJpT3Kxd4ToJGlvcGmkaYTpc44h[XO\|YYm=			NGGxNWhKdmirYnn0bY9vKG:oIHj1cYFvKEWWSz2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAyPC5yOEi1JO69VS5?	MkmyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVU{Nyd-U1HOS2VTRC:jPh?=
ES4	Mn;ZS5Jwf3SqIFnubIljcXSrb36gZZN{[Xl?			NGjyZmRKdmirYnn0bY9vKG:oIHj1cYFvKEWVNDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gNVQvQDR2NTFOwG0v	MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1OVMwLz6VQV7HSXI9N2F-
K-562	NUHGWJZQT3Kxd4ToJGlvcGmkaYTpc44h[XO\|YYm=			MVXJcohq[mm2aX;uJI9nKGi3bXHuJGsuPTZ{IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTCxOU45OTRizszNMi=>	NW\jSJd3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTV\|Lze+V2FPT0WUPD;hQi=>
D-502MG	MnXmS5Jwf3SqIFnubIljcXSrb36gZZN{[Xl?			MlTnTY5pcWKrdHnvckBw\iCqdX3hckBFNTVyMl3HJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAyPy5\|NE[4JO69VS5?	NV2xdXBwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTV\|Lze+V2FPT0WUPD;hQi=>
LB647-SCLC	NV65V2txT3Kxd4ToJGlvcGmkaYTpc44h[XO\|YYm=			NXfvdo5sUW6qaXLpeIlwdiCxZjDoeY1idiCOQk[0O{1US0yFIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTCxO{44PzJ4IN88UU4>	NF\DU\|g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2PTNxJ{7TRW5ITVJ:L3G+
TE-10	NU\JUIdNT3Kxd4ToJGlvcGmkaYTpc44h[XO\|YYm=			MnfPTY5pcWKrdHnvckBw\iCqdX3hckBVTS1zMDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gNVgvOTF\|ODFOwG0v	NWrKS5JnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTV\|Lze+V2FPT0WUPD;hQi=>
MZ1-PC	MU\Hdo94fGhiSX7obYJqfGmxbjDhd5NigQ>?			MV;Jcohq[mm2aX;uJI9nKGi3bXHuJG1bOS2SQzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gNVgvOzd5NDFOwG0v	NHrFWG49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2PTNxJ{7TRW5ITVJ:L3G+
CTB-1	M2rYcGdzd3e2aDDJcohq[mm2aX;uJIF{e2G7			MW\Jcohq[mm2aX;uJI9nKGi3bXHuJGNVSi1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTCxPE42ODd3IN88UU4>	NEOwUIs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2PTNxJ{7TRW5ITVJ:L3G+
NMC-G1	M1nLVGdzd3e2aDDJcohq[mm2aX;uJIF{e2G7			Mkm4TY5pcWKrdHnvckBw\iCqdX3hckBPVUNvR{GgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFE5NjhyMkmg{txONg>?	NWW4cFdXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTV\|Lze+V2FPT0WUPD;hQi=>
C2BBe1	NXTSc4RKT3Kxd4ToJGlvcGmkaYTpc44h[XO\|YYm=			NGH0VFdKdmirYnn0bY9vKG:oIHj1cYFvKEN{QlLlNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOThwOE[2OEDPxE1w	NGfZZlM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2PTNxJ{7TRW5ITVJ:L3G+
SK-PN-DW	NF7hVnNIem:5dHigTY5pcWKrdHnvckBie3OjeR?=			NWq4e3RqUW6qaXLpeIlwdiCxZjDoeY1idiCVSz3QUk1FXyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxKD1iMUmuOVQ5OiEQvF2u	NVnlPG5CRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTV\|Lze+V2FPT0WUPD;hQi=>
HCC2157	M4nHRmdzd3e2aDDJcohq[mm2aX;uJIF{e2G7			NUfiNZRsUW6qaXLpeIlwdiCxZjDoeY1idiCKQ1OyNVU4KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSB{MD6zN\|YyKM7:TT6=	NYC5PJlwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTV\|Lze+V2FPT0WUPD;hQi=>
Becker	NH33Z5ZIem:5dHigTY5pcWKrdHnvckBie3OjeR?=			MoO0TY5pcWKrdHnvckBw\iCqdX3hckBD\WOtZYKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFIxNjN3NEGg{txONg>?	MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1OVMwLz6VQV7HSXI9N2F-
ST486	MYHHdo94fGhiSX7obYJqfGmxbjDhd5NigQ>?			Ml\LTY5pcWKrdHnvckBw\iCqdX3hckBUXDR6NjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gNlAvPDB7MzFOwG0v	MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1OVMwLz6VQV7HSXI9N2F-
LC-2-ad	M2C1dmdzd3e2aDDJcohq[mm2aX;uJIF{e2G7			M2rtT2lvcGmkaYTpc44hd2ZiaIXtZY4hVENvMj3h[EBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOjBwOU[zO{DPxE1w	NEfyR409[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2PTNxJ{7TRW5ITVJ:L3G+
NCI-H747	MlLPS5Jwf3SqIFnubIljcXSrb36gZZN{[Xl?			NXvheZR1UW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFc1PyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxKD1iMkGuOVE{QSEQvF2u	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1OVMwLz6VQV7HSXI9N2F-
BE-13	M{TLNGdzd3e2aDDJcohq[mm2aX;uJIF{e2G7			NF3EOY1KdmirYnn0bY9vKG:oIHj1cYFvKEKHLUGzJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAzOS56MUW4JO69VS5?	NFLMOo49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2PTNxJ{7TRW5ITVJ:L3G+
no-11	M2W1dWdzd3e2aDDJcohq[mm2aX;uJIF{e2G7			M1nidmlvcGmkaYTpc44hd2ZiaIXtZY4hdm9vMUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFIyNjlzME[g{txONg>?	M1\2SVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFU2Oy9pPmPBUmdGWjxxYU6=
TE-8	M334Nmdzd3e2aDDJcohq[mm2aX;uJIF{e2G7			MlLzTY5pcWKrdHnvckBw\iCqdX3hckBVTS16IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTCyNk43OzF6IN88UU4>	NFrCO\|A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2PTNxJ{7TRW5ITVJ:L3G+
NB6	NHXpXGdIem:5dHigTY5pcWKrdHnvckBie3OjeR?=			M1jnXmlvcGmkaYTpc44hd2ZiaIXtZY4hVkJ4IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTCyNk45OzB\|IN88UU4>	NV;pToFwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTV\|Lze+V2FPT0WUPD;hQi=>
BB65-RCC	NYDJVIRHT3Kxd4ToJGlvcGmkaYTpc44h[XO\|YYm=			MlHNTY5pcWKrdHnvckBw\iCqdX3hckBDSjZ3LWLDR{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOjJwOU[yN{DPxE1w	MnHxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVU{Nyd-U1HOS2VTRC:jPh?=
SK-UT-1	MlK0S5Jwf3SqIFnubIljcXSrb36gZZN{[Xl?			NY\TU41WUW6qaXLpeIlwdiCxZjDoeY1idiCVSz3VWE0yKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSB{Mz6xOFk4KM7:TT6=	NVrMTYY1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTV\|Lze+V2FPT0WUPD;hQi=>
D-392MG	MmL2S5Jwf3SqIFnubIljcXSrb36gZZN{[Xl?			NEPUPXNKdmirYnn0bY9vKG:oIHj1cYFvKERvM{myUWch[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDJ2LkK5N\|Qh\|ryPLh?=	NFPDelM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2PTNxJ{7TRW5ITVJ:L3G+
JVM-2	MmXTS5Jwf3SqIFnubIljcXSrb36gZZN{[Xl?			MlvRTY5pcWKrdHnvckBw\iCqdX3hckBLXk1vMjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gNlQvPTN\|MzFOwG0v	NGizNnU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2PTNxJ{7TRW5ITVJ:L3G+
SW954	M1;VXmdzd3e2aDDJcohq[mm2aX;uJIF{e2G7			M3S3emlvcGmkaYTpc44hd2ZiaIXtZY4hW1d7NUSgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFI1NjV7MU[g{txONg>?	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1OVMwLz6VQV7HSXI9N2F-
QIMR-WIL	MVrHdo94fGhiSX7obYJqfGmxbjDhd5NigQ>?			NYX3OnJqUW6qaXLpeIlwdiCxZjDoeY1idiCTSV3SMXdKVCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxKD1iMkWuNVk4OyEQvF2u	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1OVMwLz6VQV7HSXI9N2F-
MEG-01	MXLHdo94fGhiSX7obYJqfGmxbjDhd5NigQ>?			MXnJcohq[mm2aX;uJI9nKGi3bXHuJG1GTy1yMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gNlUvQTBzNjFOwG0v	NFnvOXY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2PTNxJ{7TRW5ITVJ:L3G+
A101D	NUjVXlJQT3Kxd4ToJGlvcGmkaYTpc44h[XO\|YYm=			M1P5cGlvcGmkaYTpc44hd2ZiaIXtZY4hSTFyMVSgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFI5NjdzM{mg{txONg>?	NEHPWlk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2PTNxJ{7TRW5ITVJ:L3G+
LB831-BLC	MYjHdo94fGhiSX7obYJqfGmxbjDhd5NigQ>?			MUnJcohq[mm2aX;uJI9nKGi3bXHuJGxDQDNzLVLMR{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOzBwNECwOEDPxE1w	NF:3e4w9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2PTNxJ{7TRW5ITVJ:L3G+
KGN	NVfQN\|EyT3Kxd4ToJGlvcGmkaYTpc44h[XO\|YYm=			NYTqSIFbUW6qaXLpeIlwdiCxZjDoeY1idiCNR16gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFMxNjh4NkGg{txONg>?	MnPsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVU{Nyd-U1HOS2VTRC:jPh?=
HC-1	MWPHdo94fGhiSX7obYJqfGmxbjDhd5NigQ>?			NF6y[4NKdmirYnn0bY9vKG:oIHj1cYFvKEiFLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFMyNjN3MEig{txONg>?	NVO3coFvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTV\|Lze+V2FPT0WUPD;hQi=>
CP66-MEL	NHu0VIhIem:5dHigTY5pcWKrdHnvckBie3OjeR?=			NEjFV\|NKdmirYnn0bY9vKG:oIHj1cYFvKEOSNk[tUWVNKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSB\|MT64N\|Y3KM7:TT6=	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1OVMwLz6VQV7HSXI9N2F-
D-542MG	MXjHdo94fGhiSX7obYJqfGmxbjDhd5NigQ>?			MV;Jcohq[mm2aX;uJI9nKGi3bXHuJGQuPTR{TVegZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFMzNjR\|M{eg{txONg>?	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1OVMwLz6VQV7HSXI9N2F-
LS-513	M3rFNmdzd3e2aDDJcohq[mm2aX;uJIF{e2G7			NFnIRYxKdmirYnn0bY9vKG:oIHj1cYFvKEyVLUWxN{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOzNwNEi0OEDPxE1w	MoDBQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVU{Nyd-U1HOS2VTRC:jPh?=
DOHH-2	Mlv1S5Jwf3SqIFnubIljcXSrb36gZZN{[Xl?			NUH4dXFQUW6qaXLpeIlwdiCxZjDoeY1idiCGT1jIMVIh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDN\|Lk[1PFkh\|ryPLh?=	NH7id2M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2PTNxJ{7TRW5ITVJ:L3G+
NB69	MVLHdo94fGhiSX7obYJqfGmxbjDhd5NigQ>?			M1jZe2lvcGmkaYTpc44hd2ZiaIXtZY4hVkJ4OTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gN\|MvQTJyNjFOwG0v	M1TjZ\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFU2Oy9pPmPBUmdGWjxxYU6=
SW962	NILafHdIem:5dHigTY5pcWKrdHnvckBie3OjeR?=			M2\pe2lvcGmkaYTpc44hd2ZiaIXtZY4hW1d7NkKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFM2Njd{MUeg{txONg>?	NHPhNoM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2PTNxJ{7TRW5ITVJ:L3G+
J-RT3-T3-5	NHL0eZpIem:5dHigTY5pcWKrdHnvckBie3OjeR?=			NIO3TWdKdmirYnn0bY9vKG:oIHj1cYFvKEpvUmSzMXQ{NTViY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OCB;IEO2MlA4OjRizszNMi=>	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1OVMwLz6VQV7HSXI9N2F-
MONO-MAC-6	M37KSmdzd3e2aDDJcohq[mm2aX;uJIF{e2G7			MVPJcohq[mm2aX;uJI9nKGi3bXHuJG1QVk9vTVHDMVYh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDN4LkWzOVkh\|ryPLh?=	NUPpRmJ7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTV\|Lze+V2FPT0WUPD;hQi=>
MLMA	MVnHdo94fGhiSX7obYJqfGmxbjDhd5NigQ>?			MVjJcohq[mm2aX;uJI9nKGi3bXHuJG1NVUFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OCB;IEO4MlY2OiEQvF2u	Mny4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVU{Nyd-U1HOS2VTRC:jPh?=
HOP-62	NIK3VGhIem:5dHigTY5pcWKrdHnvckBie3OjeR?=			NGf5eoxKdmirYnn0bY9vKG:oIHj1cYFvKEiRUD22NkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOzlwMUe2OUDPxE1w	NVjpRnRiRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTV\|Lze+V2FPT0WUPD;hQi=>
LP-1	Mkm4S5Jwf3SqIFnubIljcXSrb36gZZN{[Xl?			NEL5OHZKdmirYnn0bY9vKG:oIHj1cYFvKEySLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFM6NjR2MUWg{txONg>?	M4\4U\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFU2Oy9pPmPBUmdGWjxxYU6=
ONS-76	MmTyS5Jwf3SqIFnubIljcXSrb36gZZN{[Xl?			MYDJcohq[mm2aX;uJI9nKGi3bXHuJG9PWy15NjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gN\|kvQTF3MjFOwG0v	NGTVSJE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2PTNxJ{7TRW5ITVJ:L3G+
KNS-42	NEHjN\|VIem:5dHigTY5pcWKrdHnvckBie3OjeR?=			M1TnWGlvcGmkaYTpc44hd2ZiaIXtZY4hU06VLUSyJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUA1OC5yNUOxJO69VS5?	NILYNJg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2PTNxJ{7TRW5ITVJ:L3G+
NCI-H1581	MXfHdo94fGhiSX7obYJqfGmxbjDhd5NigQ>?			Mn[5TY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEG1PFEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDRzLkG4OFIh\|ryPLh?=	Mmr3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVU{Nyd-U1HOS2VTRC:jPh?=
DSH1	M3vVbmdzd3e2aDDJcohq[mm2aX;uJIF{e2G7			MY\Jcohq[mm2aX;uJI9nKGi3bXHuJGRUUDFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OCB;IESyMlQxPyEQvF2u	MlTEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVU{Nyd-U1HOS2VTRC:jPh?=
NCI-H1355	NEXnS5VIem:5dHigTY5pcWKrdHnvckBie3OjeR?=			M4DNSWlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVixN\|U2KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSB2Mj64N\|kh\|ryPLh?=	MnzXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVU{Nyd-U1HOS2VTRC:jPh?=
D-247MG	M4rRdGdzd3e2aDDJcohq[mm2aX;uJIF{e2G7			NFW0TVNKdmirYnn0bY9vKG:oIHj1cYFvKERvMkS3UWch[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDR3LkexPUDPxE1w	NGjJbII9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2PTNxJ{7TRW5ITVJ:L3G+
MC-CAR	M3nTWWdzd3e2aDDJcohq[mm2aX;uJIF{e2G7			MlzLTY5pcWKrdHnvckBw\iCqdX3hckBOSy2FQWKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFQ2Njl4OUGg{txONg>?	Ml\MQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVU{Nyd-U1HOS2VTRC:jPh?=
EW-1	MXLHdo94fGhiSX7obYJqfGmxbjDhd5NigQ>?			NGnOV3JKdmirYnn0bY9vKG:oIHj1cYFvKEWZLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFQ4NjV4MkSg{txONg>?	NGKyWGY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2PTNxJ{7TRW5ITVJ:L3G+
GI-ME-N	MWfHdo94fGhiSX7obYJqfGmxbjDhd5NigQ>?			MkDhTY5pcWKrdHnvckBw\iCqdX3hckBIUS2PRT3OJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUA1QC5zM{i0JO69VS5?	NXHuc\|BpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTV\|Lze+V2FPT0WUPD;hQi=>
BT-474	NF3LSZlIem:5dHigTY5pcWKrdHnvckBie3OjeR?=			MkDUTY5pcWKrdHnvckBw\iCqdX3hckBDXC12N{SgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFQ5NjF5M{ig{txONg>?	M3XkUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFU2Oy9pPmPBUmdGWjxxYU6=
LB373-MEL-D	M4rNWmdzd3e2aDDJcohq[mm2aX;uJIF{e2G7			M1nKcWlvcGmkaYTpc44hd2ZiaIXtZY4hVEJ\|N{OtUWVNNURiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OCB;IES4Mlc2PjNizszNMi=>	M{TnTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFU2Oy9pPmPBUmdGWjxxYU6=
BHT-101	MkPaS5Jwf3SqIFnubIljcXSrb36gZZN{[Xl?			NWnDVGNsUW6qaXLpeIlwdiCxZjDoeY1idiCESGStNVAyKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSB{Mj6wOlI6KM7:TT6=	Ml;pQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVU{Nyd-U1HOS2VTRC:jPh?=
OVCAR-4	MV3Hdo94fGhiSX7obYJqfGmxbjDhd5NigQ>?			NVjRNXNTUW6qaXLpeIlwdiCxZjDoeY1idiCRVlPBVk01KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSB{Mj60O{DPxE1w	NETHTmc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2PTNxJ{7TRW5ITVJ:L3G+
SW1573	MYHHdo94fGhiSX7obYJqfGmxbjDhd5NigQ>?			M33L[GlvcGmkaYTpc44hd2ZiaIXtZY4hW1dzNUezJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAzOi55OUO0JO69VS5?	MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1OVMwLz6VQV7HSXI9N2F-
CHL-1	MoG4S5Jwf3SqIFnubIljcXSrb36gZZN{[Xl?			NEXweFBKdmirYnn0bY9vKG:oIHj1cYFvKEOKTD2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAzOy5{OEOzJO69VS5?	MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1OVMwLz6VQV7HSXI9N2F-
BFTC-905	NFy0UJFIem:5dHigTY5pcWKrdHnvckBie3OjeR?=			MXnJcohq[mm2aX;uJI9nKGi3bXHuJGJHXENvOUC1JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAzOy5{OEmyJO69VS5?	Mn;zQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVU{Nyd-U1HOS2VTRC:jPh?=
TE-12	NWKyO4I2T3Kxd4ToJGlvcGmkaYTpc44h[XO\|YYm=			NUXuNFNFUW6qaXLpeIlwdiCxZjDoeY1idiCWRT2xNkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOjNwNUe4NkDPxE1w	MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1OVMwLz6VQV7HSXI9N2F-
NCI-H358	NF;qb4tIem:5dHigTY5pcWKrdHnvckBie3OjeR?=			Mlm3TY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEO1PEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOjNwNkS3O{DPxE1w	NIKyO2k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2PTNxJ{7TRW5ITVJ:L3G+
OVCAR-5	MmD4S5Jwf3SqIFnubIljcXSrb36gZZN{[Xl?			NF;WS2NKdmirYnn0bY9vKG:oIHj1cYFvKE:YQ1HSMVUh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDJ2LkGwOEDPxE1w	MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1OVMwLz6VQV7HSXI9N2F-
CGTH-W-1	MWLHdo94fGhiSX7obYJqfGmxbjDhd5NigQ>?			Ml3hTY5pcWKrdHnvckBw\iCqdX3hckBET1SKLWetNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOjVwMEiwOEDPxE1w	NXLNS4lZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTV\|Lze+V2FPT0WUPD;hQi=>
SNU-423	NWDsd3ZOT3Kxd4ToJGlvcGmkaYTpc44h[XO\|YYm=			MWLJcohq[mm2aX;uJI9nKGi3bXHuJHNPXS12MkOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFI2NjN4NjFOwG0v	NFHGN2M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2PTNxJ{7TRW5ITVJ:L3G+
CP50-MEL-B	M1HjNGdzd3e2aDDJcohq[mm2aX;uJIF{e2G7			NFrmbHhKdmirYnn0bY9vKG:oIHj1cYFvKEOSNUCtUWVNNUJiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OCB;IEK1Mlc{QTlizszNMi=>	Ml;pQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVU{Nyd-U1HOS2VTRC:jPh?=
NCI-H2087	MXLHdo94fGhiSX7obYJqfGmxbjDhd5NigQ>?			M{KwSWlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLViyNFg4KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSB{NT64OlU2KM7:TT6=	NGrXTWc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2PTNxJ{7TRW5ITVJ:L3G+
RMG-I	NWfqSHpsT3Kxd4ToJGlvcGmkaYTpc44h[XO\|YYm=			NF3yUmFKdmirYnn0bY9vKG:oIHj1cYFvKFKPRz3JJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUAzPS57MkG5JO69VS5?	MmXKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVU{Nyd-U1HOS2VTRC:jPh?=
KP-N-YS	MWHHdo94fGhiSX7obYJqfGmxbjDhd5NigQ>?			MVnJcohq[mm2aX;uJI9nKGi3bXHuJGtRNU5vWWOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFI3NjJyMjFOwG0v	NH;0SZc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2PTNxJ{7TRW5ITVJ:L3G+
OMC-1	MmnzS5Jwf3SqIFnubIljcXSrb36gZZN{[Xl?			Mke3TY5pcWKrdHnvckBw\iCqdX3hckBQVUNvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gNlYvPTB6IN88UU4>	M3uzSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFU2Oy9pPmPBUmdGWjxxYU6=
DMS-114	M3jocGdzd3e2aDDJcohq[mm2aX;uJIF{e2G7			NF62fm9KdmirYnn0bY9vKG:oIHj1cYFvKESPUz2xNVQh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDJ5LkO5OlYh\|ryPLh?=	NGG5SFA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2PTNxJ{7TRW5ITVJ:L3G+
SHP-77	NEHGZoxIem:5dHigTY5pcWKrdHnvckBie3OjeR?=			MULJcohq[mm2aX;uJI9nKGi3bXHuJHNJWC15NzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gNlcvPDh6IN88UU4>	MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1OVMwLz6VQV7HSXI9N2F-
MPP-89	M3v6VGdzd3e2aDDJcohq[mm2aX;uJIF{e2G7			MXnJcohq[mm2aX;uJI9nKGi3bXHuJG1RWC16OTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gNlcvQTR\|ODFOwG0v	NHzrOWo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2PTNxJ{7TRW5ITVJ:L3G+
NCI-H1581	MkDWS5Jwf3SqIFnubIljcXSrb36gZZN{[Xl?			NEnHW5NKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3INVU5OSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxKD1iMkiuOFU{PSEQvF2u	MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1OVMwLz6VQV7HSXI9N2F-
D-283MED	NI\yb3BIem:5dHigTY5pcWKrdHnvckBie3OjeR?=			NH;pPYFKdmirYnn0bY9vKG:oIHj1cYFvKERvMkizUWVFKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSB{OD60Olc1KM7:TT6=	Mk\xQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVU{Nyd-U1HOS2VTRC:jPh?=
MOLT-4	MXXHdo94fGhiSX7obYJqfGmxbjDhd5NigQ>?			MV7Jcohq[mm2aX;uJI9nKGi3bXHuJG1QVFRvNDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gNlgvQTB5MjFOwG0v	MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1OVMwLz6VQV7HSXI9N2F-
ES6	MWXHdo94fGhiSX7obYJqfGmxbjDhd5NigQ>?			MVvJcohq[mm2aX;uJI9nKGi3bXHuJGVUPiClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxKD1iMkmuOlQ{PiEQvF2u	M13uXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFU2Oy9pPmPBUmdGWjxxYU6=
NB6	M3Xme2dzd3e2aDDJcohq[mm2aX;uJIF{e2G7			MXXJcohq[mm2aX;uJI9nKGi3bXHuJG5DPiClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxKD1iMkmuPFY{QCEQvF2u	M3jCfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFU2Oy9pPmPBUmdGWjxxYU6=
SW954	MXrHdo94fGhiSX7obYJqfGmxbjDhd5NigQ>?			MXzJcohq[mm2aX;uJI9nKGi3bXHuJHNYQTV2IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTCyPU46PDB5IN88UU4>	MmrSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVU{Nyd-U1HOS2VTRC:jPh?=
A388	NG\HNXZIem:5dHigTY5pcWKrdHnvckBie3OjeR?=			M1XmWmlvcGmkaYTpc44hd2ZiaIXtZY4hSTN6ODDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gNlkvQTR{MjFOwG0v	MkLFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVU{Nyd-U1HOS2VTRC:jPh?=
OAW-28	MUDHdo94fGhiSX7obYJqfGmxbjDhd5NigQ>?			NGm1U29KdmirYnn0bY9vKG:oIHj1cYFvKE:DVz2yPEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOzBwMkK3PEDPxE1w	NX;DWZZlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTV\|Lze+V2FPT0WUPD;hQi=>
SK-MES-1	NFi2SYRIem:5dHigTY5pcWKrdHnvckBie3OjeR?=			MoT5TY5pcWKrdHnvckBw\iCqdX3hckBUUy2PRWOtNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOzFwMkKwPEDPxE1w	NHnXeW89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2PTNxJ{7TRW5ITVJ:L3G+
NCI-H441	M1i2U2dzd3e2aDDJcohq[mm2aX;uJIF{e2G7			MXnJcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KNESxJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUA{OS57OE[4JO69VS5?	MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1OVMwLz6VQV7HSXI9N2F-
HOP-92	Ml\XS5Jwf3SqIFnubIljcXSrb36gZZN{[Xl?			M{fDPGlvcGmkaYTpc44hd2ZiaIXtZY4hUE:SLUmyJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUA{Oi5{M{W2JO69VS5?	MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1OVMwLz6VQV7HSXI9N2F-
NB14	NH\pbGFIem:5dHigTY5pcWKrdHnvckBie3OjeR?=			Mlf0TY5pcWKrdHnvckBw\iCqdX3hckBPSjF2IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTCzNk44OjVzIN88UU4>	NFOzeXM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2PTNxJ{7TRW5ITVJ:L3G+
MS-1	NUjxd5hTT3Kxd4ToJGlvcGmkaYTpc44h[XO\|YYm=			NXi3dG83UW6qaXLpeIlwdiCxZjDoeY1idiCPUz2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUA{Oi55NkC0JO69VS5?	MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1OVMwLz6VQV7HSXI9N2F-
YKG-1	NWrvU5lpT3Kxd4ToJGlvcGmkaYTpc44h[XO\|YYm=			MnfDTY5pcWKrdHnvckBw\iCqdX3hckB[U0dvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gN\|IvQDN\|NjFOwG0v	NIHye3k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2PTNxJ{7TRW5ITVJ:L3G+
SiHa	MmnqS5Jwf3SqIFnubIljcXSrb36gZZN{[Xl?			MkPVTY5pcWKrdHnvckBw\iCqdX3hckBUcUijIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTCzN{4{QDJ7IN88UU4>	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1OVMwLz6VQV7HSXI9N2F-
HAL-01	NYexXm4{T3Kxd4ToJGlvcGmkaYTpc44h[XO\|YYm=			MoTlTY5pcWKrdHnvckBw\iCqdX3hckBJSUxvMEGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFM1NjJ\|N{[g{txONg>?	NIXxU\|Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2PTNxJ{7TRW5ITVJ:L3G+
Ca-Ski	M1;sN2dzd3e2aDDJcohq[mm2aX;uJIF{e2G7			NU\0bldUUW6qaXLpeIlwdiCxZjDoeY1idiCFYT3Tb4kh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDN2Lke2Olkh\|ryPLh?=	NGW5[4c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2PTNxJ{7TRW5ITVJ:L3G+
NCI-H747	Mo\pS5Jwf3SqIFnubIljcXSrb36gZZN{[Xl?			MX\Jcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KN{S3JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUA{PC57OEe1JO69VS5?	M17uWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFU2Oy9pPmPBUmdGWjxxYU6=
KYSE-510	M1G1U2dzd3e2aDDJcohq[mm2aX;uJIF{e2G7			M1Xib2lvcGmkaYTpc44hd2ZiaIXtZY4hU1mVRT21NVAh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDN3Lk[0PFUh\|ryPLh?=	MoHSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVU{Nyd-U1HOS2VTRC:jPh?=
A204	M4D3[Wdzd3e2aDDJcohq[mm2aX;uJIF{e2G7			M1fnRmlvcGmkaYTpc44hd2ZiaIXtZY4hSTJyNDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gN\|UvPzJyOTFOwG0v	NWfQfnp3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTV\|Lze+V2FPT0WUPD;hQi=>
HSC-3	NYLIbZNJT3Kxd4ToJGlvcGmkaYTpc44h[XO\|YYm=			MknUTY5pcWKrdHnvckBw\iCqdX3hckBJW0NvMzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gN\|YvODB6NjFOwG0v	MlfhQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVU{Nyd-U1HOS2VTRC:jPh?=
HuP-T3	MXHHdo94fGhiSX7obYJqfGmxbjDhd5NigQ>?			MnzUTY5pcWKrdHnvckBw\iCqdX3hckBJfVBvVEOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFM3NjR6M{Kg{txONg>?	NFyxbGI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2PTNxJ{7TRW5ITVJ:L3G+
RPMI-8226	M4fXc2dzd3e2aDDJcohq[mm2aX;uJIF{e2G7			MXnJcohq[mm2aX;uJI9nKGi3bXHuJHJRVUlvOEKyOkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOzZwNkKwPEDPxE1w	M1Hyd\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFU2Oy9pPmPBUmdGWjxxYU6=
QIMR-WIL	M3XjZ2dzd3e2aDDJcohq[mm2aX;uJIF{e2G7			M{fT[GlvcGmkaYTpc44hd2ZiaIXtZY4hWUmPUj3XTWwh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDN4Lk[0OEDPxE1w	NVvQOWpbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTV\|Lze+V2FPT0WUPD;hQi=>
HuH-7	Mnu2S5Jwf3SqIFnubIljcXSrb36gZZN{[Xl?			MXfJcohq[mm2aX;uJI9nKGi3bXHuJGh2UC15IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTCzPE43OTh2IN88UU4>	MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1OVMwLz6VQV7HSXI9N2F-
CAL-12T	MYLHdo94fGhiSX7obYJqfGmxbjDhd5NigQ>?			MWjJcohq[mm2aX;uJI9nKGi3bXHuJGNCVC1zMmSgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3MDC9JFM5Njl2MU[g{txONg>?	M2KyTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFU2Oy9pPmPBUmdGWjxxYU6=
GT3TKB	M1npWWdzd3e2aDDJcohq[mm2aX;uJIF{e2G7			NFnIR5VKdmirYnn0bY9vKG:oIHj1cYFvKEeWM2TLRkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOzlwMUmyNUDPxE1w	NFvu[XY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2PTNxJ{7TRW5ITVJ:L3G+
OC-314	NG\JUnhIem:5dHigTY5pcWKrdHnvckBie3OjeR?=			NFPk[lZKdmirYnn0bY9vKG:oIHj1cYFvKE:FLUOxOEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hOzlwN{GyOUDPxE1w	NFzWdXg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2PTNxJ{7TRW5ITVJ:L3G+
NCI-H2228	NXXqS3N2T3Kxd4ToJGlvcGmkaYTpc44h[XO\|YYm=			Ml;STY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEKyNlgh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDRyLkG0NFMh\|ryPLh?=	MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1OVMwLz6VQV7HSXI9N2F-
NCI-H727	NGfQeWhIem:5dHigTY5pcWKrdHnvckBie3OjeR?=			MWXJcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KN{K3JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUA1OC5{NUOxJO69VS5?	MnTEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVU{Nyd-U1HOS2VTRC:jPh?=
NTERA-S-cl-D1	MXnHdo94fGhiSX7obYJqfGmxbjDhd5NigQ>?			M4nKO2lvcGmkaYTpc44hd2ZiaIXtZY4hVlSHUlGtV{1kdC2GMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gOFAvPDdyNjFOwG0v	MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1OVMwLz6VQV7HSXI9N2F-
MMAC-SF	NFLydGNIem:5dHigTY5pcWKrdHnvckBie3OjeR?=			NYTkOIJrUW6qaXLpeIlwdiCxZjDoeY1idiCPTVHDMXNHKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSB2MD65NlM2KM7:TT6=	M2nLXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFU2Oy9pPmPBUmdGWjxxYU6=
HTC-C3	M375RWdzd3e2aDDJcohq[mm2aX;uJIF{e2G7			NFLQVlFKdmirYnn0bY9vKG:oIHj1cYFvKEiWQz3DN{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hPDFwNEG2PUDPxE1w	Ml\iQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVU{Nyd-U1HOS2VTRC:jPh?=
SF295	NWDpNHA1T3Kxd4ToJGlvcGmkaYTpc44h[XO\|YYm=			NIXlbVRKdmirYnn0bY9vKG:oIHj1cYFvKFOIMkm1JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUA1OS53M{e5JO69VS5?	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1OVMwLz6VQV7HSXI9N2F-
U-2-OS	MW\Hdo94fGhiSX7obYJqfGmxbjDhd5NigQ>?			M4Dw[2lvcGmkaYTpc44hd2ZiaIXtZY4hXS1{LV;TJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUA1OS56NU[3JO69VS5?	NX;ac2F1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTV\|Lze+V2FPT0WUPD;hQi=>
HPAF-II	MmTMS5Jwf3SqIFnubIljcXSrb36gZZN{[Xl?			M1;xe2lvcGmkaYTpc44hd2ZiaIXtZY4hUFCDRj3JTUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hPDFwOUO4NkDPxE1w	NVK1XG1FRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTV\|Lze+V2FPT0WUPD;hQi=>
KYSE-450	MkW1S5Jwf3SqIFnubIljcXSrb36gZZN{[Xl?			NVrV[Hl1UW6qaXLpeIlwdiCxZjDoeY1idiCNWWPFMVQ2OCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxKD1iNEKuOFcxPyEQvF2u	NFyz[YE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2PTNxJ{7TRW5ITVJ:L3G+
DMS-273	M2j2RWdzd3e2aDDJcohq[mm2aX;uJIF{e2G7			NV3ZPZFkUW6qaXLpeIlwdiCxZjDoeY1idiCGTWOtNlc{KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSB2Mz6yPFM3KM7:TT6=	NWK2UGxDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTV\|Lze+V2FPT0WUPD;hQi=>
HT-1376	M3XOOGdzd3e2aDDJcohq[mm2aX;uJIF{e2G7			MkD5TY5pcWKrdHnvckBw\iCqdX3hckBJXC1zM{e2JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUA1Oy5\|MUW2JO69VS5?	MnrWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVU{Nyd-U1HOS2VTRC:jPh?=
786-0	M{nGSGdzd3e2aDDJcohq[mm2aX;uJIF{e2G7			MWjJcohq[mm2aX;uJI9nKGi3bXHuJFc5Pi1yIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTC0N{43OjZzIN88UU4>	NH:1R\|M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2PTNxJ{7TRW5ITVJ:L3G+
NCI-H810	M3fiRWdzd3e2aDDJcohq[mm2aX;uJIF{e2G7			Ml7pTY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEixNEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hPDRwMEGzOkDPxE1w	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1OVMwLz6VQV7HSXI9N2F-
8305C	NGrzdWFIem:5dHigTY5pcWKrdHnvckBie3OjeR?=			NFLSeIpKdmirYnn0bY9vKG:oIHj1cYFvKDh\|MEXDJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUA1PC54NEWg{txONg>?	NGK3Npk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2PTNxJ{7TRW5ITVJ:L3G+
DSH1	M1TW[Wdzd3e2aDDJcohq[mm2aX;uJIF{e2G7			NYjkO2d4UW6qaXLpeIlwdiCxZjDoeY1idiCGU1ixJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUA1PS55MESyJO69VS5?	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1OVMwLz6VQV7HSXI9N2F-
KYSE-520	MWTHdo94fGhiSX7obYJqfGmxbjDhd5NigQ>?			M4rafWlvcGmkaYTpc44hd2ZiaIXtZY4hU1mVRT21NlAh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDR4LkW3NlEh\|ryPLh?=	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1OVMwLz6VQV7HSXI9N2F-
TYK-nu	M33JZmdzd3e2aDDJcohq[mm2aX;uJIF{e2G7			NFLyWIZKdmirYnn0bY9vKG:oIHj1cYFvKFS\Sz3ueUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hPDZwN{C5NkDPxE1w	M3vkeVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFU2Oy9pPmPBUmdGWjxxYU6=
EPLC-272H	NWHafnlbT3Kxd4ToJGlvcGmkaYTpc44h[XO\|YYm=			MV7Jcohq[mm2aX;uJI9nKGi3bXHuJGVRVENvMkeyTEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hPDZwN{K4N{DPxE1w	MnThQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVU{Nyd-U1HOS2VTRC:jPh?=
T-24	NH;JSYtIem:5dHigTY5pcWKrdHnvckBie3OjeR?=			M3rMbGlvcGmkaYTpc44hd2ZiaIXtZY4hXC1{NDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gOFcvQTJ7MjFOwG0v	M2HiVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFU2Oy9pPmPBUmdGWjxxYU6=
BHY	MU\Hdo94fGhiSX7obYJqfGmxbjDhd5NigQ>?			MVjJcohq[mm2aX;uJI9nKGi3bXHuJGJJYSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxKD1iNEeuPVk6KM7:TT6=	NGXlWXY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2PTNxJ{7TRW5ITVJ:L3G+
NCI-H82	NFfzXGlIem:5dHigTY5pcWKrdHnvckBie3OjeR?=			MmXJTY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEiyJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUA1QC5{MUeg{txONg>?	MkHzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVU{Nyd-U1HOS2VTRC:jPh?=
SF268	NX7BNpp[T3Kxd4ToJGlvcGmkaYTpc44h[XO\|YYm=			MXPJcohq[mm2aX;uJI9nKGi3bXHuJHNHOjZ6IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTC0PE43OTh7IN88UU4>	MmD6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVU{Nyd-U1HOS2VTRC:jPh?=
C-33-A	M2\UOGdzd3e2aDDJcohq[mm2aX;uJIF{e2G7			NH:4WnVKdmirYnn0bY9vKG:oIHj1cYFvKENvM{OtRUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hPDhwN{W1OEDPxE1w	NFPPdHk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;3e5cv\WKrLnHjMpVsN2OqZX3icE9kd22yb4Xu[H9z\XCxcoTfZ4Fz\C:FSFXNRmw2PTNxJ{7TRW5ITVJ:L3G+
MIA-PaCa-2	MYDHdo94fGhiSX7obYJqfGmxbjDhd5NigQ>?			M4T0[2lvcGmkaYTpc44hd2ZiaIXtZY4hVUmDLWDhR4EuOiClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR\|UxKD1iNEiuPFM5QCEQvF2u	MnfNQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVU{Nyd-U1HOS2VTRC:jPh?=
HCC1954	NXzlR4dMT3Kxd4ToJGlvcGmkaYTpc44h[XO\|YYm=			NFf3OppKdmirYnn0bY9vKG:oIHj1cYFvKEiFQ{G5OVQh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NEA:KDR7LkC4O\|Eh\|ryPLh?=	M3PjcVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFU2Oy9pPmPBUmdGWjxxYU6=
NCI-H1666	MlXiS5Jwf3SqIFnubIljcXSrb36gZZN{[Xl?			M3POU2lvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVixOlY3KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVAhRSB2OT6zOlQzKM7:TT6=	MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1OVMwLz6VQV7HSXI9N2F-
GR-ST	NELzfopIem:5dHigTY5pcWKrdHnvckBie3OjeR?=			MW\Jcohq[mm2aX;uJI9nKGi3bXHuJGdTNVOWIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO\|YYmsJGlEPTBiPTC0PU4{Pjl3IN88UU4>	M2HhdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFU2Oy9pPmPBUmdGWjxxYU6=
Ca9-22	M4T3bGdzd3e2aDDJcohq[mm2aX;uJIF{e2G7			NFfW[IZKdmirYnn0bY9vKG:oIHj1cYFvKEOjOT2yNkBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwJF0hPDlwNECxN{DPxE1w	MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:5d4eu[YJqNmGlLoXrM4Np\W2kbD;jc41xd3WwZG;y[ZBwenShY3Hy[E9EUEWPQly1OVMwLz6VQV7HSXI9N2F-
D-502MG	NVTMOXFxT3Kxd4ToJGlvcGmkaYTpc44h[XO\|YYm=			MonpTY5pcWKrdHnvckBw\iCqdX3hckBFNTVyMl3HJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUCgQUA1QS52MUeg{txONg>?	M{XoUlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4f3e{5m[mlwYXOueYsw[2inbXLsM4NwdXCxdX7kY5JmeG:{dG;jZZJlN0OKRV3CUFU2Oy9pPmPBUmdGWjxxYU6=
SCC-4	M1m2OGdzd3e2aDDJcohq[mm2aX;uJIF{e2G7			Mnq4TY5pcWKrdHnvckBw\iCqdX3hckBUS0NvNDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gOFkvPTZyMjFOwG0v	NWCzVWhRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:ve5d4NmWkaT7hZ{52cy:laHXtZoww[2:vcH;1coRgemWyb4L0Y4NiemRxQ1jFUWJNPTV\|Lze+V2FPT0WUPD;hQi=>
RKO	M1vLb2dzd3e2aDDJcohq[mm2aX;uJIF{e2G7			NIPvNIhKdmirYnn0bY9vKG:oIHj1cYFvKFKNTzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG\|c3H5MEBKSzVyIE2gOFkvQDN3NjFOwG0v	MnjaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xd4f3MoVjcS6jYz71b{9kcGWvYnyvZ49ueG:3bnTfdoVxd3K2X3PhdoQwS0iHTVLMOVU{Nyd-U1HOS2VTRC:jPh?=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	Cleaved PARP / PARP ; PubMed: 27508092 Am J Cancer Res HCC827 or H1650 cells were treated with DMSO, celecoxib, erlotinib alone, or in combination for 48 h. Western blot analysis showed that cleaved PARP was higher in cells after combination treatment. P-Raf-1 / t-Raf-1 / p-MEK / t-MEK / p-ERK / t-ERK / p-PI3K / t-PI3K / p-AKT / AKT; PubMed: 27508092 Am J Cancer Res Cells from both ER and ECR groups were treated with 3 μM erlotinib for 72 h. Cell lysates were used for Western blotting with indicated antibodies. p-STAT3 / STAT3 / PTPMeg2 / p-EGFR / EGFR / pJAK2 / JAK2 / Bcl2 / Bcl-xl / Survivin; PubMed: 24019973 PLoS One Tu212 and Tu686 cells were treated with erlotinib (0.1µM) for various times. Levels of various proteins (pSTAT3, PTPMeg2, pEGFR, Bcl2, Bcl-XL, etc.) were analyzed by Western blot.	27508092 24019973
Immunofluorescence	β-catenin; PubMed: 25209444 Cancer Distribution of β-catenin by immunofluorescence staining after erlotinib treatment for 48h. These experiments were repeated in triplicate. E-cadherin / Vimentin ; PubMed: 19825949 Clin Cancer Res SUM149 cells were plated in 3D culture without or with erlotinib for 4 days. Immunofluorescence analysis was performed to detect E-cadherin, β-catenin, and vimentin. Nuclei were visualized with DAPI. D, SUM149 cells were transfected with control or ERK si䲧疝Ỵ疞㧀疜膉痘 瘿�෋ᾰƌ෋à 㺣痖帉痖Ѐ瑖堘𢡄빢᎒෋à鑸᎒彿堙奋堙巫堙᎒ﻺ᎒彿堙ﻮ᎒塚堙ﻺ᎒ꍈ堞빢᎒學堙漸堞圔堙빢᎒圞堙圭堙𢡄玚Wᾰƌ	25209444 19825949
Growth inhibition assay	Cell viability ; PubMed: 30377412 Cancer Cell Int a The MTT assay for PANC-1 viability. Different doses of erlotinib were added to the medium of PANC-1 cells. c The MTT assay for PaCa-2 cells in the presence of erlotinib treatment. IC50; PubMed: 17671085 Mol Cancer Ther dose-response curves of A-431 cells and 10 breast cancer cell lines after treatment with erlotinib at final concentrations of 0.03, 0.06, 0.1, 0.2, 0.3, 0.6, 1, 2, 3, 6, 10, or 20 μmol/L for 72 h. The surviving fractions were determined by MTT assay. Poin䲧疝Ỵ疞㧀疜膉痘 瘿�෋ᾰƌ෋à 㺣痖帉痖Ѐ	30377412 17671085

In vivo

At doses of 100 mg/kg, Erlotinib HCl completely prevents EGF-induced autophosphorylation of EGFR in human HN5 tumors growing as xenografts in athymic mice and of the hepatic EGFR of the treated mice. ^[1] Erlotinib HCl (100 mg/Kg) inhibits H460a and A549 tumor models with 71 and 93% inhibition rate. ^[5]

Protocol

Kinase Assay: ^[1]	- Collapse Kinase assays: 96-well plates are coated by incubation overnight at 37 °C with 100 μL per well of 0.25 mg/mL PGT in PBS. Excess PGT is removed by aspiration, and the plate is washed 3 times with washing buffer (0.1% Tween 20 in PBS). The kinase reaction is performed in 50 μL of 50 mM HEPES (pH 7.3), containing 125 mM sodium chloride, 24 mM magnesium chloride, 0.1 mM sodium orthovanadate, 20 μM ATP, 1.6 μg/mL EGF, and 15 ng of EGFR, affinity purified from A431 cell membranes. Erlotinib HCl in DMSO is added to give a final DMSO concentration of 2.5%. Phosphorylation is initiated by addition of ATP and proceeded for 8 minutes at room temperature, with constant shaking. The kinase reaction is terminated by aspiration of the reaction mixture and is washed 4 times with washing buffer. Phosphorylated PGT is measured by 25 minutes of incubation with 50 μL per well HRP-conjugated PY54 antiphosphotyrosine antibody, diluted to 0.2 μg/mL in blocking buffer (3% BSA and 0.05% Tween 20 in PBS). Antibody is removed by aspiration, and the plate is washed 4 times with washing buffer. The colorimetric signal is developed by addition of TMB Microwell Peroxidase Substrate, 50μL per well, and stopped by the addition of 0.09 M sulfuric acid, 50 μL per well. Phosphotyrosine is estimated by measurement of absorbance at 450 nm. The signal for controls is typically 0.6-1.2 absorbance units, with essentially no back ground in wells without AlP, EGFR, or PGT and is proportional to the time of incubation for 10 minutes.
Cell Research: ^[2]	- Collapse Cell lines: A549, H322, H3255, H358 H661, H1650, H1975, H1299, H596 cells Concentrations: 30 nM-20 μM Incubation Time: 72 hours Method: Exponentially growing cells are seeded in 96-well plastic plates and exposed to serial dilutions of erlotinib, pemetrexed, or the combination at a constant concentration ratio of 4:1 in triplicates for 72 h. Cell viability is assayed by cell count and the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. Growth inhibition is expressed as the percentage of surviving cells in drug-treated versus PBS-treated control cells (which is considered as 100% viability). The IC50 value is the concentration resulting in 50% cell growth inhibition by a 72-h exposure to drug(s) compared with untreated control cells and is calculated by the CalcuSyn software. (Only for Reference)
Animal Research: ^[6]	- Collapse Animal Models: Male 5-week-old BALB-nu/nu mice with HPAC cells Dosages: 50 mg/kg Administration: Oral administration (Only for Reference)

References

- Collapse

Solubility (25°C)

In vitro	DMSO	78 mg/mL (198.25 mM)
	Water	Insoluble
	Ethanol	'15 mg/mL warmed
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 5% DMSO+30% PEG 300+5% Tween 80+ddH2O For best results, use promptly after mixing.	6mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Erlotinib SDF

Molecular Weight	393.44
Formula	C₂₂H₂₃N₃O₄
CAS No.	183321-74-6
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	CP358774, NSC 718781
Smiles	COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2020-01-06)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04172779	Not yet recruiting	Drug: Erlotinib Hydrochloride	Cirrhosis Liver	University of Texas Southwestern Medical Center	July 2021	Phase 2
NCT03460678	Terminated	Drug: Pemetrexed\|Drug: Erlotinib	Carcinoma Non-Small-Cell Lung	Hikma Pharmaceuticals LLC	February 28 2018	Phase 4
NCT02942095	Active not recruiting	Drug: Ixazomib\|Drug: Erlotinib	Solid Tumors	M.D. Anderson Cancer Center\|Millennium: The Takeda Oncology Company	March 6 2017	Phase 1
NCT02991651	Recruiting	Drug: IRX4204\|Drug: erlotinib	Lung Cancer Nonsmall Cell	Io Therapeutics\|Dartmouth College	May 2016	Phase 1
NCT02762877	Terminated	--	Non Small Cell Lung Carcinoma	Genomic Health® Inc.	April 2016	--

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
Can you please give me some advice for which solvent we should use to dissolve it for animal studies?
Answer:
For in vivo application, we recommend to use 5% DMSO+45% PEG 300+ddH2O up to 6mg/ml.

EGFR Signaling Pathway Map

Related EGFR Products

Afatinib (BIBW2992) Dimaleate ^New

Afatinib (BIBW2992) Dimaleate irreversibly inhibits EGFR/HER2 including EGFR(wt), EGFR(L858R), EGFR(L858R/T790M) and HER2 with IC50 of 0.5 nM, 0.4 nM, 10 nM and 14 nM, respectively; 100-fold more active against Gefitinib-resistant L858R-T790M EGFR mutant. Afatinib (BIBW2992) Dimaleate induces autophagy.
Poziotinib (HM781-36B) ^New

Poziotinib (HM781-36B, NOV120101) is an irreversible pan-HER inhibitor with IC50 of 3.2 nM, 5.3 nM and 23.5 nM for HER1, HER2, and HER4, respectively. Poziotinib also induces apoptosis and G1 cell cycle arrest. Phase 2.
AZ5104 ^New

AZ5104, the demethylated metabolite of AZD-9291, is a potent EGFR inhibitor with IC50 of <1 nM, 6 nM, 1 nM, and 25 nM for EGFR (L858R/T790M), EGFR (L858R), EGFR (L861Q), and EGFR (wildtype), respectively. Phase 1.
Gefitinib (ZD1839)

Gefitinib (ZD-1839, Iressa) is an EGFR inhibitor for Tyr1173, Tyr992, Tyr1173 and Tyr992 in the NR6wtEGFR and NR6W cells with IC50 of 37 nM, 37nM, 26 nM and 57 nM, respectively. Gefitinib promotes autophagy and apoptosis of lung cancer cells via blockade of the PI3K/AKT/mTOR pathway.

Features:A potent EGFR tyrosine kinase inhibitor.
Erlotinib HCl (OSI-744)

Erlotinib HCl (OSI-744, CP358774, NSC 718781) is an EGFR inhibitor with IC50 of 2 nM in cell-free assays, >1000-fold more sensitive for EGFR than human c-Src or v-Abl.
Afatinib (BIBW2992)

Afatinib (BIBW2992) inhibits EGFR/ErbB irreversibly in vitro with IC50 of 0.5, 0.4, 10, 14, 1 nM for EGFR^wt, EGFR^L858R, EGFR^L858R/T790M ErbB2 (HER2) and ErbB4 (HER4), respectively. Afatinib induces autophagy.
Osimertinib (AZD9291)

Osimertinib (AZD9291) is an oral, irreversible, and mutant-selective EGFR inhibitor with IC50 of 12.92, 11.44 and 493.8 nM for Exon 19 deletion EGFR, L858R/T790M EGFR, and WT EGFR in LoVo cells, respectively. Phase 3.
Lapatinib

Lapatinib (GSK572016), used in the form of Lapatinib Ditosylate, is a potent EGFR and ErbB2 inhibitor with IC50 of 10.8 and 9.2 nM in cell-free assays, respectively. Lapatinib induces ferroptosis and autophagic cell death.
AG-490 (Tyrphostin B42)

AG-490 (Tyrphostin B42, Zinc02557947) is an inhibitor of EGFR with IC50 of 0.1 μM in cell-free assays, 135-fold more selective for EGFR versus ErbB2, also inhibits JAK2 with no activity to Lck, Lyn, Btk, Syk and Src.
Rociletinib (CO-1686)

Rociletinib (CO-1686, AVL-301) is an irreversible, mutant-selective EGFR inhibitor with K_i of 21.5 nM and 303.3 nM for EGFR^L858R/T790M and EGFR^WT in cell-free assays, respectively. Phase 2.

Choose Your Country or Region

By Signaling Pathways

By product type

Erlotinib